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ABSTRACT 
 
The earlier optimism generated by the efficacy of antiretroviral drugs in human immuno-
deficiency virus (HIV) patients has been dissipated in the face of the enormous chal-
lenge of maintaining a nearly perfect adherence indefinitely. This study set to determine 
the influence of HIV adherence self-efficacy and beliefs about medicines on antiretrovi-
ral therapy adherence, with the aim of developing a framework for enhancing antiretrovi-
ral therapy (ART) adherence through focused intervention on modifiable factors from 
study variables that are strongly associated with ART adherence. 
 
A descriptive correlational design was used to assess the predictive relationships of HIV 
adherence Self-Efficacy, Beliefs about Medicines and ART adherence among 232 HIV-
infected patients in a large public health facility in Pretoria. Participants' medication be-
liefs were assessed using the Beliefs about Medicines Questionnaire, HIV adherence 
self-efficacy was assessed with HIV adherence self-efficacy scale (HIV-ASES) and ART 
adherence was assessed using the AIDS Clinical Trial Group questionnaire. Pearson 
correlation analysis was used to assess bivariate associations among the variables, and 
multiple regression analysis was used to examine the relationships among the inde-
pendent variables and ART adherence.  
 
Mean adherence for the 232 participants was 95% (SD=13.2). Correlation analysis re-
vealed positive bivariate associations between perceived general harm and overuse of 
medications, and ART adherence (p<0.05); between specific necessity and concerns 
about ARVs, and perceived general harm and overuse of medications (p<0.05); be-
tween HIV adherence self efficacy and ART non-adherence (p<0.05). Multiple regres-
sion analysis showed significance for perceived general harm and overuse of medica-
tions on ART adherence (F(1;231)=11,583;p<0,001) with perceived general harmful ef-
 
 
fects and overuse of medications explaining 4.8% of the variance. There was signifi-
cance for HIV adherence self-efficacy on ART non-adherence (F(1;41)=4.440; 
p<0.041), with HIV-ASES explaining 9,8% of the variance. Based on the results, a 
framework for enhancing ART adherence was developed. Activities in the framework 
consist of baseline screening for adherence facilitators and barriers using the beliefs 
about medicine questionnaire and HIV ASES, this is followed by focused interventions 
on identified barriers of ART adherence. 
 
Key concepts: HIV adherence self-efficacy, beliefs about medicines, antiretroviral ther-
apy adherence, antiretroviral therapy, human immunodeficiency virus. 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
 
The Human immunodeficiency virus (HIV) and Acquired immune deficiency syndrome 
(AIDS) have become the most challenging public health concern of this generation. The 
pandemic has affected all age groups, causing premature deaths and depleting both 
human and capital resources especially in Sub-Saharan Africa leaving on its trail ethi-
cal, legal, and political issues together with economic and human rights implications. 
Although no definite cure has been found to treat this infectious disease, the introduc-
tion of antiretroviral therapy (ART) has enabled the disease to be managed as a chronic 
life-threatening disease producing substantial reduction in both AIDS-related morbidity 
and mortality (Abdool Karim, Naidoo, Grobler, Padayatchi, Baxter, Gray, Gengiah, Nair, 
Bamber, Singh, Khan, Pienaar, El-Sadr, Friedland & Abdool Karim 2010:700; Lawrence, 
Ndamage, Kayirangwa, Ndagije, Lo, Hoover, Hanson, Elul, Ayaba, Ellebrock, Rukundo, 
Shumbusho, Nash, Mugabo & Assimwe 2009:54; Wools-Kaloustian, Kimayo, Diero, 
Siika, Sidle, Yiannoustsos, Musick, Einterz, Fife & Tierney 2006:44). 
 
While clinical outcomes of HIV-infected patients have been improved by highly active 
antiretroviral therapy (HAART), the earlier optimism generated by the efficacy of HAART 
in preserving the quality of lives of HIV/AIDS patients has been dissipated in the face of 
the enormous challenge of maintaining a nearly perfect adherence indefinitely (Simoni, 
Frick, Pantalone & Turner 2003:193). Although adherence to ART is a strong predictor 
of good clinical outcomes and survival among HIV-infected patients (Wang, Zhou, He, 
Luo, Li, Yang, Fennie & Williams 2009:759; Wools-Kaloustian et al 2006:44), the fact 
that high level of adherence is required in ART is very challenging and without this pa-
tients risk adverse outcomes for themselves and put extra burden on the already over-
stretched public health system (Rajasekran, Jeyaseelan, Vijila, Gomathi & Raja 
2007:48). Furthermore, the complicated dosing requirements, adverse drug reactions 
and socio-economic factors often constitute challenges to patients and influence their 
adherence to treatment (Dahab, Charalambous, Hamilton, Fielding, Kielmann, Church-
 
2 
yard & Grant 2008:63; Curioso, Kepka, Cabello, Segura & Kurth 2010:13; Amberbir, 
Woldemichael, Getachew, Girma, & Deribe 2008:265). 
 
Treatment adherence is the act or quality of sticking to a particular advice as instructed 
by the health care provider (Kenreigh & Wagner 2005). It is broader than mere compli-
ance with medications; it includes adhering to dietary instructions, clinic appointments 
and lifestyle adjustment. This is why long-term treatment adherence in chronic diseases 
such as HIV/AIDS is a very complex and dynamic phenomenon which involves the pa-
tients, health providers, the health system within which they operate and the broader 
socio-economic and political context around all the above (Miller, Ketlhapile, Rybasack-
Smith & Rosen 2010:52). 
 
Understanding the processes that influence adherence is helpful when trying to identify 
barriers and promote treatment adherence. The cognitive perspective of health behav-
iour provides a good framework in understanding some of these processes. This per-
spective assumes that attitudes and beliefs as well as expectations and outcomes de-
termine patients’ health behaviour (Munro, Lewin, Swart & Volmink 2007:104). Self-
efficacy and beliefs about medications are cognitive variables from this perspective 
(Kagee 2008:421), and are constructs which are influential in terms of task choice, per-
formance, effort, and perseverance as they pertain to the ability to successfully engage 
in behaviours that lead to desired outcomes (Skovdal, Campbell, Nhongo, Nyamukapa 
& Gregson 2011:309; Munro et al 2007:104). These cognitive variables have been 
found to be associated with medication adherence in chronic medical conditions like hy-
pertension, diabetes, asthma (Ireland & Wilsher 2010:40; Neame & Hammond 
2005:765).  
 
The current study was designed to identify predictive relationships among self-efficacy, 
beliefs about medicines and ART adherence, and to explore cognitive factors that are 
strongly associated with adherence in order to suggest strategies for improving ART 
adherence among HIV patients through a framework development. 
 
  
 
3 
1.2 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
 
1.2.1 The source of and background to the research problem 
 
Adherence among patients on ART in developing countries, including South Africa, con-
tinues to pose challenges to the health care delivery system, although various studies in 
sub-Saharan Africa have shown that high levels of adherence, viral suppression and 
good clinical outcome are achievable in these resource-limited settings (Nachega, 
Hislop, Dowdy, Lo, Omer, Regensberg, Chaisson & Maartens 2006a:82; San Lio, 
Carbini, Germano, Guidotti, Mancinelli, Magid, Narciso, Palombi, Renzi, Zimba & 
Marazzi 2008:1614; Nachega, Hislop, Nguyen, Dowdy, Regensberg, Chaisson, Cotton 
& Maartens 2009:68; Mills, Nachega, Buchan, Orbinski, Attaran, Singh, Rachlis, Wu, 
Cooper, Thabane, Wilson, Guyatt & Bangsberg 2006:685; Hardon, Akurut, Comoro, 
Ekezie, Irunde, Gerrits, Kglatwane, Kinsman, Kwasa, Maridadi, Moroka, Moyo, 
Nakiyemba, Nsimba, Ogenyi, Oyabba, Temu & Laing  2007; Oyugi, Byakika-Tusiime, 
Charlebois, Kityo, Mugerwa, Mugyenyi & Bangsberg 2004:1101; Fox & Rosen 2010:11), 
it is very challenging to adhere to ART, and strict adherence is not common (Montesso-
ri, Press, Harris, Akagi & Montaner 2004:229).  
 
A major review of studies on ART adherence puts it at 77% in Sub-Saharan Africa and 
estimates non-adherence in adult population at 33-88% depending on the measure of 
adherence employed (Mills et al 2006:685). In other studies across sub-Saharan Africa 
ART adherence varies widely from 25-56% (Amberbir et al 2008:265; Uzochukwu, 
Onwujekwe, Onoka, Okoli, Uguru & Chukwuogo 2009:4; Malangu 2008:49; Peltzer, Du 
Preez, Ramlagan & Anderson 2010:111). These percentages are low considering that 
adherence of 95% is necessary to achieve optimum benefit of ART (Nachega et al 
2006a:81). Low adherence levels are linked to development of resistant virus, rapid dis-
ease progression, poor quality of life and premature mortality (Graham, Masese, Gitau, 
Jalalian-Lechak, Richardson, Peshu, Mandaliya, Kiarie, Jaoko, Ndinya-Achola, 
Overbaugh & McClelland 2010:1541; Nachega et al 2006a:83; Wools-Kaloustian et al 
2006:44).  
 
The consequences of non-adherence in HIV management is so costly and researchers 
have advocated that health behaviour theories needed to be well examined to enhance 
the understanding of how relevance they are concerning adherence to medication in 
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chronic condition such as HIV/AIDS (Gill, Hamer, Simon, Thea & Sabin 2005:1247; 
Peltzer et al 2010:111).  
 
Adherence self-efficacy is the personal belief regarding the capabilities to plan and per-
form a desired behaviour to comply with prescribed medications and health instructions 
in managing a disease condition (Bandura 2004:144). Adherence self-efficacy is a 
known predictor of a wide range of health behaviour of patients on chronic medication 
including medication adherence (Kott 2008:60; Sleath et al 2010:628; Zebracki & Drotar 
2004:142; Johnson et al 2007:367; Rudy, Murphy, Harris, Muenz & Ellen 2009:188).  
 
Beliefs about medicines is another variable from the cognitive perspective of health be-
haviour, it describes a person’s beliefs about the potential costs and benefits of taking 
medication and it is an important factor that has influence on medication use behaviour 
(Horne, Weinman & Hankins 1999:20).Various studies across a range of chronic medi-
cal conditions have identified similarities in beliefs that influence medication adherence. 
These studies have found low rates of adherence to be consistently related to doubts 
about personal need for medications (Magadza, Radloff & Srinivas 2009:369; Neame & 
Hammond 2005:764; Porteous, Francis, Bond & Hannaford 2010:228; Ireland & Wilsher 
2010:39). 
 
Whereas studies from developed countries where the socio-economic dynamics are 
quite different to what obtains in sub-Saharan Africa countries have already document-
ed positive association among adherence self-efficacy, beliefs about medicines and 
medication adherence in diseases like HIV, asthma, diabetes, glaucoma and depres-
sion; and that poor adherence is likely to occur in patients with low self-efficacy (Horne 
2006:67; Rudy et al 2009:190; Zebracki & Drotar 2004:142; Johnson, Neilands, Dil-
worth, Morin, Remien & Chesney 2007:367; Sleath et al 2010:628; Gifford, Bormann, 
Shively, Wright, Richman & Bozzette 2000:394), few studies have examined this rela-
tionship in developing countries (Kagee 2008:420; Peltzer et al 2010:111).  
 
An extensive search of the literature for previous studies was conducted using data-
bases such as ProQuest, PubMed, MEDLINE, NiPAD, SocINDEX and PsycINFO as 
well as Google Scholar search engine using keywords such as self-efficacy, antiretrovi-
ral therapy adherence and beliefs about medications. By using these search terms over 
250 research papers were generated, the researcher narrowed down the search to re-
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search articles that dealt with adherence to chronic medications, self-efficacy in the con-
text of chronic medical conditions and medication beliefs among patients who were on 
chronic treatment for medical ailments. In addition, descriptive, methodological and con-
textual factors from each research article were done to gain better understanding of 
work done in this area.  
 
The researcher identified that relationships among adherence self-efficacy, antiretroviral 
therapy adherence and beliefs about medications have not been examined thoroughly 
in South Africa setting that has the largest ART program worldwide despite a rapidly 
growing body of literature addressing issues associated with adherence to ART. Given 
the dearth of research on the combination of variables that relate to patients’ adherence 
behaviour and intentions to adhere in South Africa, studies that consider some of these 
explanatory factors simultaneously are urgently needed as psychosocial variables that 
are amenable to intervention, such as self-efficacy and belief about medicines, may im-
prove the body of knowledge in the area of ART adherence (Reynolds, Testa, Marc, 
Chesney, Neidig, Smith, Vella, Robbins and the ACTG teams 2004:148).  
 
1.3 RESEARCH PROBLEM  
 
According to cognitive perspective of health behaviour, persons who are likely to per-
form certain health behaviour are those who believe that such behaviour is going to 
benefit them (Munro et al 2007:104). Rather than identifying the characteristics of ad-
herent or non-adherent patients as previous studies have done, there is need to better 
understand the interaction of the individual with the disease and its treatment modali-
ties. Extending knowledge of HIV/AIDS to an understanding of the process and predic-
tors of behaviour change may provide an insight about the successful self-management 
of this chronic disease (Gauchet, Tarquinio & Fischer 2007:147). 
 
Further research is therefore needed as psychosocial variables that are amenable to 
intervention such as self-efficacy and belief about medicines provide a good framework 
for understanding ART adherence. However, more information regarding the role of 
these variables in adhering to ART needs to be established by research in our local set-
ting. It was anticipated that the results of this study would offer additional support to ex-
isting body of knowledge that self-management behaviour improves with beliefs of self-
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efficacy and need for medication; and the expectation that by performing the behaviour 
a positive outcome will result. 
 
As research has indicated that adherence needed for maximal benefit in ART differ sig-
nificantly from those of other chronic medical conditions (Simoni, Frick, Pantalone & 
Turner 2003:185-198). By implication, HIV-infected patients on ART need to demon-
strate self-management skills and good knowledge of their disease as well as having a 
high level of self-confidence in adhering to their medications. These relationships how-
ever have not yet been tested empirically in South African patients. It is clearly in the 
interest of ART adherence monitoring to know the cognitive factors that will predict high 
and low adherence for purposes of focused intervention. 
 
The researcher is an HIV clinician and previously served as Technical advisor on HIV 
treatment programmes with an international donor organisation in Pretoria where he 
witnessed the various challenges faced by patients in adhering to ART and was per-
suaded that cognitive perspective of health behaviour could be used to gain better un-
derstanding of ART adherence. The researcher was therefore motivated to conduct an 
investigation into the influence of adherence self-efficacy and beliefs about medicines 
on ART adherence among HIV-infected patients within the Tshwane area. Identifying 
the predictive relationships of these variables will enhance the patients’ and the health 
providers’ understanding of cognitive factors associated with ART adherence in the lo-
cal setting where the study was based.  
 
Based on the introduction, background information and the description of the problem 
stated above, the researcher arrived at this research question: How can adherence self-
efficacy and Beliefs about Medicines be utilized in HIV/AIDS service delivery to develop 
strategies that would enhance adherence to ART in South Africa, thereby minimizing 
development of adverse outcomes in patients in forms of loss of virologic control and 
subsequent viral rebound; development of viral resistance and the transmission of resis-
tant virus to others; and repeated patients hospitalizations with high economic impor-
tance to the already overwhelmed public health system?  
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1.4 AIM OF THE STUDY 
 
This study aimed to provide a framework for ART adherence improvement through fo-
cused intervention on modifiable factors that are strongly associated with ART adhe-
rence. 
 
1.4.1 Research purpose 
 
The purpose of this study was to determine the influence of adherence self-efficacy and 
beliefs about medicines on ART adherence among patients on lifelong treatment. The 
information obtained would be used to provide a framework for enhancing adherence to 
antiretroviral therapy. 
 
1.4.2 Research objectives 
 
The specific objectives of this research are to: 
 
1. Explore the cognitive variables of adherence self-efficacy and beliefs about 
medicines that influence adherence among patients on ART. 
 
2. Determine the inter-relationships among adherence self-efficacy, beliefs about 
medicines and ART adherence. 
 
3. Describe the modalities of enhancing adherence to ART through focused inter-
ventions on the identified factors that are strongly associated with ART adher-
ence. 
 
4. Develop a framework for the improvement of ART adherence based on the fac-
tors identified in this study. 
 
1.5 SIGNIFICANCE OF THE STUDY 
 
HIV/AIDS is a chronic life threatening disease that constitutes the largest burden of dis-
ease in South Africa (NDOH 2010:10). The management of the disease is complex and 
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requires a team approach involving the patient, doctors, nurses, adherence counselors, 
and many others. As part of the multidisciplinary team, HIV patients have a role to play 
in the management of their disease. They are expected to take their medications regu-
larly, maintain healthy diet, observe some dietary restrictions and avoid risky behav-
iours, and all these are based on the constructs of the cognitive perspective of health 
behaviour. 
 
Since adherence in persons with HIV/AIDS varies within each person, identifying varia-
bles to improve adherence monitoring offers an additional perspective about HIV/AIDS 
management and ART adherence monitoring in South Africa.  
 
Identifying the cognitive factors that are predictive of ART adherence will make signifi-
cant contributions to the field of adherence monitoring in HIV/AIDS management in 
South Africa. Exploring cognitive variables that are strongly associated with ART adher-
ence would assist in identifying factors that require focused interventions to improve ad-
herence among HIV-infected patients. Interventions could then be manipulated to pro-
mote these factors among patients on ART. In addition, identification of these factors 
will enable for baseline screening for adherence predictors prior to ART initiation. Health 
providers could then use patients’ responses to prioritize them for further education to 
assist in improving their adherence. 
 
1.6 DEFINITION OF TERMS 
 
1.6.1 Acquired immune deficiency syndrome (AIDS) 
 
AIDS is this study refers to the late stage of HIV infection when a person’s immune sys-
tem which serves as the body’s natural response to infections is severely damaged due 
to decrease in the number and functions of CD4+ T-lymphocytes cells. This causes a 
severe immunodeficiency state that leaves the body susceptible to a variety of potential-
ly fatal infections which are otherwise non virulence (Wilkinson & Gotch 2001:188). 
 
1.6.2 Antiretroviral therapy (ART) 
 
Antiretroviral (ARV) are drugs used in the treatment of HIV/AIDS, they are meant to in-
terrupt the life cycle of HIV; and they do so at different points to reduce the replication of 
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the virus (Montessori et al 2004:229).The drugs that make up ART usually consist of at 
least two classes of antiretroviral agents (Boyd & Pett 2008:66; Palmer 2003:59). An-
tiretroviral therapy in this study is refers to the combination of three or more antiretrovi-
ral agents used for maximal suppression of viral replication in the treatment of 
HIV/AIDS. 
 
1.6.3 Antiretroviral therapy adherence 
 
Treatment adherence is the act or quality of sticking to a particular advice as instructed 
by the health care provider (Kenreigh & Wagner 2005). ART Adherence in this research 
refers to the extent to which HIV-infected patients behaviour corresponds to the pre-
scribed medical advice in terms of antiretroviral use. 
 
1.6.4 Beliefs about medicines 
 
Describes a person’s beliefs about the potential costs and benefits of taking medication 
and it is an important factor influencing medication use behaviour (Horne et al 1999:20). 
‘’Beliefs about medicines’’ in this study is a construct that describes a patient’s beliefs 
about the potential costs and benefits of taking antiretroviral therapy. The measure to 
gauge these beliefs is the “beliefs about medicine questionnaire”.  
 
1.6.5 Human immune-deficiency virus (HIV) 
 
HIV is a retrovirus of the lentiviruses family; infections with lentiviruses are often charac-
terized by a long period of clinical latency, persistent viral replication and follow a chron-
ic course of disease. The HIV comprises of two species namely HIV-1 and HIV-2 which 
researchers believe to have originated as zoonotic infection from primate host that har-
bour certain lentiviruses called the simian immune-deficiency (Rubbert, Behrens & 
Ostrowski 2007:60).  
 
1.6.6 HIV adherence self-efficacy 
 
Self-efficacy is a personal belief regarding the capabilities to carry out a specific task to 
achieve a desired outcome, it describes an individual’s belief that he can alter a behav-
iour or action required to achieve positive health outcomes in managing a disease con-
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dition (Bandura 2004:144; 1977:193). HIV adherence self-efficacy in this research is 
described as one’s belief in the ability to plan and perform a desired behaviour leading 
to ART adherence. 
 
1.6.7 HIV-infected person 
 
This is a person whose HIV specific antibodies or viral antigens have been demon-
strated in their blood or body fluids through standardized tests. These markers are 
found in HIV-infected individuals and their presence is used to make the diagnosis of 
HIV infection (Preiser & Korsman 2007:41). An HIV-infected person in this study is one 
who has been diagnosed with the prescribed standardized laboratory tests. 
 
1.7 FOUNDATION OF THE STUDY 
 
1.7.1 Meta-theoretical assumptions 
 
The term ‘meta- theory’ explores the underlying assumptions of theory and attempts to 
understand the consequences of such assumptions on the act of theorizing and the 
practice of empirical research (Wallis 2010:78). It does not take a specific event, phe-
nomenon, or series of empirical real world practices as its object of analysis. Meta-
theoretical assumption typically addresses issues such as the nature and the structure 
of scientific theories, the nature of scientific growth, the meaning of truth, explanations 
and objectivity (Wallis 2010:98-99). Meta-theoretical assumptions reflect the re-
searcher's view, they are beliefs which origin is philosophical in nature, and therefore 
not meant to be tested but are accepted to be true for the researcher. Meta-theory de-
fines the context in which theoretical and methodological concepts are constructed, the-
ories and methods refer directly to the empirical world, while meta-theories refer to 
methods themselves (Overton 2007:154). The theoretical assumptions are deducted 
from the meta-theoretical assumptions and can be formulated into central statements or 
hypothesis which could be validated through research. The cognitive perspective of 
health behaviour was used in this study; this study draws from the Self-Efficacy Model 
and the Health Belief Model (HBM).  
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1.7.2 Theoretical framework 
 
Health behaviour theories provide ground for target interventions aimed at changing be-
haviour or establishing good health habits, and ways by which health behaviour can be 
modified to achieve the desired outcome is increasingly becoming the focus of research 
in medication adherence. The broad overarching theoretical framework behind this re-
search was aimed at explaining how HIV patients on ART conceptualize threats to their 
health (HIV/AIDS disease); how they conceptualize one specific solution to the health 
threat (treatment or medication use) and why actual medication use behaviour may or 
may not take place. There are several theories related to health behaviour that apply to 
an individual that could be used to describe and guide interventions related to cognitive 
factors and medication adherence in the HIV-infected persons. The cognitive perspec-
tive of health behaviour guided this study; theories that emphasize cognitive variables 
and processes were applied in understanding health behaviour among patients on ART.  
 
The meta-theoretical assumption of this research is based on the assumption that pos-
sessing a high level of self-efficacy towards ART adherence and positive beliefs about 
medicines increase the likelihood that an individual would be more motivated to actively 
achieve high adherence to ART and good clinical outcome. Two theories from the cog-
nitive perspective of health behaviour, the Self-Efficacy Model and the Health Belief 
Model (HBM) were used in this study. These two models were chosen for this study be-
cause they contain the cognitive variables under investigation in the current research.  
 
1.7.2.1 Self-Efficacy Model 
 
Self-efficacy, a concept articulated by Bandura postulates that although social cognitive 
theory acknowledges that knowledge of health risk and benefits of treatment are neces-
sary to perform health behaviour; these are not enough, additional self-influences are 
necessary to achieve changes that will result in the desired health behaviour (Bandura 
2004:145). Self-efficacy is an individual’s personal belief regarding their capabilities to 
carry out a specific task to achieve a desired outcome. Self-Efficacy Model begins with 
a perception of the existence of a problem followed by the belief that the desired result 
can be achieved with one’s actions, thus creating an incentive to persevere (Bandura 
2004:145). The Adherence Self-Efficacy Scale (ASES) is designed to measure self-
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efficacy for adherence to HIV treatment plans; this includes taking ART and other self 
care behaviour. 
 
1.7.2.2 Health belief model (HBM) 
 
HBM is a psychosocial approach to explaining health behaviour that deals with value 
expectancies related to health. The model was introduced by psychologists Rosenstock, 
Hockbaum, Leventhal and Kegeles in the 1950s and has been used widely by various 
researchers. It is a cognitive and interpersonal approach that view human as a rational 
being who behave in certain ways to minimize what they perceived as threat (e.g. dis-
ease symptoms) and enhance what are perceived as benefits (e.g. adherence to treat-
ment) (Bandura 2004:145). HBM postulates that health seeking behaviour is influenced 
by a person’s perceptions of threat posed by a health problem and the perceived bene-
fits of taking action to minimise such threat (Kagee 2008:420). Beliefs about Medicines, 
a construct that was developed from the elaboration of HBM by Horne et al (1999:1-24) 
describes a person’s beliefs about the potential costs and benefits of taking medicines. 
The Beliefs about Medicines Questionnaire (BMQ) that was developed as a measure to 
gauge patients’ beliefs about medicines, is used to score beliefs about medicines. 
 
 
Figure 1.1 Analytical representations of cognitive variables of adherence 
(Adapted from Horne 2006:71S) 
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As shown in Figure 1.1, ART adherence is influenced by self-efficacy, beliefs about 
medications, perceived severity of the disease and individual’s past experience. The 
cognitive perspective of health behaviour assisted the researcher to understand how 
HIV-infected patients on ART interpret and evaluate situations around them as well as 
their self-conception as to whether they will have self-efficacy in adhering to treatment. 
Prediction of medication adherence is very complex, and health-related knowledge and 
beliefs alone are insufficient to achieve behaviour change especially in chronic condition 
like HIV/AIDS. In this study, the researcher examined a theoretical framework encom-
passing health beliefs/attitudes, ART self-efficacy and demographic characteristics in 
relationship to antiretroviral therapy adherence. This research examined the relation-
ships between two individual factors (self-efficacy and beliefs about medicines) and the 
health behaviour (HIV medication adherence) in an attempt to identify the potential area 
for focused interventions that could be used in enhancing ART adherence. 
 
1.8 RESEARCH DESIGN AND METHOD 
 
1.8.1 Research paradigm 
 
Quantitative research involves collection of numerical data that can be subjected to sta-
tistical analysis which results in quantifiable information (Terre Blanche & Durrheim 
2008:7). According to Baum (1995:466), some public health issues need quantification 
while others are more qualitative in nature; methodologies for health research need to 
be diverse and chosen to suit the problem being investigated. The variables under in-
vestigation in this study consist of cognitive mechanisms that are quantifiable; the re-
searcher therefore adopted an objective and detached epistemological stance towards 
the study variables and followed positivist approach in undertaking this research.  
 
1.8.2 Research design 
 
A non-experimental quantitative research methodology was employed using descriptive 
correlational design. Correlational research is a measure of the association or co-
variation of two or more dependent variables and is used in exploring causal relation-
ships (Walker 2005:573). This research design was used to assess the predictive rela-
tionships of adherence self-efficacy, beliefs about medicines and ART adherence in 
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HIV-infected patients. The chosen research design is best suited for this research as it 
involves examining relationships among variables without introduction of any interven-
tion (Terre Blanche & Durrheim 2008:7).+-9 
 
1.8.3 Power of the study and sample size 
 
Power of a study is the ability of the study to demonstrate an association or causal rela-
tionship between two variables, given that an association exists. In quantitative research 
it is necessary to specify the desired study power and to calculate the sample size 
needed to achieve this power when planning the study to avoid conducting a study with 
insufficient power. Traditionally, researchers consider a study power of 80% to be the 
minimum, although higher values are commonly used (Harvey & Lang 2010:736). An 
exact binomial test with a nominal two-sided significance level will have 87% power to 
detect the difference between the Null hypothesis proportion π0 of 0.6 and the Alterna-
tive proportion πA of 0.7 when the sample size is 232 (Chernick & Liu 2002:149-155). 
The sample size for this study was 232 patients, which represented 10% of the study 
population.  
 
1.8.4 Population and sample selection  
 
The study population consisted of male and female, older than 18 years, of all races 
and socio-economic groups who were on ART at a large district hospital within the 
Tshwane Metropolitan area. This hospital is part of the Comprehensive Care, Manage-
ment and Treatment program of the Gauteng Department of Health. This area was se-
lected because it is an area where the researcher believes one can find the entire popu-
lation groups in South Africa representing a heterogeneous population. According to 
hospital records, there were 2312 adult patients on ART in the hospital at the time of 
this study (Antiretroviral Clinic Statistics 2011).  
 
Systematic random sampling method was employed in selecting 232 patients on ART at 
the study setting using the inclusion criteria of (a) 18 years and above, (b) Free of se-
vere opportunistic infections (c) No cognitive impairment as determined by the mini-
mental state examination (d) Ability to understand English or any of the South African 
official languages (e) Have been on ART for at least one year.  The file numbers of all 
the 2312 patients were listed in ascending order and every tenth person on the list was 
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selected to participate in the study until the desired sample size was reached. Where a 
selected respondent declined to participate in the study or ineligible the next person on 
the list was included. 
 
1.8.5 Data collection procedures 
 
Two research assistants were trained to assist in recruitment of study respondents and 
administration of questionnaires. In order to ensure consistency in data collection, role-
play was used to ensure standard procedures of obtaining informed consent, comple-
tion of questionnaires, and handling questions before or in the process of administration 
of the questionnaires. The research assistants were also informed of the need to re-
solve difficult issues with the principal investigator before or during the administration of 
the questionnaires. The questionnaires were written in English and the research assis-
tants were able to communicate effectively with respondents and clarify their queries. 
 
Patients on ART at the study setting were informed about the study and that they were 
all potential participants. The risk, benefits, time commitment and eligibility for the study 
were also explained. Informed consent was obtained from selected respondents and 
appointment fixed for the completion of the questionnaires. The study made use of 
questionnaires that were completed with the assistance of the researcher and his assis-
tants. Completions of the questionnaires were conducted in separate rooms and data 
were collected using four quantitative instruments combined into one (Annexure D). 
These are: the Demographic Data Questionnaire (developed by the researcher); The 
HIV Treatment Adherence Self-Efficacy Scales (HIV-ASES); the Beliefs about Medi-
cines Questionnaire (BMQ) and the AIDS Clinical Trial Group (ACTG) Questionnaire 
Adherence. Permission to use the ACTG and HIV-ASES is granted for HIV research 
purposes by the Center for AIDS Prevention Studies (CAPS) at University of California, 
San Francisco (Center for AIDS Prevention Studies 2011). The researcher obtained 
permission to use the BMQ from the copyright holder (Annexure F). 
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1.8.6 Content validity of the research instruments 
 
Content validity is based on the extent to which a measurement reflects the specific in-
tended domain of content; it focuses on the adequacy with which the domain of the 
characteristics is captured by the measure (Vogt, King & King 2004:232). To ensure that 
all the measures in this study represent the facets of the constructs under investigation, 
the following steps were taken by the researcher: 
 
 An extensive review of relevant literature on the constructs being investigated; 
this enabled the researcher to conceptually define the domains of the character-
istics i.e. specifying what the variables are and what they are not. 
 Ongoing refinement of definitions of the constructs being investigated. 
 Consultation with members of the target population to increase the chance that 
items are content valid for their intended purpose.  
 Consultation with subject matter experts in the field of this research for content 
validity of the instruments.  
 Development of the items for administration in survey form before actual data 
collection commences. 
 
1.8.7 Measurement of variables 
 
The variables measured in this study include demographic characteristics assessed by 
the demographic data questionnaire; the ability to carry out tasks that results in adher-
ence to ART was measured with the HIV adherence self-efficacy scale, the Beliefs 
about medicine questionnaire measured specific and general beliefs of patients on anti-
retroviral medicines and other medications used in chronic medical conditions. Finally, 
ART adherence was measured with the ACTG questionnaire. 
 
1.8.8 Data analysis 
 
The data collected were captured into Excel spreadsheet and analysed with the Statisti-
cal Package for Social Sciences (SPSS) version 19.0 manufactured by IBM.  Before 
data analysis each questionnaire was checked for completion by the research assis-
tants to ensure that they were answered correctly and subsequently scrutinized twice by 
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the researcher before the data was eventually entered into the Excel spreadsheet using 
double entry method, checked for errors, cleaned and then exported into the SPSS pro-
gramme for processing and analysis. The data that differed during double entry were 
cross-checked against the questionnaires concerned. Before data analysis each vari-
able was examined separately through various SPSS functions for accuracy of data en-
try, missing values, and fit between their distributions and the assumptions of multivari-
ate analysis. Accuracy of data entry was confirmed by checking univariate descriptive 
statistics for strange data such as values out of range, means, standard deviations and 
univariate outliers.  
 
Descriptive statistics including means, percentages and frequency distribution were 
used to summarize the demographic data, HIV-ASES, BMQ and ACTG questionnaire. 
Measures of variability were applied to characterize the differences that exist among the 
scores and the central tendency of the data. Pearson correlation analysis was used to 
assess the bivariate associations among the variables, and multivariable logistic regres-
sion was used to determine predictors of medication adherence. The significance of 
each independent variable as well as the combined significance of the independent 
variables to the dependent variable was explained by the variance observed in the de-
pendent variable. Variables that were included in the model are summary scores from 
the BMQ and HIV-ASES that are significantly associated with adherence as measured 
by ACTG questionnaire. 
 
1.8.9 Pilot study 
 
Pilot study assists researchers in identifying possible problems in the proposed study 
and allows for revision of the methods and instruments before data collection (Van der 
Riet & Durrheim 2008:94). The researcher carried out a pilot study at a separate clinic 
that was not included in the final study sample. The four instruments were tested among 
randomly selected 30 participants that had similar characteristics to the sample selected 
for this study for contents clarity before being administered to the selected sample. The 
respondents were asked to give constructive feedback with regard to clarity of the ques-
tions, comprehension and time necessary to answer all the questions in the question-
naire. The respondents did not experience difficulty in completing the questionnaires but 
made some valuable comments described below which were considered during the 
administration of the questionnaires to the 232 patients selected for this study.  
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The following were the comments made by the 30 participants who participated in the 
pilot study: 
 
Question 9 on the demographic data questionnaire: What is/are the most likely way(s) 
that you became infected with HIV? When asked about the modality of acquiring HIV 
infection, about half of the respondents indicated they did not know. This prompted the 
researcher to include an option “Don’t know” in the revised questionnaire. 
 
Question 14 on the demographic data questionnaire: What is the number of pills you 
swallow every day? Participants queried what the number of pills meant; as there were 
some participants who had co-morbidities e.g. asthma, diabetes, hypertension etc. who 
were also on ART. They wanted to know if they should add up all the ARVs and other 
pills. In the revised questionnaire the researcher specified the number of pills to mean 
ARVs only to avoid confusing the participants.  
 
Furthermore, the participants in the pilot study identified some similarity between ques-
tions 4 & 7 in the HIV-ASES questionnaire. Question 4 asked: ‘’How confident are you 
that you can stick to your treatment schedule even when your daily routine is dis-
rupted?’’ Question 7 asked: “How confident are you that you can continue with your 
treatment even if doing so interferes with your daily activities?” The researcher clarified 
the ambiguity noted here with the participants during the administration of the question-
naires to the 232 selected individuals. Sticking to treatment schedule mentioned in 
question 4 meant continuing taking medication as prescribed in terms of dosing, sched-
uling and dietary instructions. To continue with treatment mentioned in question 7 meant 
continuing taking medication without emphasizing sticking to dosing, scheduling and 
dietary instructions. 
 
Some participants indicated they did not know the meaning of T-cells in question 8, 
where participants were asked how confident they were in continuing with their treat-
ment plan prescribed by their physician even if their T-cell drops significantly in the next 
three months. The researcher changed T-cell to CD4 in the revised questionnaire that 
was eventually used in this study since all HIV-infected patients on ART know what CD4 
means; they are informed of it during the counselling process. 
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1.9 ETHICAL CONSIDERATIONS 
 
All the respondents gave consent to participate in the research; and completed study 
questionnaires after their clinic appointment to avoid inconveniences. They did not re-
ceive any monetary incentive and were informed that they could withdraw from the 
study at any time with no consequences. The author throughout the study observed 
strict confidentiality and anonymity. Identification numbers were used for the question-
naires that bear no link with respondents’ names or hospital numbers. Collected data 
were stored electronically and protected with password. The sample respondents were 
not identified in published or disseminated results. Name and phone numbers of the re-
searcher and his supervisor were provided in the event that any concerns regarding the 
research arise. Counselling services were readily available for any participant who de-
veloped emotional trauma as a result of participating in the study. Furthermore, ethical 
clearance was obtained from the Department of Health Studies Higher Degree Commit-
tee at UNISA and permission was sought from the management of the health institution 
where the study was carried before the study commenced. 
 
1.10 STRUCTURE OF THE THESIS 
This thesis is presented in five chapters and outlined as follows:  
 
Chapter 1: Orientation to the study  
 
This chapter provides the introduction and background information about the research 
problem, the statement of the research problem, aim of the study, the research purpose 
guiding the study and the objectives. In addition, the chapter also discussed the signifi-
cance of the study, definition of terms used, foundation of the study which include meta-
theoretical assumptions and theoretical framework. Finally, the research methodology 
and ethical considerations are also discussed in this chapter.  
 
Chapter 2: Literature review 
 
Includes the literature review on epidemiology of HIV/AIDS, clinical aspect of HIV and 
antiretroviral therapy, theories associated with adherence in chronic medical conditions, 
adherence in ART, factors associated with ART adherence, consequences of non-
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adherence in ART, adherence monitoring in ART and strategies and tools for enhancing 
adherence. The chapter concludes by highlighting some limitations of previous studies 
done on adherence to ART.  
 
Chapter 3: Methodology  
 
The chapter covers the methodological approach including aims and objectives of the 
study, research design, sampling and study population, Research instruments, data col-
lection technique, pilot study, internal and external validity of the study, reliability of re-
search instruments, data management, procedure for data analysis and ethical consid-
eration for the study.  
 
Chapter 4: Analysis, presentation and description of the research findings  
 
The chapter describes the results of the study findings including the descriptive and an-
alytical statistics conducted.  
 
Chapter 5: Discussion, conclusions and recommendations 
 
Chapter 5 includes the discussion of the study findings, conclusion of the study and 
gives recommendation and future directions for research.  
 
1.11 CONCLUSION 
 
Antiretroviral therapy results in viral suppression, improved immune function and delay 
disease progression in HIV/AIDS patients. However, this treatment is indefinite and 
achieving high level of adherence is difficult. Various studies conducted in developed 
nations have identified some cognitive correlates and predictors of adherence to ART, 
but few studies have been conducted among people living in sub-Saharan Africa, where 
over two-thirds of people living with HIV reside and particularly in South Africa with the 
largest ART program worldwide. 
 
This study aimed to explore the cognitive correlates of adherence to ART in people liv-
ing with HIV in South Africa. The research examined the relationship between ART ad-
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herence self-efficacy, beliefs about medicines and adherence to ART. The meta-
theoretical assumption of this study is based on the assumption that an individual living 
with HIV may adhere to ART because of the beliefs they have about medications and 
personal belief regarding their capabilities to carry out specific tasks in adhering to med-
ications. 
 
The confidence in a person’s ability to carry out specific task in adhering to medications 
may depend on his or her beliefs about the medications. The researcher investigated 
whether beliefs about medicines correlates with adherence to ART among people living 
with HIV, whether beliefs about medicines correlates with ART adherence self-efficacy, 
and whether ART adherence self-efficacy correlates with adherence to ART and deter-
mine whether ART adherence self-efficacy mediates the relation between beliefs about 
medicines and adherence to ART.  
 
Achieving high levels of adherence is difficult in chronic medical conditions; identifying 
the predictive relationships of the study variables has enhanced our understanding of 
cognitive factors associated with the management of HIV/AIDS, which is a good source 
for focused intervention in enhancing ART adherence.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
Literature review identifies gaps in knowledge on the topic which is being researched 
and serves as the foundation on which the new knowledge generated in research activ-
ity is based. According to Kaniki (2008:19), a research project cannot exist in isolation; it 
has to be done within the context of prior knowledge. In other words, literature review 
puts the research into context, provides the readership with the necessary background 
information that would allow for proper understanding and comprehension of the topic 
under investigation.  
 
An extensive search of the literature for previous studies was conducted using data-
bases such as ProQuest, PubMed, MEDLINE, NiPAD, SocINDEX and PsycINFO as 
well as Google Scholar search engine using keywords such as self-efficacy, antiretrovi-
ral therapy adherence and beliefs about medications. In addition, a thorough literature 
review of other relevant journals, books, articles, research reports, policy documents 
and other information sources was done to identify available knowledge on ART adher-
ence and cognitive variables associated with adherence. 
 
The following areas are covered in the literature review: theoretical framework of the re-
search, epidemiology of HIV/AIDS, clinical aspect of HIV and antiretroviral therapy, the-
ories associated with adherence in chronic medical conditions, adherence in ART, fac-
tors associated with ART adherence, consequences of non-adherence in ART, adher-
ence monitoring in ART, and strategies and tools for enhancing adherence. 
 
2.2 THEORETICAL FRAMEWORK  
 
2.2.1 Cognitive perspective of health behaviour 
 
Health behaviour theories provide ground for target interventions aimed at changing be-
haviour or establishing good health habits (Horne 2006:71S), and ways by which health 
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behaviour can be modified to achieve desired outcome is increasingly becoming the fo-
cus of research in medication adherence. The broad overarching theoretical framework 
behind this research was aimed at explaining how HIV patients on ART conceptualize 
threats to their health (HIV/AIDS disease); how they conceptualize one specific solution 
to the health threat (treatment or medication use) and why actual medication use behav-
ior may or may not take place. There are several theories related to health behavior that 
apply to an individual that could be used to describe and guide interventions related to 
cognitive factors and medication adherence in the HIV-infected persons. The cognitive 
perspective of health behaviour guided this study; theories that emphasize cognitive 
variables and processes were applied in understanding health behaviour among pa-
tients on ART. 
 
Cognitive perspective of health behaviour focuses attention on ways in which patients 
conceptualize health threats and appraise factors that facilitate adherence or serve as 
barriers (Sabate 2003:140). Although this perspective has been criticized for not ade-
quately addressing the issue of behavioural skills needed for adherence among patients 
and for paying little attention to the origin of beliefs and how such beliefs influence other 
behaviours (Munro et al 2007:104), the cognitive perspective of health behaviour pro-
vides a good theoretical framework for organizing thoughts about adherence and other 
health behaviours in patients on lifelong ART. The theoretical framework for this re-
search is based on two theories from the cognitive perspective of health behaviour, 
which are the Self-Efficacy Model (SEM) and the Health Belief Model (HBM). 
 
2.2.1.1 Self-Efficacy Model 
 
Self-efficacy is an individual’s personal belief regarding their capabilities to carry out a 
specific task to achieve a desired outcome. However, such behaviours are likely to be 
carried out by the patient if the patient believes he can perform such, meaning that self-
efficacy is required for a person to perform a behaviour that is expected to result in a 
desired outcome. The Self-Efficacy Model begins with a perception of the existence of a 
problem followed by the belief that the desired result can be achieved with one’s ac-
tions, thus creating an incentive to persevere (Bandura 2004:145). 
 
Bandura's Self-Efficacy Model is defined by constructs such as: self-efficacy, outcome 
expectation, self-care behavior and outcome. The Self-Efficacy Model provides a 
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framework for predicting self-efficacy and self-care behaviors for a given task. Behav-
iour change is said to occur as a result of the person's belief about how capable one is 
of performing the behavior leading to the desired outcome. HIV-infected patients on 
ART will choose to adhere to their medication if they believe that doing so will result in 
getting better and living quality life. Self-care behavioral skills in persons with HIV/AIDS 
can be a major challenge as it requires high level of self-efficacy (Saberi & Johnson 
2011:6); self-care, defined as the daily regimen tasks that an individual performs to 
manage HIV/AIDS is not limited to taking pills; it involves behaviors such as sticking to 
healthy diet, regular exercise, avoidance of risky behaviour and medication adherence.  
 
Self-efficacy is a known predictor of a wide range of health behaviour of patients on 
chronic medication including medication adherence (Kott 2008:60; Ogedegbe, 
Mancuso, Allegrante & Charlson 2003:523; Sleath, Blalock, Robin, Hartnett, Covert, 
DeVellis & Giangiacomo 2010:628; Zebracki & Drotar 2004:142; Hewlett et al 
2001:1228), and has also been shown to influence adherence to ART (Johnson, 
Neilands, Dilworth, Morin, Remien & Chesney 2007:367; Rudy, Murphy, Harris, Muenz 
& Ellen 2009:188). In this study, it is conceptualized that self-efficacy in ART can be de-
picted as an individual’s ability to continue taking ARV despite the various challenges 
that could be encountered in doing so. 
 
2.2.1.2 Beliefs about medicines 
 
The Health Belief Model (HBM) has been used in explaining variation in adherence to 
treatment in chronic medical conditions. Researchers have postulated that beliefs about 
medicines which is a component of the HBM is an important factor influencing medica-
tion use behaviour (Horne et al 1999:20). The Model postulates four key elements that 
determine a patient’s adherence to treatment: firstly, the threat of the illness (perceived 
severity and susceptibility); secondly, positive outcome expectancy (perceived benefits 
from treatment); thirdly, barriers to using the treatment (e.g. expected disadvantages of 
treatment); and fourthly, intent (intention to adhere to the treatment regimen) (Kagee 
2008:420). According to self-regulatory theory, patients’ treatment perceptions and ill-
ness representations influence medication adherence (Reynolds 2003:117-124). There-
fore, patients on chronic treatment often undertake a cost-benefit analysis, considering 
whether their beliefs about the necessity of medications for maintaining health outweigh 
their concerns about the potential adverse effects of taking them (Lennerling & Forsberg 
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2012:44; Gonzalez, Penedo, Llabre, Duran, Antoni, Schneiderman & Horne 2007:51). 
This perspective led to the development of the Beliefs about Medicines Questionnaire 
(BMQ) by Horne et al (1999) who reason that a separate, specific measure to gauge 
patients’ beliefs about medicines would add to the explanatory power of the HBM. The 
authors argue that an enhanced understanding of patient’s beliefs about their medica-
tions could inform the development of interventions to improve adherence and optimize 
the benefits they derive from such medicines (Horne et al 1999:20). 
 
The use of medication is strongly influenced by patient’s perception on the benefits of 
taking such medication (Redding et al 2000:183; Gauchet, Tarquinio & Fischer 
2007:145). One could easily assume that positive or negative medication beliefs would 
influence medication use behaviour, but variables such as medication cost and the level 
of patient trust in the prescriber may also influence non-adherence in persons with fa-
vourable attitudes towards their medications (Gauchet et al 2007:145). Patients often 
conceptualize the use of medication as necessary to achieve specific health goal. In this 
research, the perceived health benefits of medication use are operationally defined as 
the perceived necessity of medication for the target condition; the target condition is HIV 
disease. The perceived necessity of medication is also driven by interaction of two vari-
ables in patients namely; the perception that they are susceptible to the target condition 
and the perceived severity of the condition should it occur (Munro et al 2007:104). Each 
of the two variables is considered to be necessary but insufficient for an individual to 
perceive that a medication is necessary for their health, and hence the model postulates 
that the interaction between these two rather than their main effects will be associated 
with the necessity for adhering to ART by patients. 
 
Health belief model also postulates perceived effectiveness of the medication to treat 
the target condition as a predictor of medication use behaviour (Munro et al 2007:104; 
Kagee 2008:420). Perceived necessity for medication is also influenced by concerns 
about the long-term safety of and dependence upon medications; patients’ concerns 
about medications are often generalized, thinking that all medications have some form 
of negative qualities which is also true of ART (Liu-Seifert et al 2007:12; Guimarães et 
al 2008:167; Menezes de Pádua et al 2007:23). Various studies across a range of 
chronic medical conditions have identified similarities in beliefs that influence medication 
adherence; these studies have found low rates of adherence to be consistently related 
to doubts about personal need for medications (Neame & Hammond 2005:764; Porte-
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ous, Francis, Bond & Hannaford 2010:228; Ireland & Wilsher 2010:39). Given that per-
ceived need for ART includes the beliefs that use of a medication is necessary to main-
tain or improve one’s health, concerns about the long-term harm of medications logically 
have a negative association with those beliefs (Gauchet et al 2007:145). 
 
Cognitive intervention in ART is aimed at changing the patient’s behaviour and attitudes 
through assisting the individual in changing unrealistic expectations or behaviour 
through education to learn how to do things in a new or different ways. People can con-
trol or influence the events that affect their lives by integrating cognitive, social, and be-
havioural sub-skills related to beliefs of personal efficacy in performing these skills 
(Bandura 2004:144). Cognitive perspective of health behaviour focuses on effective 
self-management behaviour of health habits that keep people healthy for the rest of 
their life (Bandura 2004:151). HIV-infected patients need to have confidence in their 
ability to perform the required self-management activities (self-efficacy) and hold posi-
tive beliefs about their medications. They must believe that exhibiting self-care behav-
iour and holding the right beliefs about their medications lead to good clinical outcomes 
which translate to quality health. This research is based on the assumptions that pos-
sessing a high level of self-efficacy towards ART adherence and positive beliefs about 
medicines will increase the likelihood that an individual would be more motivated to ac-
tively achieve high adherence to ART and good clinical outcome.  
 
Prediction of medication adherence is very complex, and health-related knowledge and 
beliefs alone are insufficient to achieve behaviour change especially in chronic condition 
like HIV/AIDS. The cognitive perspective of health behaviour assisted the researcher to 
understand how HIV-infected patients on ART interpret and evaluate situations around 
them as well as their self-conception as to whether they will have self-efficacy in adher-
ing to treatment. In this study, the researcher examined a theoretical framework encom-
passing health beliefs/attitudes, ART self-efficacy and demographic characteristics in 
relationship to antiretroviral therapy adherence as shown in Figure 2.1 below.  
 
This research examined the relationships between two individual factors (self-efficacy 
and beliefs about medicines) and the health behaviour (HIV medication adherence) in 
an attempt to identify the potential area for focused interventions that could be used in 
developing a framework for enhancing ART adherence.  
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Figure 2.1 Theoretical framework: ART adherence is influenced by self-efficacy, be-
liefs about medications, perceived severity of the disease and individual’s past experi-
ence 
(Adapted from Horne 2006:71S) 
 
 
2.3 EPIDEMIOLOGY OF HIV/AIDS 
 
The HIV and AIDS have become the most challenging public health concern of this 
generation especially in sub-Saharan Africa that is saddled with over two-thirds of the 
global HIV/AIDS caseload despite having limited resources (UNAIDS 2010). At present, 
an estimated 35 million people are living with HIV/AIDS worldwide of which 31 million 
are adults, 16 million women, and over 2.5 million are children. The estimated number 
of AIDS-related deaths was around 2 million in year 2009 alone. In Sub-Saharan Africa, 
an estimated 22.5 million people live with HIV/AIDS, and since 1981 when the first case 
of AIDS was discovered, over 60 million people have been infected with HIV and close 
to 25 million people have died of AIDS-related complications (UNAIDS 2010). 
 
Most sub-Saharan African countries including South Africa have reported decline or 
stabilization in the rate of new infections but according to recent statistics, about 5.7 mil-
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lion South Africans are living with HIV (UNAIDS 2010), which makes South Africa epi-
demic the highest globally. AIDS-related death is nearly 450,000 annually in South Afri-
ca and the number of AIDS orphans in the country is over 1.9 million (StatSA 2009; 
WHO/UNAIDS 2009). There is no doubt that HIV/AIDS places huge economic burden 
on the government of South Africa considering the cost of HIV Counselling and Testing 
(HCT) services, antiretroviral therapy, treatment of opportunistic infections associated 
with HIV, loss of manpower and the enormous human resources involved in the provi-
sion of HIV/AIDS services. Therefore, reduction in the prevalence of HIV/AIDS, the rate 
of new infection and comprehensive management of the present caseload of the dis-
ease are global priorities that are particularly relevant to South Africa (Sawers & 
Stillwaggon 2010:216-217). 
 
Key drivers of the HIV epidemic in sub-Saharan Africa include multiple and concurrent 
sexual partners, intergenerational sex, commercial and transactional sex, sero-
discordant couples, low rates of male circumcision, lack of consistent condom use, high 
rate of sexually transmitted infections, especially genital herpes and high level of alcohol 
abuse (Simon, Ho & Abdool Karim 2006:490). Effective HIV prevention is therefore a 
major strategy to reverse the continued global spread of the disease and to safeguard a 
sustainable response to the enormous growing needs for HIV/AIDS care and treatment.  
 
2.4 CLINICAL ASPECT OF HIV 
  
2.4.1 Pathogenesis of HIV 
 
The HIV is a retrovirus of the lentiviruses family; infections with lentiviruses are often 
characterized by a long period of clinical latency, persistent viral replication and follow a 
chronic course of disease (Rubbert, Behrens & Ostrowski 2007:60). HIV comprises of 
two species namely HIV-1 and HIV-2 which originated as zoonotic infection from pri-
mate hosts that harbour certain lentiviruses called the simian immune-deficiency virus 
(SIV). This virus is sexually transmitted among primates but does not result in frank im-
munodeficiency despite lifelong infection and levels of viraemia that exceed those in 
HIV-infected human subject (Kaur & Johnson 2003:80). HIV-1 originated from Central 
Africa from chimpanzee lentivirus and HIV-2 from monkey, it is assumed that human 
beings became infected during the slaughtering of these animals for the consumption of 
their meat (Volberding & Deeks 2010:49; Rubbert et al 2007:60). 
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HIV-1 was first isolated in 1983 (Barre-Sinoussi, Chermann, Rey et al 1983:870); it is 
found worldwide and is made of four groups the M (major), N (non-M, non-O), O (out-
liers) and P. Most of the HIV-1 infections are caused by the M type which is further sub-
divided into 10 subtypes A to J. The subtype-C is the commonest HIV-1 in Central and 
Southern Africa regions and in the Western Europe and America the subtype-B is the 
commonest (Volberding & Deeks 2010:50). HIV-2 on the other hand was isolated in 
1986, is made of subtypes A to E, mostly confined to West Africa and is mainly acquired 
through heterosexual intercourse (Clavel, Guetard, Brun-Vezinet et al 1986:344). Under 
the electron microscope HIV-1 and HIV-2 look similar, the differences are in the molecu-
lar weight of their proteins and their accessory genes. Although actual immune defi-
ciency may be less severe in HIV-2, both HIV-1 and HIV-2 replicate using the CD4 T 
cells (Rubbert et al 2007:60). 
 
The diameter of an HIV-1 viral particle is about 100nm and is made up of two copies of 
the single-stranded RNA viral genome packed inside a protein core, this protein core 
comprises of the structural proteins namely; p24 (capsid), p17 (matrix), p7 
(nucleocapsid) and the p55 (Gag-Pol precursor protein). The viral particle is also made 
up of the polymerase proteins which are p66/p51 (reverse transcriptase), p11 (protease) 
and the p31 (endonuclease/integrase) used in the early stage of the virus life during 
replication (Greenberg & Cammack, 2004). A lipid envelope surrounds the HIV capsid, 
this envelope is derived from the cell that has been infected by the virus and contains 
the gp120 (outer glycoproteins), gp41 (transmembrane glycoproteins) and the gp160 
(precursor glycoproteins) (Wilson et al 2007:51:19). 
 
The cells that express CD4 receptor are the ones that are usually infected by HIV alt-
hough some cells like neurons that do not express CD4 may also be infected by HIV 
(Wilkins 2011:387-389). Cells that express CD4 that are targets of HIV include T-helper 
cells and other white blood cell like monocytes and macrophages; glial cells in the cen-
tral nervous system; Langerhans cells in skin and mucous membrane and the 
chromaffin cells in the intestine. In addition to the CD4 receptor, certain human cell sur-
face proteins are necessary for HIV entry into the human body. These proteins are 
called co-receptors and two of them have been identified for HIV-1 to be fused to its tar-
get cell. The first is CCR-5, a chemokine receptor which is expressed by monocytes and 
lymphocytes and mediates the entry of syncytium-inducing (NSI) monocytotropic strains 
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of the HIV-1 (Greenberg & Cammack 2004:334). The second chemokine receptor is 
CXCR-4 which is expressed on T-lymphocytes and mediates the entry of syncytium-
inducing T-cell tropic strains of HIV-1. This means that monocytotropic strains of HIV 
can infect both monocytes and primary lymphocytes which express CCR-5 but cannot 
infect T-cell which lack CCR-5. Conversely the T-cell tropic strains of HIV-1 cannot in-
fect monocytes which lack the CXCR-4 (Wilkins 2011:388). 
 
2.4.1.1 The life cycle of human immuno-deficiency virus 
 
The virus binds to the T-Helper cells with the aid of two proteins; these are the gp120 on 
the surface of the HIV itself and the CD4 on the surface of the T-Helper cells (Rubbert 
et al 2007:60). Thereafter the virus fuses with the plasma membrane of the T-Helper 
cell and releases its genetic material a single stranded RNA into the host. Once the viral 
RNA is released into the cytoplasm of T-helper the viral reverse transcriptase enzyme 
uses it to produce a single complementary strand of DNA using the nucleotides from the 
host cell. The single-stranded virally encoded DNA acts as a template for the production 
of a complementary DNA strand, forming a double stranded DNA molecule which then 
migrates into the nucleus of the host and incorporates into the genome of the host with 
the aid of the enzyme integrase, this incorporated virus is called the provirus. The virus 
at this stage is not infectious and can be latent for several months, which is the reason 
why antibodies are not produced immediately after infection since the immune system 
has to wait for macrophages to present the viral antigens for it to start producing anti-
bodies (Greenberg & Cammack 2004:334). 
 
The latter stage of the cycle includes the transcription of the DNA provirus into RNA 
which are divided into two parts; the mRNA which is used as template for translation of 
viral proteins and the viral RNA which forms the viral genetic material (Wilson, Naidoo, 
Bekker, Cotton & Maartens 2007:20; Boyd & Pett 2008:66). An HIV enzyme called pro-
tease cleaves p24, p17, p9 and p7 gag proteins. New viruses then bud from the cell and 
each may then go to infect and destroy other T-cells weakening the immune system of 
the host (Wilson et al 2007:21). 
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2.4.1.2 The natural history of HIV infection 
 
Immediately following infection, the acute viral syndrome of primary HIV infection fol-
lows; this is the interval between infection and development of antibody response by the 
host. The virus titre rises and the patient experience a flu-like symptoms often charac-
terized by fever, rash and swollen glands. These usually appear within days or weeks 
following infection although not all patients exhibit these mononucleosis symptoms 
(Volberding & Deeks 2010:50) 
 
 
Figure 2.2 Natural history of HIV infection  
(Kamps & Hoffman 2007:25) 
 
There is an initial fall in the number of CD4 cell and a minimal rise in the CD8 cells, this 
number quickly return to normal shortly thereafter. A strong defence against the virus is 
mounted by both cytotoxic B and T lymphocytes and this greatly reduces the amount of 
virus in circulation (Wilkins 2011:387-389). Over 10 billion new viral particles are pro-
duced daily at this stage and they are cleared rapidly from the blood stream. Most of the 
viruses produced at this stage are from recently infected proliferating CD4 cells, these 
infected cells are destroyed by either the immune system or the virus itself. At this stage 
the rate of CD4 production can still compensate for the loss of cells. This is the most in-
fectious phase of the HIV disease and most individuals exposed to HIV will seroconvert 
within one to four weeks (Wilkins 2011:387-389). 
 
Following acute infection a state of equilibrium may be reached between host immune 
system and viral replication and the patient may not show any clinical symptoms for 
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years. This clinical latency stage though devoid of symptoms, viral replication and CD4 
destruction in the host continues (Wilkins 2011:387-389). The immune response of the 
cytotoxic B and T lymphocytes clears the virus from the blood but it persists in lymph 
nodes especially in association with dendritic cells. Because CD4 T helper cells are the 
target of HIV, the immune system will fail to control the infection. In addition, the dendrit-
ic cells are supposed to present antigen to CD4 cell; in doing this they bring the virus 
(antigen) into contact with the CD4 cells thereby further destroying the CD4 cells (Wil-
kins 2011:387-389). 
 
The cytotoxic T CD8 and the virus continue to destroy the T cells and the T cells also 
decline through apoptosis. This results in fall in CD4 cell, rise in viral load and decline in 
immune system activity. This loss in immune activity enables benign organisms such as 
the fungi and protozoa to cause diseases. At the stage the CD4 is usually below 200 
cells/cm and mortality is high if patients are not commenced on ART. The CD4 cells de-
cline as a result of direct or indirect destruction of CD4 cells in the peripheral immune 
system (Napolitano 2003:160). After many of the T-Helper cells have been destroyed, 
the immune system of the host would have been weakened to the point of developing 
opportunistic infections and is therefore said to have acquired immune-deficiency syn-
drome (AIDS). The CD4 cell count is therefore often used as a prognostic factor or in 
determining when to initiate treatment, as it gives the extent of damage to the immune 
system of the patient (Wilson et al 2007:51). 
 
2.4.1.3 Modes of HIV transmission 
 
Unprotected heterosexual intercourse has been described as the major route of HIV 
transmission worldwide and is closely followed by homosexual intercourse (UNAIDS 
2010). The risk of acquisition of HIV from an infected person varies and some other fac-
tors affect the transmission of HIV through heterosexual intercourse, some of the factors 
include STIs, viral load of source patient, male circumcision (Wilkins 2011:387). The risk 
of HIV transmission also increases in cases of multiple concurrent sexual partners and 
as proportion of unprotected sexual acts increases (UNAIDS 2010; Wilson et al 
2007:62).  
 
High rates of HIV infection have been reported among men who have sex with men 
(MSM) in all regions of the world (Ndiaye et al 2009:250; Baral, Sifakis, Cleghorn & 
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Beyrer 2007:1905). A systematic review of data from 38 low and middle income coun-
tries found that MSM are 19 times more likely to have HIV than the general population 
(Baral et al 2007:1905). Receptive anal intercourse carries the highest risk of HIV infec-
tion and the presence of STI also increase the risk. Most HIV-1 infections contacted 
through sexual intercourse result from exposure to virus in semen, what remains un-
clear is whether transmitted strains originate as RNA virions in seminal plasma or as 
integrated proviral DNA in infected seminal leukocytes. A recent study done among six 
transmitting pairs of men who have sex with men showed that virus found free in semi-
nal plasma of the transmitting partner consistently bore the closest resemblance to the 
virus found in the newly infected individual. The authors acknowledge that these results 
provide the most compelling experimental confirmation that cell-free HIV RNA in semi-
nal plasma, and not cell-associated HIV DNA in seminal cells, is the origin of sexually 
transmitted virus between MSM (Butler et al 2010:18) 
 
Injection drug use also carries a high risk for HIV transmission, about 3 million of the es-
timated 13-16 million injection drug users (IDU) population worldwide are living with 
HIV/AIDS (Mathers et al 2008:1742; Aceijas et al 2004:2296). It is estimated that be-
tween 5-10% (2-4 million cases) of all HIV infections globally are attributable to injection 
drug use (Mathers et al 2008:1739). There is wide variation in the incidence of HIV 
transmission among injecting drug users (IDU) worldwide, Eastern Europe, East and 
South East Asia and Latin America  have the largest estimated populations (40%) of in-
jecting drug users who are HIV positive (Mathers et al 2008:1742). About 10% of new 
HIV infection in Africa, Southeast Asia and the Caribbean occur in children, an estimat-
ed 370,000 new HIV infections in children was reported in 2009 and about 90% of these 
HIV infections were acquired in-utero, during delivery or through breastfeeding 
(UNAIDS 2010). 
 
2.4.2 Prevention 
 
2.4.2.1 Sexual transmission 
 
This involves activities to promote abstinence, including delay of sexual activity or sec-
ondary abstinence, fidelity, reducing multiple and concurrent partners, and related social 
and community norms that impact these behaviours. According to Kennedy, Medley, 
Sweat and O’Reilly (2010:620), these activities should provide individuals being target-
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ed with the relevant motivation and skills needed to adopt safer behaviors rather than 
solely focusing on improving knowledge or awareness of HIV. Provision of both male 
and female condoms made available widely through health facilities, social marketing 
and retail outlets with emphasis on consistent and correct use has been shown to re-
duce HIV transmission (Kennedy et al 2010:620). 
 
Research has shown that sex workers experience higher rates of HIV infection than 
most other population groups, however, worldwide less than 50% of sex workers have 
access to a package of prevention services (Bertozzi, Laga, Bautista-Arredondo & 
Coutinho 2008:831-844; UNAIDS 2009). Even where services are theoretically avail-
able, sex workers face substantial obstacles to accessing HIV prevention, treatment 
care and support, particularly where sex work is criminalized. Therefore, an effective 
preventive strategy addressing sexual workers has been described as highly necessary 
to curb the spread of HIV by this high-risk group (UNAIDS 2009). 
 
Medical male circumcision (MMC), the surgical removal of the penis foreskin is an effec-
tive intervention to reduce the risk of male heterosexually acquired HIV infection. Al-
ready three randomized control trials have indicated that MMC in adult reduces men‘s 
risk of HIV acquisition by at least 60%, a potential protective effect equivalent to a vac-
cine (Auvert et al 2005:11; Bailey, Moses, Parker et al 2007:651; Gray, Kigozi, Ser-
wadda et al 2007:664). In addition, observational studies indicate that MMC may be 
even more protective among Most at Risk Persons (MARPs) engaging in sex with 
women (Auvert et al 2005:11). Based on modelling studies done on MMC, it has been 
predicted that the benefits of the procedure are likely to be significant in populations 
with high HIV prevalence and low MMC uptake, with one HIV infection averted for every 
five to fifteen MMC performed (UNAIDS 2007; UNAIDS 2009). Although the ultimate ef-
fect may only be apparent in ten to twenty years from now; as HIV prevalence de-
creases among circumcised men, there is an indirect protective effect against HIV for 
women, women‘s uncircumcised male sexual partners, and ultimately the whole popula-
tion (UNAIDS 2009).  
 
The Pre-exposure Prophylaxis Initiative (iPrEx) study on oral pre-exposure prophylaxis 
(PrEP) for HIV prevention among MSM using oral co-formulated emtricitabine 200 
mg/tenofovir 300 mg (truvada) or placebo found that a daily dose of oral truvada re-
duced HIV infection risk among men and transgender women who have sex with men 
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(MSM) by an average of 43.8% (Grant, Lama et al 2010:2597). Although the research 
findings are promising in the prevention of HIV, the authors cautioned that their data on 
the biological activity of the PrEP drug has to be confirmed through further studies. 
 
Microbicides are being tried as a protective measure for HIV transmission especially for 
use by women. Microbicides are medical products that can be applied vaginally to pre-
vent sexual transmission of HIV; it could be in forms of gels or tablets. Although 
microbicides have shown promising results, more research is still needed before it can 
be made available as a means of HIV prevention. Tenofovir gel, one of such 
microbicides that have been researched has shown new dimension in preventing HIV 
infection and could help empower women to take control of their own risk of HIV infec-
tion, it demonstrated overall protection of 39% among women and increased to 54% in 
women that used the gel consistently (Abdool Karim et al 2010:1171).  
 
Some researchers have even proposed highly active antiretroviral treatment (HAART) 
to be used as a form of prevention for HIV transmission since research has shown that 
transmission is very low at viral load less than 400copies/ml (Simoni et al 2006:S30). In 
a mathematical modelling by Granich et al (2010:1) they predicted that if adults are 
started on treatment immediately irrespective of CD4 count, the incidence and mortality 
of HIV would be reduced to less than one case per 1000 people within ten years, alt-
hough the authors acknowledge that the cost; ethical and human rights consequences 
make this option a distant choice in most developing nations for now (Granich et al 
2010:1). 
 
2.4.2.2 Prevention for Injecting and non-injecting drug users 
 
The use of illicit drugs promotes behaviours that increase the risk for HIV infection. The 
nature of the drug being abused, its quantity as well as the route of administration is im-
portant in determining drug use that promotes high risk behaviors for HIV infection (Kerr 
et al 2005:546). People who inject drugs are at risk for acquiring and transmitting HIV 
through high-risk sexual behaviours, including but not limited to unprotected sex and 
engaging in sexual behaviours under the influence of drugs or in exchange for drugs. 
Substance abuse treatment has been shown to reduce the frequency of drug use which 
in turn reduces HIV risk behaviours, it also improves adherence to treatment regimens 
of disease condition (Xing, Sun, Cao et al 2012:758). Methadone maintenance therapy 
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(MMT) is associated with reduced HIV risk behaviours including reduced frequency of 
injecting and sharing of injection equipment, reductions in the number of sex partners, 
and exchanges of sex for drugs or money (Xing, Sun, Cao et al 2012:758; Zaric, 
Brandeau & Barnett 2000:1022:Tran, Ohinmaa, Duong, Do, Nguyen, Mills, Houston & 
Jacobs 2012:286). 
 
2.4.2.3 Prevention of mother-to-child transmission (PMTCT)  
 
An estimated 25% of HIV-infected mothers will infect their babies if no intervention were 
made (Coovadia 2009:319), but with the introduction of ART to prevent mother to child 
transmission, the risk in-utero and during delivery has been drastically reduced (Kilewo 
et al 2009:400), the main concern in resource-limited settings at present is the high risk 
of postnatal transmission of HIV in the infant (Wilfert & Fowler 2007). Although infant 
feeding options have shown promising results in the reduction of mother to child trans-
mission (Nduati, John, Mbori-Ngacha, Richardson, Overbaugh, Mwatha, Ndinya-Achola, 
Bwayo, Onyango 2000:1171), higher infant mortality have been reported among infants 
who were formula fed compared to breastfed infants. In a Botswana study, infant mor-
tality at 7 months was significantly higher for the formula fed group than for the breast-
fed plus zidovudine group (9.3% vs 4.9%). This demonstrates the risk of infant formula 
in sub-Saharan Africa with widespread unsafe practices in preparation of the infant for-
mula (Thior, Lockman, Smeaton, Shapiro, Wester, Heymann, Gilbert, Stevens, Peter, 
Kim, Van Widenfelt, Moffat, Ndase, Arimi, Kebaabetswe, Mazonde, Makhema, McIn-
tosh, Novitsky, Lee, Marlink, Lagakos, Essex & the Mashi Study Team 2006:798). 
 
Recently the use of extended prophylaxis with nevirapine or with nevirapine and 
zidovudine for the first 4-6 weeks of life in HIV-exposed infants have been advocated as 
research has shown that it significantly reduces postnatal transmission of HIV infection 
(WHO 2012; Kumwenda, Hoover, Mofenson et al 2008:122). Experts have advocated 
for the use of HAART among HIV-infected pregnant women and this is also recom-
mended by South African national guidelines on ART (NDOH 2010b). 
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2.5 ANTIRETROVIRAL THERAPY 
 
Antiretrovirals (ARV) are drugs used in the treatment of HIV/AIDS, the mechanism of 
actions of the drugs are based on the life cycle of the virus. Therefore, ARV is meant to 
interrupt the life cycle of HIV; and it does so at different points to reduce the replication 
of the virus. ARVs were introduced in early 1980 when a nucleoside reverse transcrip-
tase inhibitor (NRTI) called zidovudine was introduced as a mono-therapy with very little 
benefit as viral replication was minimally suppressed and resistance was quick to de-
velop (Clumeck & De Wit 2000:8). The development of more drugs in the same class 
with zidovudine in early 1990s made dual therapy available but this also failed to sup-
press viral replication effectively. The introduction of non-nucleoside reverse transcrip-
tase inhibitors (NNRTI) and protease inhibitors (PIs) in mid 1990s allowed for the com-
bination of ARV of different classes which effectively suppressed viral replication result-
ing in reduction of morbidity and mortality associated with HIV/AIDS (Clumeck & De Wit 
2000:9). 
 
2.5.1 Goals of antiretroviral therapy 
 
The main objective of antiretrovirals is to decrease the plasma HIV RNA and maintain it 
below the limit of detection, viral level < 400 copies/ml is arbitrarily assumed to be a 
point at which viral level is below detection (Clumeck & De Wit 2000:7) although low 
level of viral replication has been documented in people with HIV RNA levels between 
50-500 copies/ml (Gross et al 2001:2113). The suppression of viral replication achieved 
by ART reduces the destruction of CD4 cells and damage to the immune system which 
in turn slows down the progression of the disease. This effect is shown in the rising CD4 
cells and reduction in the viral load. In addition, there is restoration or preservation of 
immunologic function, improved quality of life and reduced HIV-related morbidity and 
mortality (Severe et al 2010:261). 
 
2.5.2 Challenges of taking antiretroviral  
 
Research has documented that using multi-therapies of ART regimens have significant-
ly improved quality of lives of HIV patients and improved survival (Reddi, Leeper, 
Grobler et al 2007:13; Wool-Kaloustian et al 2006:43). However, high levels of adher-
ence are very important for this to be realized. The ART regimen is so complex; it con-
 
38 
sists of 3 or more drugs that have to be taken in combination. In addition, it involves tim-
ing of the medication intake, dietary and fluid restrictions all which influence medication 
adherence (Curioso, Kepka, Cabello, Segura & Kurth 2010:13).  
 
The pill burden is a major challenge for patients taking ART as some of these patients 
may also have co-morbidities like asthma, diabetes, hypertension and arthritis. They are 
therefore required to take treatment for these and some other prophylaxes against op-
portunistic infections, multi vitamins and even be on treatment for tuberculosis. The pill 
burden, therefore becomes enormous and constitutes a major challenge in the admin-
istration of ART (Frank 2002:S10). 
 
The side-effects of ART are another major challenge of taking the medications and this 
has been reported as the reasons why some do not adhere to their treatment (Frank 
2002:S10). The stigma and discrimination associated with HIV/AIDS within the society 
unlike any other chronic illnesses constitute one of the greatest challenges facing peo-
ple on ART (Elliott, Utyasheva & Zack 2009:29). Due to this stigma, taking ART without 
considering what onlookers would say or think is a great concern for people living with 
HIV/AIDS (PLWHA) as some would rather take the drugs in secrecy which otherwise 
may affect their compliance to the treatment (Hardon et al 2007:662; Weiser et al 
2003:285). 
 
2.5.3 Initiation of antiretroviral therapy 
 
The decision to initiate ART requires weighing the benefit of treatment on the morbidity 
and mortality of HIV/AIDS, the adverse drug reactions, cost of the treatment, drug inter-
action and the ability of the patient to maintain a lifelong therapy on HAART (Thompson 
et al 2010:322). Therefore, HAART regimens need to be individualized after a full base-
line assessment, HIV resistance testing, hepatitis screening, cardiovascular risk as-
sessment, screening for diabetes and renal problems. For women it is advisable to dis-
cuss issue of pregnancy, and there is also need for psychosocial history of the patients 
to identify psychiatric problems, alcohol use and recreational drug use. ART regimens 
have to be chosen taking into consideration the patient’s working and family life, espe-
cially the cost implication of the drugs to ensure continuous uninterrupted supply so that 
adherence could be optimized (Volberding & Deeks 2010:53). 
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Total CD4 cell counts are used worldwide as an indicator of when treatment should be 
initiated; this is often combined with the viral load. Using CD4 percentage has been ad-
vocated by clinicians as it has some additional prognostic value independent of the total 
CD4 count. The limitation of this is that it may result in deferral of treatment in some pa-
tients with CD4 count less than 350 cells/mm3 but high CD4 percentages, or support ini-
tiation of ART earlier in patients with CD4 count higher than 350 but low CD4 percent-
ages (Gazzard et al 2008:570). 
 
Starting ART at CD4 below 350 cells/mm3 or in symptomatic disease is associated with 
higher risk of disease progression and death (Thompson et al 2010:322). Recent trends 
in ART have shifted the therapeutic risk-benefit balance towards earlier treatment of 
HIV/AIDS (Severe et al 2010:263). The WHO recommends ART to be started in all HIV-
infected patients with CD4 ≤ 350 cells/mm3 and those who are in WHO clinical stage III 
or IV whose CD4 test is not available (WHO 2010:29). According to the British HIV As-
sociation guidelines, HIV-infected patients should be initiated on ART when the CD4 cell 
count is ≤ 350 cells/mm3 (Gazzard et al 2008:570). The International AIDS Society of 
the USA guidelines recommend initiation of ART for all symptomatic HIV-infected indi-
viduals irrespective of CD4 cell count and for asymptomatic individuals; treatment 
should be started at CD4 ≤ 500 cells/mm3. For patients with CD4 > 500 cells/mm3 and 
have co-morbidities, it is suggested that ART initiation should be highly considered 
(Thompson et al 2010:322).  
 
Studies have shown that initiating ART at CD4 between 350 – 500 cells/mm3 was bene-
ficial to patients as it decreased death rates and incident of TB, what is not fully clear is 
the benefit of initiating ART at CD4 above 500 cells/mm3 (Thompson et al 2010:323; 
Severe et al 2010:262). It is now fully acknowledged that older age is associated with 
higher risks of AIDS and non-AIDS death, therefore early ART initiation is highly indi-
cated among elderly HIV-infected population. Pregnant women should also be treated 
early at least by the second trimester to reduce the chances of vertical transmission and 
therapy should continue after delivery of the baby (Severe et al 2010:262). 
 
Several current guidelines on ART have advised that the following factors be consid-
ered when initiating ART in a patient: co-morbid conditions (e.g. cardiovascular disease, 
liver disease, psychiatric disease, renal diseases, or tuberculosis); potential adverse 
drug effects; potential drug interactions with other medications; pregnancy or pregnancy 
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potential; results of genotypic drug resistance testing; gender and pretreatment CD4 T-
cell count if considering nevirapine; HLA-B*5701 testing if considering abacavir; patient 
adherence potential; and convenience (e.g. pill burden, dosing frequency, and food and 
fluid considerations (Gazzard et al 2008:570; WHO 2010:41; Severe et al 2010:262). 
 
2.5.3.1 Initiation of ART in South Africa 
 
South Africa with the huge burden of the epidemic and limited resources has placed the 
cut-off point at CD4 of ≤ 250 cells/mm3 for all patients with the exception of infants who 
qualify for ART irrespective of CD4 counts. Pregnant women and HIV patient with TB 
co-infection also qualify for ART at CD4 ≤ 350 cells/mm3. In addition, HIV patients in 
WHO stage IV and those with MDR/XDR TB are to be initiated on ART irrespective of 
CD4 count (NDOH 2010a:6). 
 
The eligibility for ART in South Africa for children includes both clinical and social crite-
ria. For children between the ages of one to five years, they have to be initiated on ART 
if they are symptomatic at WHO stage III or IV. In addition, if their absolute count is < 
750 cells/mm3 or CD4 < 25%, they also qualify for ART (NDOH 2010b:26). For those 
who are five years or older, they qualify for ART if they are symptomatic at WHO stage 
III or IV and if their CD4 < 350 cells/mm3 (NDOH 2010b:26). 
 
The social criteria are hinged on the potential for adherence on ART. The national 
guidelines in South Africa dictate that at least one person is identified as a caregiver 
who is able to supervise the child and ensure that the medication is taken according to 
prescription. Furthermore, it is recommended that the HIV status of the child is dis-
closed to another adult living in the same house with the identified caregiver so that 
there is someone else who can assist with the treatment (NDOH 2010b:26). The base-
line clinical and laboratory work up necessary before the treatment is commenced are 
measurement of the child’s weight and height, staging of the disease, screening for TB, 
Full blood count test, CD4 count test and viral load testing. In addition to these, the 
health care worker may proceed to do some other specific tests depending on the regi-
men proposed for the child (NDOH 2010a:12). 
 
For HIV-infected adult, following the establishing eligibility for ART, all patients have to 
be screened for TB, have CD4 test and viral load done together with full blood count. 
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Women of child bearing age are screened to rule out pregnancy, and WHO stage of the 
HIV disease is also determined. Serum creatinine test is compulsory if patient is going 
to start tenofovir, alanine transaminase test is also necessary if nevirapine will be in-
cluded in the regimen and at least serum haemoglobin should be done before 
zidovudine is initiated in an HIV-infected adult (NDOH 2010a:15). 
 
2.5.4 Antiretroviral drugs (ARV) 
 
The six classes of ARV that are commonly used are the nucleoside reverse transcrip-
tase inhibitors (NRTIs), the non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
protease inhibitors (PIs), fusion inhibitors, integrase inhibitors and chemokine co-
receptor antagonists. The later three are not readily available in resource-limited set-
tings at present, South Africa ART regimens follow the WHO guidelines and they are 
informed by available resources. Standard therapy of combination ART includes two 
nucleoside reverse transcriptase inhibitors (NRTIs) and at least one PI. Another is two 
NRTIs plus on NNRTIs (WHO 2010:31). 
 
2.5.4.1 Nucleoside reverse transcriptase inhibitors (NRTIs) 
 
These were the first ARV used to treat HIV infections (Clumeck & De Wit 2000:8). 
NRTIs target the HIV reverse transcriptase enzyme and prevent the synthesis of viral 
DNA, therefore inhibiting the elongation of new DNA chain and stopping the viral repli-
cation process (Grigsby, Pham, Mansky, Gopalakrishnan & Mansky 2010:41). Dual-
NRTIs have the class advantage as the established “backbone” of ART regimens when 
used in combination with other classes of ARV in the management of HIV/AIDS (Grigs-
by et al 2010:41). The major drawback is the potential of the dual-NRTIs causing lactic 
acidosis with hepatic steatosis which have been reported for most of the drugs in this 
class (Montessori, Press, Harris, Akagi & Montaner 2004:229). Examples of NRTIs in-
clude zalcitabine (ddC), zidovudine (AZT), stavudine (d4T), lamivudine (3TC), 
didanosine (ddI) and abacavir (ABC). Tenofovir is a newer NRTI which is used in com-
bination with other antiretrovirals, it retains its viral suppressive activity against most 
NRTI-resistant HIV strains (Grigsby et al 2010:41). Addition of tenofovir to failing ART 
regimen has been shown to result in durable viral load suppression in treatment-
experienced patients (WHO 2010:32; Grigsby et al 2010:41). 
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2.5.4.2 Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
 
NNRTI targets the reverse transcriptase enzyme binding in a reversible and non-
competitive manner to a unique site on the enzyme that eventually alters its ability to 
function. When the NNRTIs were developed, their use was initially hampered by being 
given as mono-therapy which resulted in rapid resistance development (Clumeck & De 
Wit 2000:8). They have good oral bioavailability and their half-life is long which allows 
for once-daily dosage for efavirenz or once or twice-daily dosing for nevirapine 
(Clumeck & De Wit 2000:8). Safety of efavirenz in pregnancy is yet to be fully estab-
lished although recent studies suggest it may be safe in early pregnancy (Bera et al 
2010:287). They also have very good viral suppressive effect when given in combina-
tion with other ARVs, but have low threshold for resistance. This high degree of cross-
resistance within the class limits the use of NNRTI (Clumeck & De Wit 2000:8). NNRTI 
have several drug-drug interactions since they induce cytochrome P450 enzyme caus-
ing other drugs to be metabolized faster and therefore reducing the concentration of 
such drug. Common NNRTI are nevirapine, delavirdine and efavirenz.  
 
2.5.4.3 Protease inhibitors (PIs) 
 
The enzyme protease is responsible for cleaving the polyproteins precursors that give 
rise to the viral envelope, core protein and enzymes; protease inhibitors inhibits this en-
zyme and halts the production of matured infectious virons. Some of the common PIs 
are saquinavir, indinavir, ritonavir, nelfinavir, amprenavir and lopinavir. These drugs are 
very efficient when used with the NNRTIs and NRTIs leading to profound and durable 
viral suppression (Clumeck & De Wit 2000:8). The major drawbacks of PIs are short 
half-lives, variability in oral absorption, dietary requirements and drug restrictions. The 
metabolic disorders associated with protease inhibitors may preclude their lifelong use 
because of the risk of artherogenesis and thrombogenesis. PIs also interact with other 
drugs metabolized by P450 because they act as inhibitor of P450 leading to elevated 
levels of many drugs that are metabolized by P450 (Volberding & Deeks 2010:51). 
 
2.5.4.4 HIV fusion inhibitors 
 
The first drug in this class is enfuvirtide; it acts by inhibiting the fusion of HIV and CD4 
cells. This drug targets a structural transition in the viral envelope glycoprotein gp41 re-
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quired for membrane fusion and virus entry (Boyd & Pett 2008:67). Enfuvirtide has a po-
tent antiretroviral activity but its major drawback is the twice-daily administration by sub-
cutaneous injection (Boyd & Pett 2008:68). It requires extensive patient counselling on 
injection technique and how to maintain strict adherence as injection site reactions may 
affect patients’ compliance with the drug. Enfuvirtide is yet to be available in most sub-
Saharan Africa countries. 
 
2.5.4.5 HIV integrase inhibitors 
 
The drugs in this class act by inhibiting the HIV integrase enzyme which is necessary 
for the incorporation of viral DNA into the host cell genome. Raltegravir is the first in this 
class and by blocking HIV integrase enzyme it inhibits HIV replication (Pommier, John-
son & Marchand 2005:236). The drug is used in combination with other ARVs and is 
very potent in treating HIV patients who have developed resistance to older medica-
tions. Currently the drug is indicated in treating patients who have developed resistance 
to other ARV as salvage therapy (Yilmaz, Gisslen et al 2009:e6877). Like the fusion in-
hibitors, raltegravir is mainly available in resource rich settings and yet to be available in 
public health sectors in most developing countries. 
 
2.5.4.6 Chemokine co-receptor antagonist 
 
Chemokine co-receptor antagonist prevents the entry of HIV-1 into host cells by block-
ing the CCR5 co-receptor. Maraviroc is a member of this class of antiretroviral agents 
and works by blocking CCR5, a protein on human immune system cells that the virus 
uses as a portal to enter and infect the cell. Maraviroc binds specifically and selectively 
to CCR5 on the surface of the CD4 cell and blocks HIV-1 binding. In a study that com-
pared maraviroc with placebo, it was demonstrated that the drug is associated with sig-
nificant reduction in HIV viral load and increase in CD4 count among patients (Gulick, 
Lalezari et al 2008:1437). Maraviroc has been used in ART with good results although 
the drug has been linked to increase in frequency of upper respiratory tract infection and 
persistent cough among patients (Ghebremedhin 2012:4).  
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2.5.5 Drugs combinations in ART 
 
Antiretroviral are used in combination to achieve maximal and durable viral suppression, 
the result in what is now called highly active antiretroviral therapy (HAART). The criteria 
used for the selection of drugs are often based on the properties of the drugs and how 
appropriate the regimen will be for the patient (Gazzard et al 2008:571). The first line 
regimen according to World Health Organization recommendations consist of two 
NRTIs plus NNRTI, one of the two NRTIs should be tenofovir or zidovudine (WHO 
2010:31-32). The British HIV Association (BHIVA) also recommends efavirenz to be 
part of all first line regimens (Gazzard et al 2008:571). The second line regimen accord-
ing to the WHO consists of a ritonavir-boosted protease inhibitor plus two NRTIs after 
considering what was used in the first line regimen (WHO 2010:53). 
 
Abacavir when used in combination with zidovudine and lamivudine was earlier shown 
to be as efficacious as the combination indinavir, zidovudine and lamivudine (Clumeck 
& De Wit 2000:8). Recent data suggest that this combination is less potent than combin-
ing two NRTIs with either an NNRTI or PI (WHO 2010:39). High virological failure was 
reported and therefore triple NRTIs are no longer recommended in ART although some 
clinicians advocate for the combination of zidovudine/lamivudine/tenofovir with or with-
out abacavir in exceptional cases when a PI or NNRTI-based regimen cannot be given 
to a patient (Gazzard et al 2008:574). 
 
Combination of two NRTIs plus a boosted PI has been proven to be clinically beneficial 
in ART. When PIs are boosted with low-dose ritonavir they produce sustained viral sup-
pression, significant CD4 cell rise and have high genetic barrier to resistance (Gazzard 
et al 2008:573). Ritonavir prolongs the half life of the PIs which makes it possible for re-
duction in pill burden and dosing frequency, in addition adherence is better achieved 
with less pill and dosing frequency (Bangsberg, Moss & Deeks 2004:697). 
 
There are various regimens being used for patients with extensive antiretroviral experi-
ence who are falling their current therapy. The failure is often due to viral resistance to 
the drugs. Tenofovir has a distinct and unique drug resistance profile, the class-
resistance that affects the NRTIs does not affect tenofovir; therefore it is useful in non-
cross-resistant HAART regimens in salvage therapy, particularly with children and ado-
lescents (Grigsby et al 2010:41). 
 
45 
2.5.6 Response to antiretroviral therapy 
 
Long-term remission of HIV disease is readily achieved by combination of ART. Once 
ART has maximally suppressed HIV replication, the CD4 count slowly increases which 
results in improved immune functioning. Consequently, there is resolution of established 
opportunistic infections, decrease in risk of new infections, improved quality of life and 
weight gain in some patients who have become emaciated as a result of advanced dis-
ease (Janssens et al 2007:1137; Ware et al 2009:43). The clear linear relationship be-
tween virologic, immunologic and clinical outcomes is not straightforward in some cas-
es, virologic non-responders and immunologic non-responders have described (Moore 
et al 2005:290). Virologic non-responders are patients with increasing CD4 cell count in 
the absence of viral suppression while immunologic non-responders are those with 
good viral suppression without increase in CD4 cell count. This discordance has been 
widely reported among poorly adherent patients and is associated with a higher risk of 
mortality (Moore et al 2005:290). 
 
Treatment with HAART should result in prompt viral load decrease within two to four 
weeks of initiating therapy, and it is expected to reach a level below 400 copies/mL with-
in four to 12 weeks and a target of below 50 copies in 24 weeks. Decline in viral load of 
at least 1log from pre-treatment levels after 6-8weeks of starting antiretroviral therapy, 
decline in viral load to < 5,000 RNA copies/ml by 12weeks after starting antiretroviral 
therapy and viral load of < 50 copies are criteria used to determine treatment success in 
HIV/AIDS when triple therapy is instituted (Volberding & Deeks 2010:51). 
 
The suppression of plasma viral loads to less than the limit of quantification is expected 
to lead to improvement in CD4 cell counts. The decrease in viral load is expected to go 
hand in hand with CD4 cell count, in the short term the impact of ART is more apparent 
in the viral load than the CD4 count because of the time delay in the two responses 
(Gross et al 2001:2114). This is the reason why immunologic response is not usually 
used in adherence studies, although some authors have reported that adherence is the 
most significant factor associated with increase in CD4 count (Gross et al 2001; Pater-
son et al 2000). The earlier misconception that CD4 count less than 350 cells/µL repre-
sented an irreparable damage to the immune system precluding a CD4 response to 
ART was disproved by Wood et al (2004:261-268). The study found that significant CD4 
increase was possible in patients with advanced stage of HIV/AIDS who adhered to 
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treatment. Wood et al (2004:261-268) revealed that adherent patients with advanced 
HIV disease showed an increase in CD4 count as low as 50 cells/µL to 200 cells/µL. 
 
Despite the high efficacy demonstrated by HAART, complete eradication of the HI virus 
is not possible. This inability of the ARVs to completely suppress the virus results in the 
selection of drug-resistant variants and therefore limits the long-term success of HAART 
(Volberding & Deeks 2010:51). Numerous factors contribute to failure of HAART, includ-
ing suboptimal drug potency and pharmacokinetics, poor adherence to complex ART 
regimens, emergence of drug-resistant strains and compromised immunologic function 
in the patient (Clotet 2004:123; Duong et al 2004:221). 
 
2.6 COGNITIVE-BEHAVIOURAL THEORIES AND MEDICATION ADHERENCE  
 
Contemporary theories of health behaviour at the individual and interpersonal levels are 
referred to as cognitive-behavioural theories, key concepts of these theories stipulates 
that behaviour is mediated by cognition i.e. knowledge and attitude of a person affect 
the person’s action (Rimer & Glanz 2005:12). In addition, cognitive-behavioural theories 
recognize knowledge alone as being insufficient to produce behavioural change; a per-
son’s perception, motivation, skills and social environment are influential in his behav-
ioural change (Rimer & Glanz 2005:12). Individual level theories explore behaviour and 
focus on intrapersonal factors such as knowledge, attitude, beliefs, motivation, self-
concept, past experience and skills. At the interpersonal level theories of health behav-
iour take into consideration that an individual exist within a society and is influenced by 
the social environment. Thoughts, behavior and opinion of people around an individual 
influence the feelings and actions of such person and the person also have reciprocal 
effects on those people (Rimer & Glanz 2005:12). Some of the theories frequently used 
in behavioural interventions are the health belief model, social cognitive theory, trans-
theorectical model and theory of planned behaviour. 
 
2.6.1 Health Belief Model 
 
This is a psychosocial approach to explaining health behaviour. This model was intro-
duced by psychologists Rosenstock, Hockbaum, Leventhal and Kegeles in the 1950s 
and has been used widely by various researchers. The model deals with value expec-
tancies related to health. It is a cognitive and interpersonal approach that view human 
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as a rational being who behave in certain ways to minimize what they perceived as 
threat (e.g. disease symptoms) and enhance what are perceived as benefits (e.g. ad-
herence to treatment) (Bandura 2004:145). The HBM comprises of some interactive 
states of belief, which collectively affect adherence. 
 
2.6.1.1 Perceived susceptibility  
 
This means that a person will seek preventive medical care if the individual believes 
he/she is at risk of developing a disease. Therefore, the perceived susceptibility of a 
disease brings to light the fact that the individual could actually get the disease (Red-
ding, Rossi, Rossi, Velicer, Prochaska 2000:181). 
 
2.6.1.2 Perceived seriousness 
 
This implies that people tend to be more proactive in prevention of serious diseases 
than the ones perceived to be less serious. In other words susceptibility and serious-
ness combine to form what an individual perceives as a threat of a disease (Redding et 
al 2000:182). Perceived seriousness of HIV/AIDS are the consequences of being in-
fected with the disease which are pain, disability, lifelong therapy on ARV and ultimately 
death (Dahab et al 2008:63). 
 
2.6.1.3 Perceived benefits 
 
The perceived benefit derived from health behaviour describes how effective an individ-
ual thinks the health behaviour will be. Health behaviour that results in an immediate 
benefit may be perceived as very effective since the effect is rapid and noticeable (Red-
ding et al 2000:182).  
 
2.6.1.3 Perceived barriers  
 
These have influence on the action to be taken by a person, and include factors which 
an individual perceived as obstacles to the health action. An individual may feel that 
treatment takes too much time, requires too much effort or is too difficult to obtain. Ac-
cording to (Redding et al 2000:182), when perceived threat of a disease is high and 
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perceive benefits outweigh the perceived barriers, then there is high likelihood of health 
action being taken. 
 
Health belief model also recognizes other factors that could influence health behaviour 
of a person. These include predisposing factors such as the individual values, beliefs, 
attitudes and perception of the disease. Another one is enabling factors such as is-
sues around availability and accessibility of health resources. The last one is reinforc-
ing factors that have to do with peer support, feedback and assurance given by health 
care worker to the patients to ensure treatment compliance (Redding et al 2000:182). 
 
Perceived susceptibility to and severity (health consequences) of a disease are postu-
lated to be driven by knowledge, attitude and practices of individuals (Bandura 
2004:144). Similarly, background belief about the disease and the symptoms experi-
enced are postulated to affect an individual’s perceived susceptibility to and severity of 
the disease (Bandura 2004:144). In the context of South Africa, the general knowledge 
of the high prevalence of HIV/AIDS in South Africa and the health consequences of the 
disease is also perceived to influence perceived personal susceptibility to and severity 
of HIV/AIDS (Dahab et al 2008:63). 
 
Medication use behaviour is also influenced by the direct experience of medication ad-
verse effects (Munro et al 2007:104). The experience of adverse drug reactions requires 
the occurrence of the adverse event and the causal attribution of the event to one or 
more of the ARVs. A patient with prior adverse drug reactions to medication which is an 
indication of personal negative experience with medications may logically strengthen 
such belief to attribute adverse event easily to ARVs. Therefore, medication use behav-
iour of such patient is influenced by belief of potential adverse effects of the medications 
(Munro et al 2007:104). 
 
The patient’s perception of their relationship with their health provider is also postulated 
to influence their medication use behaviour. Health providers potentially have substan-
tial influence over the level of knowledge that patients have about the target condition 
and the adverse health consequences of that condition as well as about the medications 
themselves (Skovdal, Campbell, Nhongo, Nyamukapa & Gregson 2011:309). In addi-
tion, the patients’ trust that their health providers are competent and knowledgeable 
about HIV/AIDS will influence the acceptance of and belief in the advice and education 
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that they receive regarding the threat to their health from the target condition and the 
risks and benefits of the proposed medication to reduce that threat (Skovdal et al 
2011:309). Further to this, the patients’ perception of health providers’ concern about 
their welfare, being involved in decision-making process regarding management of their 
health, and good communication with the health providers are all influential in patients’ 
medication use behaviour (Gauchet, Tarquinio & Fischer 2007:141–150). 
 
2.6.2 The social cognitive theory 
  
Social cognitive theory (SCT) explains human behaviour in terms of a dynamic, recipro-
cal and continuous interaction between the individual and the environment (Bandura 
1988:276). The common theoretical basis of cognitive theory is learning as human be-
haviour is learned, therefore, SCT proposes that behaviour is the result of cognitive 
processes that people develop through the social acquisition of knowledge (Bandura 
1988:299). This theory focuses on the concept of behavioural capability, which states 
that before an individual acts in a given circumstance the person needs to know what to 
do and how to do it. Bandura's conceptual model of reciprocal determinism addresses 
the personal determinant of health; he postulates that a person engages in cognitive, 
vicarious, self-reflective, and self-regulatory processes to achieve a set goal (Bandura & 
Adams 1977:288; Rosenstock et al 1988:176). He goes further to say people effect 
change in themselves through their actions in anticipatory, proactive ways by exercising 
control over their behaviour through their thought processes, motivation, and action 
(Bandura 2004:145). Without aspirations, Bandura claims people remain unmotivated 
and uncertain about their capabilities.  
 
Individuals with health promoting behaviour possess self-beliefs, enabling them to exer-
cise control over their thoughts, feelings, and actions (Clark & Dodge 1999:84). There-
fore, people who engage in self-management of health habits reduce major health risks 
and live healthier and more productive lives (Clark & Dodge 1999:86). According to 
Bandura (2004:145), although SCT acknowledges that knowledge of health risk and 
benefit of treatment are necessary to perform health behaviour, this in itself is not 
enough, additional self-influences are necessary to achieve changes that will result in 
the desired health behaviour, this concept is called self-efficacy.  
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Cognitive technique in counselling by health care worker assist the patient to learn rele-
vant information about HIV/AIDS and the courses of action to make in taking decision 
about their disease and solving problems (Skovdal et al 2011:309). The support groups 
in HIV/AIDS use cognitive and behavioural strategies to empower patients to handle 
problem and establish supportive relationships. Issues around disclosure of HIV status, 
relaxation skills, anxiety management and treatment education are skills taught in these 
groups that may result in better adherence to treatment (Skovdal et al 2011:309). The 
two cognitive processes that influence behaviour have been described as outcome ex-
pectation and self-efficacy expectations. 
  
2.6.2.1 Outcome expectation  
 
An outcome expectation is the belief that a particular behaviour will result in a specified 
outcome or effect, and outcomes can either be positive or negative.  This theory postu-
lates that an individual will choose an action that he or she believes will maximize a 
positive outcome and minimize a negative outcome (Redding et al 2000:185). Cognitive 
intervention in ART is aimed at changing the patient’s behaviour and attitude through 
assisting the individual in changing unrealistic expectations or behaviour through educa-
tion to learn how to do things in a new or different ways. 
 
2.6.2.2 Self-efficacy  
 
Self-efficacy, a concept articulated by Bandura postulates that although social cognitive 
theory acknowledges that knowledge of health risk and benefit of treatment are neces-
sary to perform health behaviour, this in itself is not enough, additional self-influences 
are necessary to achieve necessary changes that will result in the desired health behav-
iour (Bandura 2004:145). It describes the belief in one’s ability to take control of behav-
iour and the confidence that one can perform a specific task. Self-efficacy has become 
a major focus area in the process of assessing patient performance of certain skills that 
are required to manage their disease condition with the aim of improving their quality of 
life. Self-efficacy theory has been increasingly recognized in health behaviour and has 
become one of the key constructs in social cognitive theory. Persons with high self-
efficacy or self-confidence that they can perform certain health behaviour such as ad-
hering to medication are more likely to carry out such behaviour (Redding et al 
2000:187). 
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Central to Bandura's work is the Self-Efficacy Model, a paradigm of the person engag-
ing in behaviour with a consequent outcome (Bandura & Adam 1977:288). According to 
Bandura, self-efficacy describes the belief in one’s ability to take control of behaviour 
and the confidence that one can perform a specific task. Self-efficacy influences how a 
person thinks, feels, acts and is motivated. Furthermore, self-efficacy affects a person’s 
choice of setting, the effort expanded on a particular task and the emotional reactions to 
situations (Jones, Owens, Lydston, Tobin, Brondolo & Weiss 2010:1503). Self-efficacy 
describes an individual belief that he can alter the behaviour or action required to 
achieve positive health outcomes in managing the disease. In this study it is conceptual-
ized that self-efficacy in ART can be depicted as an individual’s ability to continue taking 
ARV despite various challenges associated with ART. 
 
Bandura describes four sources of information that influence self-efficacy: performance 
mastery, vicarious experience, verbal persuasion, and physiological symptoms. Integra-
tion of information from one or more different sources forms a self-efficacy judgment 
(Bandura 1988:285). Performance mastery refers to knowledge and skill gained 
through experience and perseverance (Bandura 1988:285). Vicarious experience oc-
curs from observing others complete a task successfully contributing as a source of 
modeling self-efficacy in performing that task (Bandura 1988:284). Verbal persuasion, 
the most often used source of self-efficacy by health care professionals, is used to try to 
convince persons that they can succeed at a task. Verbal or social persuasion serves to 
reinforce feelings of efficacy when facing the minor failures mentioned above (Bandura 
1988:285). Physiological symptoms also serve as sources of information toward an 
individual’s self-evaluation of competence.  A person’s physical reaction to difficult situa-
tions can influence how prepared that person feels to effectively handle the situation 
(Bandura 1988:285).  
 
2.6.2.3 Observational learning or modelling  
 
Other influences that are recognized by the Cognitive theory are observational learning 
or modelling which describes how a person acquires skills and information through the 
actions of other people (Redding et al 2000:185). Through observation, a person can 
learn from other people’s actions and go further to develop an understanding of and be 
prepared for the consequences of such actions. The support groups that are formed 
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among HIV-infected patients may serve as a good model where people learn how to do 
certain things by observing others within the group (Skovdal et al 2011:309). 
 
2.6.2.4 Reinforcement  
 
This is another influence in Cognitive theory, here the response to a person’s behaviour 
can influence whether or not that behaviour will be repeated. Reinforcement can be 
positive or negative. When health behaviour is positively reinforced, it makes it more 
likely that the individual will repeat such behaviour. On the other hand lack of response 
or negative reinforcement of a person’s behaviour tends to make repetition of such be-
haviour less likely (Redding et al 2000:185). The behavioural theory of adherence is 
based on the operant conditioning such as reinforcement of action that leads to adher-
ence. For example, reward for completion of medication in form of compliment or if the 
patient feel healthier after complying with instructions of health giver. Negative rein-
forcement has limited role in ART adherence, but may be applicable in patient who con-
tinuously fail to adhere and developed resistant strain of the virus with very little re-
sources available to initiate other regimens of ARV. 
 
2.6.3 Trans-theoretical model (stages of change) 
 
This theory was developed by Prochaska and DiClemente (1983:390-395), and is also 
called Stages of Change theory. The basic premise of the model is that behaviour 
change is not a once off event but a process in which an individual attempting to change 
his behaviour moves along a series of motivational changes namely; pre-contemplation, 
contemplation, determination, action, maintenance and relapse (Rimer & Glan 2005:15). 
The stages of change model is not linear but circular in nature, a person does not pro-
gress automatically from one stage to the next, but he or she enters the change process 
at any stage, progresses or relapses to an earlier stage and starts the process all over 
(Redding et al, 2000:188). Trans-theoretical Model has been used in various behaviour-
al interventions at both individual and organizational levels; persons at different stages 
in this process often have varying informational needs and only benefit from intervention 
designed specifically for the stage they are in (Rimer & Glanz 2005:15).  
 
In the pre-contemplation stage, the person has not given a thought about the particu-
lar health behaviour to be taken and therefore has no intention of adopting such behav-
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iour. At the contemplation stage the person is said to be seriously considering taking 
the health behaviour but has not taken any action about it. The person proceeds to 
make a plan to adopt the health behaviour at the determination stage. During the ac-
tion phase, the person makes an initial behavioural change and this phase usually co-
vers the first six months of adopting the health behaviour. After a period of six months 
the individual enters the maintenance phase and this is sustained for a period of time 
(Redding et al 2000:188). 
The patients who started ART often comply at the early stage; this trans-theoretical 
model applies to those who become non-adherent after complying with treatment on 
previous occasions. Relapse stage describes the reversion back to the earlier stage af-
ter failing to maintain the health behaviour; this is often referred to as a secondary stage 
of change. The relapse may occur any time after action is taken to adopt the specified 
behaviour. 
 
2.6.4 The precaution adoption process model (PAPM)  
 
This model comprises of seven stages beginning from lack of awareness to adoption or 
maintenance of desired health behaviour. At the first stage, a person is unaware of the 
health risk; the individual may become aware in Stage 2 but remained unengaged. In 
Stage 3 the individual is faced with the decision to act, and may decide to act (Stage 4), 
of decide not to (Stage 5). Stage 6 is action stage, and Stage 7 is maintenance of the 
action taken in earlier stage (Rimer & Glanz 2005:19). In the Precaution Adoption Proc-
ess Model, an individual moves sequentially through all the stages without skipping any 
of them, though it is possible to move backwards from some later stages to earlier ones, 
people do not return to the first two stages once completed. This model recognizes that 
the barriers faced by people who are unaware of health risks or hazards differ from 
those who are aware of such risks but decided not to take action (Rimer & Glanz 
2005:19). In PAPM, interventions that target stages that precede active decision making 
have been advocated to address adherence in medical conditions. 
 
2.6.5 The theory of reasoned action/planned behaviour 
 
The theory of planned behaviour (TRP) and the associated theory of reasoned action 
(TRA) stipulate that the determinant of behaviour is behavioural intention (Rimer & 
Glanz 2005:19:16). Theory of reasoned action predicts behaviour from intention and 
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explores the relationship between beliefs, attitudes, intentions and behaviour (Redding 
et al, 2000:183). The modified version of the TRA is the theory of planned behaviour 
which includes one additional construct, perceived behavioural control; this construct 
has to do with people’s beliefs that they can control a specific behaviour (Redding et al 
2000:183). The perceived control construct was added to TRA to gain better under-
standing of situations where behaviour or behaviour intention is influenced by factors 
which are beyond a person’s control (Rimer & Glanz 2005:19:16). 
 
TRA predicts behaviour from intention; this intention is influenced by three factors which 
are subjective norms, attitudes and self-efficacy (Redding et al 2000:183). According to 
TRA, behavioural intention is influenced by an individual’s attitude towards such behav-
iour and by the individual’s beliefs about whether people who are significant in the life of 
such individual approve or disapprove of the behaviour (subjective norm), while self-
efficacy is the confidence a person has that certain behaviour can be performed (Red-
ding et al 2000:183). 
 
Two beliefs in TRA that influence behavioural intentions are the normative and behav-
ioural beliefs, normative beliefs are based on social expectations which are often con-
sidered the rule; they influence subjective norms while beliefs about the behaviour influ-
ence the attitude. Attitudes are usually conceptualized in terms of values, a person’s at-
titudes toward health behaviour are said to be determined by the outcome expectations 
of performing such behaviour and the extent to which the individual values the outcome 
(Redding et al 2000:183). According to TRA, an individual will perform certain health 
behaviour to reduce health risks if convinced such behaviour will prevent the risks and 
extent to which the individual perceives the benefit of performing the behaviour will out-
weigh the cost (Redding et al 2000:183). 
 
The current study was guided by the self-efficacy model and the health belief model. 
These two models were chosen for this study because they contain the cognitive vari-
ables under investigation in the current research.  
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2.7 ADHERENCE AND ANTIRETROVIRAL THERAPY 
 
Adherence is the act or quality of sticking to a particular instruction or advice.  In the 
management of chronic medical ailments, adherence is considered non-judgmental and 
is preferred over the term "compliance," which is an act of conforming, yielding or ac-
quiescing (Castro 2005:e338). Compliance implies a lack of patient participation; carries 
negative connotations and suggests blame for the patient. In the context of chronic 
medical conditions the word adherence translates to a collaborate process between the 
patient and health care provider (Castro 2005:e338). Medication adherence in actual 
word is described as the extent to which the individual’s behaviour corresponds to the 
prescribed medical advice of the health care provider (Kenreigh & Wagner 2005). The 
treatment of HIV/AIDS extends beyond knowledge development in patients; a partner-
ship between patients and healthcare providers is required, with the patient assuming 
the major responsibility of self-care leading to adherence and good clinical outcome 
(Sanjobo, Frich & Fretheim 2008:142).  
 
2.7.1 Adherence to antiretroviral therapy  
 
Based on the definition of adherence, non-adherence is not limited to missing medica-
tion intake; it includes other acts like not following instructions regarding dietary or fluid 
restrictions and not taking medication at the prescribed time. It is difficult to predict 
which patient will adhere to treatment; past adherence is the only predictor of future ad-
herence (Ickovics & Meade 2002:S100). Adherence levels change over time; clinical 
experience and research indicate that adherence is a “moving target”, the longer a pa-
tient stays on ART the poorer the adherence is likely to become (Cauldbeck et al 
2009:7; Ickovics & Meade 2002:S100). In the study done by Orell et al (2003:1369-
1375), it was shown that adherence should not be a barrier in ART initiation in develop-
ing countries with limited resources if there is adequate access to ART, proper patient 
education, social support, and issues around social barriers are well addressed. 
 
Generally, adherence rates are shown to be high among patients who are taking medi-
cations for acute medical conditions compared to those with chronic medical condition 
(McDonald, Garg & Haynes 2002:2870). In addition to this, adherence levels among pa-
tients with chronic diseases, no matter how impressive initially have been reported to 
drop dramatically after six months (Van Dulmen et al 2007:55). Numerous interventional 
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studies have been done in the past to address the problem of non-adherence among 
patients (Amico, Harman & Johnson 2006:295; Van Dulmen et al 2007:55; Munro et al 
2007:104). The unfortunate thing is that most of these interventions seem to have mod-
est impact (Amico et al 2006:295; Simoni et al 2003:193; Munro et al 2007:104). There 
is a big challenge for behavioural sciences in developing interventions aimed at enhanc-
ing ART adherence, the lack of appropriate theories to explain and predict non-
adherence among patients on chronic medications may have a role to play in the slow 
progress made in this field of knowledge (Kagee 2008:424; Van Dulmen et al 2007:55). 
 
Various studies have been done to establish the levels of adherence to ART although 
most of these were done in the developed world. The earlier studies on adherence and 
its impact on outcome were done using electronic monitoring, pill counts, and self-
reports and they all demonstrated inverse relationship between adherence and viral 
load (Paterson et al 2000:22; Bangsberg et al 2006:226; Gross et al 2001:2112). 
 
2.7.2 Adherence required for optimal results in antiretroviral 
 
The study of Paterson et al (2000:21-30) has been used widely in establishing the level 
required for optimal adherence (> 95%) necessary to maintain viral suppression. In the 
study, the authors revealed virologic failure (HIV RNA > 400 copies/mL) in 22% of pa-
tients with adherence level of 95% and above, 61% in patients with adherence level of 
80-94.9% and 80% virologic failure in patients whose adherence level fell below 80% 
(Paterson et al, 2000:26). Any adherence below 95% in ART has been linked to treat-
ment failure, the risk of developing resistance to ARV is also shown to be highest be-
tween 80-90% level of adherence (Bangsberg, Moss & Deeks 2004:697), this is be-
cause the virus is not likely to develop resistance at low concentration of the drugs but 
at high drug concentration which is suboptimal for suppression of viral replication the 
chances of viral resistance are high (Clotet 2004:123; Bangsberg, Moss & Deeks 
2004:697).  
 
The earlier estimates of adherence levels necessary for viral suppression were done 
among patients receiving the unboosted PIs regimens which have been described as 
less potent than the NNRTI regimens (Gazzard et al 2008:573; Thompson et al 
2010:326). Recent studies on adherence levels required to maintain good viral suppres-
sion with NNRTI-based regimens revealed that viral suppression was still achievable in 
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patients with adherence level below 80% (Nachega et al 2007:567; Bangsberg 
2006:940). The study of Nachega et al (2007:567) done in South Africa showed that 
there was improvement in patients’ virologic outcomes as adherence to NNRTI-based 
regimens went beyond 50%. In addition, 73% patients achieved maximal viral suppres-
sion with adherence levels of 90-100% (Nachega et al 2007:567). This study shows that 
the NNRTI-based regimens may be appropriate alternative to the PI-based regimens 
where adherence between 70-94% is anticipated, although the authors warned that ad-
herence should be enhanced in any patients on HAART irrespective of the patterns of 
adherence among populations groups. 
 
HIV patients have been shown to adhere better than the general population; the aver-
age adherence to chronic medications among the general population is 50% which is far 
below self-report adherence rate between 55-77% reported among patients on ART 
(Mills et al 2006:687). Despite this, non-adherence is common among patients on ART, 
which is estimated between 30-50% among patients and more than 10% of patients 
usually miss one or more of their daily doses of antiretroviral drugs (Chesney 
2000:S172).  
 
The level of adherence among adolescents has been reported to be lower than adults 
and elderly patients on ART (Protopopescu et al 2009:602). In a study done in the USA 
among adolescents on ARV, only 28% took prescribed ARVs in the previous month 
(Murphy et al 2003:253). Another cohort study in nine countries within the Southern Af-
rica region also reported poor adherence among adolescents (Nachega et al 2009:67). 
A recent survey done among HIV patients in India also revealed poor adherence among 
people who were aged below forty years (Cauldbeck et al 2009:7). The explanatory fac-
tors responsible for this discrepancy may be due to the fact that older individuals are 
more likely to have prior experience taking medication for age-related diseases and may 
have already become accustomed to such. Another reason may be related to the fact 
that lifestyle adjustments necessary for successful adherence are often less burden-
some for adults compared to young patients. 
 
Several studies in sub-Saharan Africa have reported low adherence among patients on 
ART, in a sample of 109 patients on ART in Botswana only 54% of the patients were 
adherent by self-report, although this increased marginally to 56% when provider as-
sessment was used (Weiser et al 2003:284). In another study in Ethiopia conducted 
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among 400 patients on ART, 24% were non-adherent when combined indicators of 
dose, time and dietary instructions were used, the authors go further to report that this 
rate increased to 27% after reassessment 3 months later (Amberbir 2008:268). A Nige-
rian study that assessed ART adherence among patients on subsidized ART pro-
gramme reported an alarming 75% of the study participants as non-adherent to their 
medications, patients in this study cited various reasons for their actions, ranging from 
ARVs side-effects and non-availability of ARVs to forgetfulness (Uzochukwu, Onwu-
jekwe, Onoka, Okoli, Uguru & Chukwuogo 2009:4). 
 
A more recent KwaZulu-Natal study among 735 HIV-infected patients, found 30% of pa-
tients to be non-adherent to dose, schedule and dietary instructions (Pelzer, Du Preez, 
Ramlagan & Anderson 2010:111). Another South African study by Malangu (2008:49) 
revealed that only about 50% of patients on ART reported taking at least or over 95% of 
their prescribed ARVs. A major review on studies conducted on ART adherence that 
involved 72 developed countries and 12 developing countries, five of which are Afri-
cans, estimates adherence level among people living with HIV/AIDS in Sub-Saharan 
Africa at 77%, surprisingly higher than 55% in North America. The authors state further 
that non-adherence to ART in adult population range between 33 to 88%, depending on 
the measure of adherence employed (Mills et al 2006:685). These percentages are low 
considering that adherence of 95% is necessary to minimize development of viral resis-
tance and to achieve optimum benefit of ART (Paterson et al 2000:26).  
 
The results obtained from some of the adherence studies in resource-limited settings 
should be interpreted with caution as there is possibility of the results skewing towards 
better adherence. The reason for this is because large majority of participants in these 
studies received free ARVs, free information and support from dedicated clinical staff, a 
beneficial experience which does not reflect the true situation of things in most re-
source-constraint settings. 
 
2.7.3 Consequences of non-adherence to ART  
 
Adherence to ART has been described as the most crucial for the expected positive 
clinical outcome in patient initiated on ART. Adherence to combination ARV therapy has 
been shown to inhibit HIV replication which has resulted in the steady decline in 
HIV/AIDS related morbidity and mortality (Janssens et al 2007:1137; Duong et al 
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2004:218; Ware et al 2009:43). Lower levels of adherence have been demonstrated to 
achieve treatment goals in chronic medical conditions like hypertension and diabetes 
where moderate adherence has been considered adequate for treatment outcomes 
(Simoni et al 2003:185). This is quite different in HIV/AIDS management where adher-
ence level greater than 95% has been described as the requirement for maximal viro-
logical suppression especially ART regimens that contain the protease inhibitors 
(Bangsberg et al 2003:1930; Paterson et al 2000:26). Although recent studies indicate 
moderate adherence at 80-90% may suppress viral replication with the non-nucleotide 
reverse transcriptase inhibitors (Bangsberg 2006:940; Nachega et al 2007:569); this 
finding has to be interpreted with caution as risk of viral resistance and mortality is high 
at such adherence levels (Nachega et al 2006a:81). 
 
Unlike other chronic diseases in which non-adherence is somehow tolerated, the high 
rate of viral replication and mutation in HIV means that high levels of adherence has to 
be maintained all times (Clotet 2004:123). Non-adherence to ART results in inadequate 
suppression of viral replication in the body which allows the virus to continuously repli-
cate and deplete the T-Helper cells; this destroys the immune system and allows the 
disease to progress at a faster rate. Non-adherence has also been shown to be associ-
ated with repeated hospital admissions, development of opportunistic infections, poor 
quality of life, loss of productivity and premature mortality (Graham et al 2010:1541; 
Moore et al 2005:290; Nachega et al 2006a:83; Wools-Kaloustian et al 2006:44). De-
velopment of resistance to ART is another implication of non-adherence because the 
virus is prone to developing resistance to ARV when exposed to suboptimal concentra-
tions of the drug (Boyd & Pett 2008:67; Clotet 2004:123). These resistant strains can be 
transmitted to other persons thereby decreasing treatment options and worsening of the 
HIV epidemic. 
 
Hogg et al (2002:1051-1058) found that patients whose adherence level is below 75% 
were three times more likely to die compared to those whose adherence level is above 
75%. In another study by Garcia de Olalla et al (2002:105-110), the authors revealed 
that patients with adherence level below 90% were 3.87 times more likely to die com-
pared to those with adherence above 90%. Likewise, Nachega et al (2007:564-573) re-
ported that patients whose adherence fell below 80% were three times more likely to die 
than those with adherence above 80%. The results of these studies have to be inter-
preted with caution bearing in mind that many of the patients in these studies were initi-
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ated on ART with advanced stage of HIV/AIDS and with very low CD4 counts. The most 
important lesson from these studies is that poor adherence in advanced stages of the 
disease carries a high risk of mortality. 
 
2.7.4 Factors influencing adherence in ART 
 
The management of HIV/AIDS with ART has resulted in significant clinical outcomes; 
but the complicated dosing requirements, ART adverse drug reactions and socio-
economic factors often constitute a challenge to patients (Dahab et 2008:63; Curioso, 
Kepka, Cabello, Segura & Kurth 2010:13; Amberbir et al 2008:265). Although various 
studies in sub-Saharan Africa have shown that high levels of adherence, viral suppres-
sion and good clinical outcome are achievable in these resource-limited settings 
(Nachega et al 2006a:82; San Lio et al 2008:1614; Nachega et al 2009:68; Mills et al 
2006:685; Hardon et al 2007:662; Oyugi et al 2004:1101; Fox & Rosen 2010:11), it is 
very challenging to adhere to ART, and strict adherence is not common (Montessori, 
Press, Harris, Akagi & Montaner 2004:229).  
 
Many studies have been done on factors associated with adherence in patients taking 
antiretroviral medication, while some focused on socio-demographic characteristics like 
race, age, income and level of education; some focused on health beliefs of patients; 
others concentrated on the interaction between patients and health care providers (Ma-
langu 2008:49; Ware et al 2009:43; Dahab et al 2008:63; Curioso et al 2010:13; Am-
berbir et al 2008:265). Although some of the factors identified in these studies are 
somehow predictive of adherence, none of them has been shown to be associated with 
adherence across studies.   
 
2.7.4.1 Patient-based factors 
 
Socio-demographic factors such as age, gender, and socio-economic status, level of 
education, income and ethnicity have been used in studies to understand their influence 
on adherence (Rougemont, Stoll, Elia & Ngang 2009:21; Gordillo, Del Amo, Soriano, & 
Gonzalez-Lahoz 1999:1765). It has not been possible to predict adherence based on 
demographic characteristics as no consistent correlation has been found between de-
mographic characteristics and patient adherence level (Rougemont et al 2009:21; 
Cauldbeck et al 2009:7). Although socio-demographic factors were not consistently cor-
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related with treatment adherence in several studies, they can be used to identify particu-
lar populations that may benefit more extensively from targeted interventions that ad-
dress specific barriers (Gordillo et al 1999:1766; Cauldbeck et al 2009:7).  
 
Medication adherence is affected by patients’ beliefs about disease origin and transmis-
sion which often form the basis for stigmatization in HIV/AIDS. Psychosocial factors like 
drugs and alcohol use, social stability, depression and psychiatric illness have also 
been used in other studies to find out if there are correlation between any of them and 
adherence to ART (Berg, Cooperman, Newville & Arnsten 2009:247; Howard et al 
2002:2179; Murphy et al 2003:253; Gordillo et al 1999:1764). What studies have found 
are barriers to adherence such as substance abuse, unstable housing, depression, 
mental illness, fear of disclosure of HIV status, decreased quality of life, work and family 
responsibility and past history of non-adherence (Glass et al 2010:200; Protopopescu et 
al 2009:603; Mills et al 2006:687). The importance of these findings in ART initiation is 
that denying an individual the benefit of ART based on the assumption that the person 
will not adhere due to his or her demographic characteristics is a futile exercise as no 
data are available to substantiate such action (Ickovics & Meade 2002:S99). 
 
Socioeconomic factors have also being implicated as part of barriers to adherence to 
ART in a number of studies, the cost of ART, and availability and accessibility to medi-
cations were the most significant barriers to adherence reported in various studies in 
Africa (Weiser et al 2003:284; Hawkins & Murphy 2007:1041; Iliyasu et al 2005:292; 
Mukhtar-Yola, Adeleke, Gwarzo & Ladan 2006:142; Hardon et al 2007:661; Tuller et al 
2009). There are indirect costs associated with ART which influence adherence; these 
are the time taken off work, the time spent in hospital and inability to fend for one’s fami-
ly during bouts of opportunistic infections (Castro 2005:1219; Hardon et al 2007:660). 
The access to drugs while away from home is another factor that has been identified 
that affects adherence among patients on ART (Nachega et al 2004:1053-1056; Garcia 
et al 2006:1251). 
 
Structural factors have also been described as having influence on adherence to ART. 
These are issues that are beyond the control of the patients, structural approach to ad-
herence does not see adherence as a simple individual behaviour but as one that oc-
curs within social and environmental context. In other words, it is difficult for some peo-
ple to adhere to ART because the adherence barriers are not generated at individual 
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level (Mukherjee et al 2006:S123-124). Some of these are out-of-pocket cost of health 
services and medication, transportation, homelessness, lack of access to food and wa-
ter and poor accessibility to health facilities. All these are structural barriers to adher-
ence that have to be addressed at the societal level in order to improve adherence 
(Hardon et al 2007:664; Mukherjee et al 2006:S124; Weiser et al 2003:284).  
 
Reduction in the structural barriers to healthcare has been shown to improve patient’s 
adherence levels in ART (Mukherjee et al 2006:S124). Adequate knowledge of the 
medication and understanding the need for strict adherence, self-efficacy, sense of self 
worth, acceptance of HIV status, making use of reminder tool and social support have 
been shown to influence adherence to ART in different settings (Garcia et al 
2006:1251). 
 
2.7.4.2 Treatment-related factors 
 
ART has been described as a complex treatment due to the pill burden, dietary and fluid 
restrictions and timing of medication intake. The complexity of drug regimen is one of 
the causes of non-adherence in patients on chronic medication (Glass et al 2010:200; 
Cauldbeck et al 2009:7). This has also been reported among HIV patients taking ARV, 
three times or more daily dosing regimens are associated with non-adherence 
(Protopopescu et al 2009:602; Frank 2002:S11; Roca, Lapuebula & Vidal-Tregedor 
2005:197). The pill burden has been described as a major challenge since combination 
ART is used and it often contains 2-20 pills that have to be taken in a day together with 
the other requirements like timing of dosages and food requirements (Protopopescu et 
al 2009:602).  
 
The numerous and potentially debilitating side-effects have also been shown to contrib-
ute to irregular drug use and deliberately stopping of medication intake by some pa-
tients (Waters & Nelson 2007:986; Weiser et al 2003:285). Regimens with significant 
side-effects profile have been associated with poor adherence (Glass et al 2010:200; 
Cauldbeck et al 2009:7).  
 
Various authors have suggested that the health care providers should consider the cir-
cumstances of patients while prescribing ART (Harries, Zachariah, Lawn & Rosen 
2010:71); a potent combination therapy may not fit into a patient’s daily schedule and 
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may therefore affect the adherence to such medication. Regimen-based strategies that 
can improve long term adherence among patients include simplification of ART regi-
mens which will assist in the long term adherence to treatment and maintaining efficacy 
of treatment (Harries, Zachariah, Lawn & Rosen 2010:72; Protopopescu et al 2009:604; 
Howard et al 2002:2180; Frank 2002:S12; Cauldbeck et al 2009:7). 
 
2.7.4.3 Provider-based factors 
 
Providers’ characteristics and the clinical setting also affect patients’ adherence; overall 
patients’ satisfaction with the level of care has been found to correlate with increased 
adherence (Gauchet, Tarquinio & Fischer 2007:145). The aspects of clinical setting that 
may positively influence adherence are friendly and supportive environment, non-
judgmental health care providers, convenience appointment schedule and confidentiali-
ty in service provision (Altice, Mostashari & Friedland 2001:54; Simoni et al 2006:S32). 
Long waiting time, poor staff attitude, intermittent drug availability and other procedural 
barriers have been found to decrease adherence to taking medications and keeping 
clinic appointments (Hawkins & Murphy 2007:1041; Iliyasu et al 2005:92). Continuous 
access to health care services and medications by patients has also been shown to in-
fluence treatment adherence (Hawkins & Murphy 2007:1042). The patient-provider rela-
tionship is another factor that has been well researched in terms of adherence to ART; 
research showed that good patient-provider relationship results in patient’s trust and 
confidence in the provider which in turn influences good adherence (Altice, Mostashari 
& Friedland 2001:54; Gauchet, Tarquinio & Fischer 2007:145). 
 
The challenge of adherence is not limited to the patient alone but extends to the health 
care provider; therefore, the relationship between the patient and the health provider is 
a form of therapeutic alliance where both parties work toward a common goal of improv-
ing the health of the patient. That is why frequent change in health care providers has 
been associated with poor adherence (Glass et al 2010:201). Discussing ART initiation 
in the context of an informed decision on the part of the patient has been reported to be 
an effective strategy that enhances patient-provider interaction. It enables an alliance 
formation which allows patient and provider to define therapy goals, side-effects, medi-
cation management and adherence monitoring (Harries, Zachariah, Lawn & Rosen 
2010:71). 
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According to Nachega et al (2006) social support and ability to disclose one’s status are 
important issues to be considered when assessing treatment adherence irrespective of 
the context. In a study done by Julius, Novitsky and Dubin (2009:34-44) on adherence 
of patients to chronic medications, the authors recommend that therapeutic alliance be-
tween patients and providers should be strengthened, time should be devoted to ad-
dress adherence among patients, and patients should be well assessed to identify bar-
riers to treatment adherence.  
 
2.7.4.4 Disease characteristics 
 
The clinical outcomes achieved with the use of ART been linked to adherence level. 
Studies have shown that prior opportunistic infections in an HIV patients before initiating 
ART has the potential of influencing adherence as the patient may perceive the disease 
to be severe enough requiring good adherence to treatment in order to achieve the 
treatment outcome (Cauldbeck et al 2009:7). Although the Swiss HIV Cohort Study re-
vealed that long standing HIV disease was among the predictors of worsening adher-
ence (Glass et al 2010:201). 
 
2.7.5 Monitoring and assessing ART Adherence 
 
Medication adherence is defined as the percentage of prescribed medications taken in 
any form for a specified period; instructions adherence is defined as the percentage of 
medications for which the correct special instructions were followed at each prescribed 
dose. Based on any of the method used, ART adherence is calculated as the percent-
age of doses taken over those prescribed within a given period. Although adherence is 
one of the modifiable variables in ART, its monitoring is difficult among patients, as no 
standard method exists to monitor adherence in ART, multiple approaches are often 
used (Nachega et al 2009:66; Mills et al 2006:687; Simoni et al 2006:S25). Some of the 
commonest methods are self-report, electronic device monitoring, pills count, pharmacy 
refill tracking, biological markers, provider estimation and therapeutic drug monitoring. 
Adequate monitoring of adherence is vital in preventing treatment failure and develop-
ment of resistance to antiretroviral drugs (Colebunders et al 2006:56). 
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2.7.5.1 Self-report of adherence 
 
Self report remains the main measure of adherence in developing countries although 
other techniques have been used widely; it involves asking patients to report their ad-
herence periodically (Kouanfack et al 2008:217). Studies have found correlation with 
actual medication intake in research done on self-report as a method of adherence 
monitoring (Oyugi et al 2004:1101; Ross-Degnan et al 2010:42). In the Ugandan study 
that used 3-day self report adherence, median adherence correlated with other 
measures of adherence (Oyugi et al 2004:1101). The major drawback of this method is 
overestimation of adherence by patients due to recall bias (Mills et al 2006:688). Adher-
ence guidelines advise that accuracy of adherence self-report can be achieved if pa-
tients are approached in a non-judgmental way during assessment (Colebunders et al 
2006:56). 
 
2.7.5.2 Pill counts method 
 
Pill count as a measure of adherence involves calculating the percentage of the number 
of pills prescribed and dispensed for the period between hospital appointments with the 
number of pills returned at the following appointment (San Lio et al 2008:1611). It can 
be done during patient visits to health facilities or unannounced at patients’ home. This 
technique is cheap and correlate well with adherence measured using viral load (San 
Lio et al 2008:1614) but its major shortcoming is manipulation of pills by the patient. 
Pills dumping prior to hospital visit has been documented which will result in overesti-
mation of adherence for the patient. Unannounced pill count is more reliable but this has 
been shown to affect the trust between the patient and health care provider which may 
eventually hinder adherence (Bangsberg 2006:939). Pill counts may be a reliable and 
economical tool for monitoring adherence in resource-limited settings although viral load 
monitoring has been described as the preferred method (San Lio et al 2008:1615). Bell, 
Kapitao, Sikwese, Van Oosterhout and Lallo (2007:560-563) assert that though they 
may overestimate adherence; pill counts and self-report are still the mainstay of meas-
uring adherence in resource-limited setting. 
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2.7.5.3 Electronic monitoring devices (EMD) 
 
This involves an electronic chip that is implanted on the bottle lid that records the open-
ing and closing of the bottle that contained the prescribed medicines, a computer pro-
gram is later used to extract information from the lid and the data is then analyzed. This 
technique assumes that opening of the bottle by the patient coincides with actual intake 
of the drug. Although this method has shown some correlation with actual drug intake in 
some studies (Howard et al 2002:2178; Paterson et al 2000:25), others have described 
it as an expensive and non-reliable device. A study in Malawi to compare methods of 
adherence monitoring found no correlation between electronic device monitoring, self-
reporting and pill counts (Bell et al 2007:562). Electronic devices may underestimate or 
overestimate adherence since it is difficult to know if a patient opening a drug bottle is 
actually taking the tablets or just opening the bottle, therefore, actual medication intake 
by patients is not measured by EMD. (Bova, Fennie, Knafi, Dieckhaus, Watrous & Wil-
liams 2005:108). A study of electronic monitoring device used among HIV patients on 
ART revealed that patients who rely on pill boxes are not likely to use EMD because pill 
boxes are the tools used by patients with numerous medications (Bova et al 2005:108). 
 
2.7.5.4 Pharmacy based-records 
 
Pharmacy record is a simple and effective tool for monitoring adherence in ART and 
has been proved to be useful in adherence monitoring in resource-limited setting 
(Rougemont et al 2009:21; Nachega et al 2006a:82). This method employs pharmacy 
records to monitor adherence among patients when collecting their medication at the 
pharmacy. Patients collecting their medication regularly are said to be adherent by the 
pharmacy. Ross-Degnan et al (2010:42) showed that pharmacy records in resource lim-
ited settings are useful in measuring adherence, in their study, adherence measured by 
pharmacy records correlated with CD4 count and weight gain in patients (Ross-Degnan 
et al 2010:42). Adequate record keeping is necessary for pharmacy refill tracking infor-
mation to be useful; the major setback is that the method only assumes that patient are 
adherent based on their empty pill boxes and the regular collection of their medication, it 
does not measure actual medication intake. The method also requires patients to be 
collecting their medication at the same pharmacy for all refills which may not be possi-
ble in all cases. 
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2.7.5.5 Biological markers monitoring 
 
Viral load level and CD4 counts are used as indicators for treatment outcomes and suc-
cess, viral load is regarded as the main indicator of the risk of therapeutic failure, they 
can also be used in measuring adherence (San Lio et al 2008:1614; Wilson et al 2009). 
Low viral load and increase in CD4 count are suggestive of good adherence although 
some patients may have high viral load despite taking the ART regularly. Research has 
shown that CD4 is a good measure of adherence and correlated with weight gain, self 
report and pharmacy records (Ross-Degnan et al 2010:42). Viral load was also found to 
correlate with pill counts and good clinical outcomes in patients (San Lio et al 
2008:1614). The major drawback is cost and availability in resource limited settings 
(Colebunders et al 2006:53). 
 
2.7.5.6 Provider estimation method 
 
In provider estimation method of measuring adherence, the health care providers esti-
mate patient‘s adherence based on factors such as socio-demographic and economic 
factors. In this method there is no correlation with actual medication intake, studies have 
shown that health care providers overestimate adherence to HIV treatment when factors 
such as demographic characteristics are used to predict adherence as it is very difficult 
to predict adherence based on demography (Paterson et al 2000:28). Ross-Degnan et 
al (2010:42) found that consistent clinic attendance did not correlate with other 
measures of adherence among patients on ART. 
 
2.7.5.7 Therapeutic drug monitoring 
 
Therapeutic drug monitoring involves measuring the levels of the drug in the blood 
stream of the HIV patient, this method is not used routinely as most ARVs have short 
circulating times in the body, couple with the fact that it is very expensive.  Presently 
therapeutic drug monitoring is restricted for research purposes. A study that combined 
therapeutic drug monitoring (TDM) and viral resistance monitoring to find causes of 
virologic failure in patients on ART revealed that TDM is necessary in patients who de-
veloped adverse reactions while on ritonavir boosting regimen as there is risk of drug 
toxicity in these patients. The researchers conclude that TDM assists clinicians in 
choosing the best regimens for their patients and should be used routinely in clinical 
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practice (Duong et al 2004:222). A prospective cohort study in Cameroon to compare 
adherence of fixed-dose combination of nevirapine, stavudine and lamivudine using 
nevirapine plasma level monitoring and self-report by patients found that self reported 
adherence was significantly higher than adherence measure by nevirapine level moni-
toring (Kouanfack et al 2008:217). The authors conclude that nevirapine plasma con-
centration monitoring provides accurate measurement of adherence compared to self-
report but caution that it is not feasible in most clinical settings in resource-limited areas 
(Kouanfack et al 2008:218).  
 
2.7.6 Strategies and tools for enhancing adherence 
 
Adherence is very complex and unpredictable among patients on chronic medications; 
several methods of enhancing adherence exist in ART and are usually used in combina-
tion for effectiveness. The interventions used to enhance adherence among patients are 
aimed at addressing potential barriers to adherence to achieve successful HIV treat-
ment outcomes. 
 
2.7.6.1 Antiretroviral therapy strategies  
 
This entails simplifying regimen characteristics; simplification of dosing schedules; re-
duction of pill burden, and adjusting dietary restrictions to match patients' activities of 
daily living. In addition, identifying previous ART use, pre-existing medical conditions 
that may affect ART use and ensuring continuous provision of ART have also been re-
ported to enhance adherence to ART (Birbeck et al 2009:672). Studies have demon-
strated improved adherence with once or twice daily dosing of ART (Kauf et al 
2012:158). Many fixed-dose combinations (FDC) of ARVs are now available and have 
been shown to improve adherence in patients (Haberer et al 2011:6; Kauf et al 
2012:158). The buddy system has been widely used in resource-limited settings where 
relatives or friends agree to assist the patient in adhering to the medication, buddies 
remind patients to take their medication, encourage them and assist in keeping hospital 
appointment, this approach has led to improved ART adherence according to docu-
mented evidence (Birbeck et al 2009:672). Social support not only assists the patient in 
adhering to ART but also provide psychological support to the patient that helps them to 
cope with the disease (Nachega et al 2006b:131). 
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2.7.6.2 Education and counselling 
 
This is usually the mainstay of ART programme in any setting in order to empower the 
patient to be part of the treatment process. Knowledge about the disease, its symptoms, 
treatment and side-effects of the medications are crucial information to be passed 
across to the patient (Magadza, Radloff & Srinivas 2009:369). During counselling, po-
tential barriers to adherence may be identified and addressed. Studies have shown that 
counselling assists the patient in developing positive beliefs and perception towards the 
disease (Barclay et al 2007:47), it also helps in setting goals and increases the self-
efficacy of the patient (Johnson et al 2007:577). A randomized controlled trial in the 
USA to compare effect of person-to-person contact and support adherence with medi-
cation alarms technique revealed improved responses to therapy and good adherence 
among the group that received interpersonal adherence support (Mannheimer et al 
2006). This finding is consistent with the literature where repeated supportive adher-
ence has been described as the most effective intervention since it provides human 
contact and support (Simoni, Pearson, Pantalone, Marks & Crepaz 2006:S30). 
 
2.7.6.3 Adherence tools for patients 
 
These tools are often combined with other behavioural interventions (Saberi & Johnson 
2011:6). Pill boxes are containers used for storing the ARV for regular use as pre-
scribed; it enables the patient to take the medication correctly. Electronic versions of pill 
boxes with reminders to the patient are also available. The major setback of this strate-
gy is the lack of confidentiality and privacy as patients may want to hide their medica-
tion, another one is the responsibility of the patient in filling out the boxes, uneducated 
patients may not be able to do this correctly. Pill chart involves visual display of the pills 
in terms of their colour and shape, name and dosage of the medication during counsel-
ling. This is very useful especially among the uneducated patients (Saberi & Johnson 
2011:6). 
  
Electronic devices such as beepers, alarm and watches that remind patients to take 
their medication according to the prescribed schedule have been used to enhance ad-
herence (Colebunders et al 2006:56). Electronic pager linked to the internet may also 
be used to send reminders to patient to take their drugs. Reminder tools have been re-
ported by patients as one of the facilitators of adherence (Skinner, Rivette & Bloomberg 
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2007:606), although the major disadvantage of this strategy is the lack of privacy asso-
ciated with it. Telephone calls are also used as reminders for patients to take their med-
ication, the shortcoming of this is the cost required to set up this kind of service and the 
challenges of the patient having the telephone with them all the time (Skinner et al 
2007:606). 
 
Medication diaries are very useful in understanding the pattern of drug use by the pa-
tient and the reason for not taking the medication regularly. Diaries are used by the pa-
tients to document the time and date of taking the medications and missed doses and 
the reasons for it. This tool may also be used to identify side-effects or other problems 
that the patient may encounter in the course of taking ART. Research has shown that 
some tools appear to be of more benefit to patients when they are combined with pa-
tient education or counselling. A large multicenter randomized trial in the USA has re-
vealed that reminder devices alone do not enhance adherence and suggests that they 
should be combined with counselling as part of comprehensive support for patients on 
ART (Mannheimer, Morse et al 2006:45). 
 
2.7.6.4 Directly administered antiretroviral therapy (DAART) 
 
This technique has been used successfully in TB by asking patients to take medication 
under the supervision of adherence counsellors. Directly administered ART can be clinic 
or home-based, once-daily, twice-weekly, or once-weekly. The challenge in ART is dif-
ferent from TB as timing of medication intake varies across ARVs and the fact that the 
treatment is for life. Although this approach has shown some benefit in improving ad-
herence, research does not support routine use of directly administered ART; Modified 
directly observed therapy (mDOT) has been suggested for use in ART and a home-
based mDOT strategy has been used to improve adherence rate in resource-limited set-
tings (Farmer et al 2001:1147), although adherence to ART was only seen in early 
weeks of an (mDOT) study in Kenya (Sarna et al 2008:617). Despite its limited use, the 
benefits of mDOT in ART seen in early stage of treatment may help patient to develop 
good understanding of the treatment and develop good treatment taking behaviour; it 
may also assist the patient in developing trusting relationship with the health care pro-
vider (Farmer et al 2001:1149).   
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2.7.6.5 Health system and service delivery interventions  
 
These include interventions that target barriers to ART adherence at the level of health 
care delivery of HIV services such as food supplements, transportation to health facili-
ties, staffing and integration of services. Research has demonstrated that ART adher-
ence and retention in care are associated with interventions that offer food supple-
ments, address transportation issues and integrated services. Serrano et al (2010:72) 
assert that family nutritional support for HIV positive patients on ART improves adher-
ence leading to good clinical outcomes, and that this could be integrated into ART ad-
herence interventions as an effective and comprehensive community-based primary 
care (Serrano et al 2010:72). In a South African study, nurse-initiated ART services 
have been shown to produce the same outcomes with ART services run by doctors, 
which indicate that where human resources are limited, nurses can be used to provide 
ART care (Sanne et al 2010:38). Another study in the USA showed that addressing is-
sue of transportation to the health facilities among HIV patients and integration of home-
based care into ART services lead to improve attendance in clinics appointments (An-
dersen et al 2007:39). 
 
2.8 CONCLUSION 
 
Adherence to ART has become one of the major challenges facing HIV/AIDS services 
following the rapid scale-up of ART to provide life-saving treatment to eligible patients. 
Health behaviour theories needed to be well examined to enhance our understanding of 
how relevance they are concerning adherence to medication in chronic condition such 
as HIV/AIDS (Gill, Hamer, Simon, Thea & Sabin 2005:1247; Peltzer et al 2010:111). 
ART adherence needs to be studied in relation to the patients’ self-efficacy and their be-
liefs about medicines considering the fact that ART is a lifelong therapy and near prefect 
adherence is required to achieve the desirable positive clinical outcome. This research 
explored patients’ self-efficacy and their beliefs about medicines and how these relate to 
ART adherence, and further make recommendations for interventions that will target 
cognitive perspective of health behaviour variables with a view to enhancing ART ad-
herence in South Africa.  
 
The literature review also looked at epidemiology and clinical aspect of HIV/AIDS as a 
chronic disease, mode of transmission of HIV infection, treatment and prevention mo-
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dalities. In addition, factors influencing ART adherence and consequences of non-
adherence were discussed; modalities for measuring adherence and strategies of im-
proving adherence were also described. The literature review further focused on the 
various cognitive-behavioural theories used in modifying health behavioural which in-
volves a number of theories that could be used in interventions that address multiple 
obstacles to medication adherence among patients on chronic medication.  
 
The literature review of the relevant resources substantiates the assumption that there 
is relationship among self-efficacy, beliefs about medicines and ART adherence. In the 
next chapter, the research methodology used for the research will be described. 
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CHAPTER 3 
 
RESEARCH METHODOLOGY 
 
3.1 INTRODUCTION 
 
The previous chapter dealt with the relevant literature on antiretroviral therapy adher-
ence, relevant health behaviour theories, theoretical framework applied in this study, 
and factors that influence adherence among patients on chronic medication. This chap-
ter describes the research methodology employed by the researcher that was used to 
investigate the interrelationship of ART adherence self-efficacy, beliefs about medicines 
and ART adherence. It includes the aims and objectives of the study, the research de-
sign, the description of the sample population and sampling procedures, the data collec-
tion tools, process of data collection, contents of the research instruments, validity and 
reliability of the research instruments, pre-testing of data collection tools and the pilot 
study. Finally, the data analysis and ethical issues relevant to the current research were 
also discussed in this chapter. 
 
3.2 AIM AND OBJECTIVES OF THE STUDY 
 
This study aimed to provide a framework for antiretroviral therapy adherence improve-
ment through focused intervention on modifiable factors that are strongly associated 
with ART adherence. 
 
The specific objectives of this research are to: 
 
1. Explore the cognitive variables of adherence self-efficacy and beliefs about 
medicines that influence adherence among patients on ART. 
 
2. Determine the inter-relationships among adherence self-efficacy, beliefs about 
medicines and ART adherence. 
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3. Describe the modalities of enhancing adherence to ART through focused inter-
ventions on the identified factors that are strongly associated with ART adher-
ence. 
4. Develop a framework for the improvement of ART adherence based on the fac-
tors identified in this study. 
 
3.3 RESEARCH DESIGN 
 
Research design is the overall plan of the study that describes the strategies and ap-
proach used in obtaining data about the phenomenon of interest; in addition, it provides 
the structure that the research follows in terms of data collection and analysis (Tredoux 
& Smith 2008:161). According to Durrheim and Painter (2008:147-152), in choosing the 
method to be used in research, there is need to aim at achieving much control over fac-
tors that may interfere with the validity and reliability of the study findings. 
 
3.3.1 Quantitative research design 
 
Quantitative research method is often referred to as the traditional scientific approach to 
research that is grounded in the philosophical paradigm for human inquiry called positiv-
ism. It involves the collection of numerical data that can be subjected to statistical anal-
ysis that results in quantifiable information (Terre Blanche & Durrheim 2008:7). Re-
search that takes the positivist approach places much emphasis on rationality, objectivi-
ty, prediction and control (Baum 1995:463). Quantitative research is often embraced by 
researchers who support the view that its design is less susceptible to bias based on 
the belief that the social world lends itself to objective forms of measurement character-
ized by a set of orderly and disciplined procedure (Sale, Lofeld & Brazil 2002:44). This 
has resulted in advocates of quantitative approach being referred to as objective scien-
tists who are committed to the discovery of quantifiable information (Baum 1995:460). 
 
Despite the strict application of standardized procedures to minimize systematic bias 
and avoid making erroneous conclusions in quantitative research, there are some 
methodological limitations of this approach especially in health research that may limit 
their applicability in practice (Walker 2005:574). Research with human participants is 
subject to certain external influences that may affect the findings, ensuring external va-
lidity in quantitative research is not sometimes possible due to practical and ethical rea-
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sons, to add to this, attaining consistent internal validity may also prove difficult in quan-
titative methods (Walker 2005:575). The sampling procedure is usually based on specif-
ic inclusion and exclusion criteria that require the researcher to select a sample from the 
study population that is representative of the parent population. Failure to achieve this 
means the findings cannot be generalized; the practical implication of this is that these 
criteria may systematically exclude certain proportion of the study population who may 
have the characteristics that the researcher is investigating. Furthermore, the Haw-
thorne effect where subjects change their behaviour or respond in a certain manner be-
cause of the awareness that they are being observed is another limitation of quantitative 
method (Leonard & Masatu 2006:2333; McCarney, Warner, Iliffe, Van Haselen, Griffin & 
Fisher 2007:30). 
 
According to Baum (1995:466), some public health issues need quantification while 
others are more qualitative in nature; methodologies for health research need to be di-
verse and chosen to suit the problem being investigated by the researcher. The varia-
bles under investigation in this study consist of cognitive mechanisms that are quantifia-
ble; the researcher therefore adopted an objective and detached epistemological stance 
towards the study variables and followed the positivist approach using quantitative de-
sign in undertaking this research.  
 
Quantitative research can be experimental, quasi-experimental or non-experimental and 
make use of descriptive and inferential statistics. Quantitative study is further divided 
into cross-sectional in which data are collected a specific point in time or longitudinal 
which extend over a period of time. This study used a non-experimental cross sectional 
design as data were collected at a point in time and there was no manipulation of the 
subjects who participated in the research. 
 
3.3.2 Non-experimental research design 
 
A non-experimental quantitative research methodology was employed using a descrip-
tive correlational design to assess the predictive relationships of ART adherence Self-
Efficacy, Beliefs about Medicines and ART adherence in HIV-infected patients on 
HAART. Correlational research is a measure of the association or co-variation of two or 
more dependent variables and is used in exploring causal relationships (Walker 
2005:573). Correlational design method has some advantages in quantitative research 
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in that it allows for examination of relationships between variables without introducing 
any interventions and also allows for generation and testing of hypotheses (Terre 
Blanche & Durrheim 2008:7). A non-experimental descriptive correlational design was 
best suited for this research; it enabled the researcher to examine the relationships be-
tween the study variables without introduction of any intervention. Data collected by 
means of quantitative instruments were used to examine the relationships between the 
independents variables and the dependent variable.  
 
3.4 RESEARCH METHODS 
 
3.4.1 Population  
 
Study population refers to the larger pool from which sample participants  are  drawn  
(Durrheim & Painter 2008:133). The study population were male and female, 18 years 
or older, of all races and socio-economic groups who were on ART at a large clinic 
within the Tshwane Metropolitan area at the time of conducting this study. This health 
institution is part of the Comprehensive Care, Management and Treatment program of 
the Gauteng Department of Health. This area was selected because it is an area where 
one can find the entire population groups in South Africa representing a heterogeneous 
population. According to the clinic records, there were 2312 adult patients 18 years or 
older on ART in the clinic as at the time of this study (Antiretroviral Clinic Statistics 
2011). These 2312 adults formed the study population for this research and the study 
samples were drawn from them. 
 
3.4.2 Power of the study 
 
Power of a study is the ability of the study to demonstrate an association or causal rela-
tionship between two variables, given that an association exists. In quantitative research 
it is necessary to specify the desired study power and to calculate the sample size 
needed to achieve this power when planning the study to avoid conducting a study with 
insufficient power. Traditionally, researchers consider a study power of 80% to be the 
minimum, although higher values are commonly used (Harvey & Lang 2010:736). An 
exact binomial test with a nominal two-sided significance level will have 87% power to 
detect the difference between the Null hypothesis proportion π0 of 0.600 and the Alter-
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native proportion πA of 0.700 when the sample size is 232 (Chernick & Liu 2002:149-
155).  
 
3.4.3 Sampling and sample size 
 
Sampling is the process of selecting a portion of the study population that is representa-
tive of the entire population (Durrheim & Painter 2008:133). Systematic random sam-
pling method was used in selecting the sample size to ensure all the study population 
had equal chance of being selected using the inclusion criteria of (a) 18 years and 
above, (b) Free of severe opportunistic infections (c) No cognitive impairment as deter-
mined by the mini-mental state examination (d) Ability to understand English or any of 
the South African official languages (e) Have been on ART for at least one year. The file 
numbers of all the 2312 patients were listed in ascending order and every tenth person 
on the list was selected to participate in the study until the desired sample size of 232 
was reached. Where a selected participant declined to participate in the study or ineligi-
ble the next person on the list was included. 
 
3.4.4 Data collection 
 
Two research assistants were recruited and trained to assist in the administration of the 
questionnaires. The assistants included a registered professional nurse who has over 
five years experience working in HIV/AIDS services; she is involved in HIV counselling 
and testing, initiation of ART to eligible patients and screening of patients for Tuberculo-
sis and other opportunistic infections associated with HIV/AIDS. She is fluent in Afri-
kaans, English, Setswana and Sesotho. The other assistant was an enrolled male nurse 
who has been working as ART adherence counsellor for over two years; his duties in-
clude identifying patients who are not adhering to their treatment and developing plan of 
action to ensure adherence. He is well acquainted with terminologies used in HIV man-
agement and speaks English, Setswana and IsiZulu very well. The two assistants were 
not working at the study setting of this research. 
 
The research assistants were given a short training on protecting human participants in 
research. In order to ensure consistency, role play was used to ensure standard proce-
dures of obtaining informed consent, in completing the questionnaires, and in handling 
questions before or in the process of administration of the questionnaires. Simulated 
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patients were used by each of the assistants to demonstrate how they would explain the 
research process to potential participants, how they would obtain informed consent, and 
how they would handle queries related to the research from the participants. The re-
search assistants were informed to resolve difficult issues with the principal investigator 
before, during and after the administration of the questionnaires. The questionnaires 
were in English and the two research assistants chosen were able to clarify issues and 
communicate effectively with study participants.  
 
The patients on ART at the study setting were informed about the study and that they 
were all potential participants. The risk, benefits, time commitment and eligibility for the 
study were explained. Informed consent was obtained from selected respondents and 
appointment fixed for the completion of the questionnaires. The study made use of 
questionnaires that were completed with the assistance of the researcher and his assis-
tants.  Almost all the participants completed the questionnaires on their own with the 
exception of fifteen people (7%) that had no formal education and were assisted in 
completion of their questionnaires by either of the research assistants who are fluent in 
their home language. Completion of the questionnaires was conducted in separate 
rooms and at the convenient of the selected participants, the average time for complet-
ing each questionnaire was 45-60 minutes. 
 
3.4.5 Research instruments 
 
The four quantitative instruments used for data collection in this study were combined 
together as a single questionnaire (Annexure D) and consists of the following: Demo-
graphic Data Questionnaire (developed by the researcher); the HIV Treatment Adher-
ence Self-Efficacy Scales (HIV-ASES); the Beliefs about Medicines Questionnaire 
(BMQ) and the AIDS Clinical Trial Group (ACTG) Adherence Questionnaire. Permission 
to use the ACTG and HIV-ASES is granted for HIV research purposes by the Center for 
AIDS Prevention Studies (CAPS) at University of California, San Francisco (Center for 
AIDS Prevention Studies 2011). The researcher also obtained permission to use the 
BMQ questionnaire from the copyright holder (Annexure F). 
 
The independent or predictor variables in this study are demographic characteristics, 
self-efficacy and beliefs about medicines. The dependent variable is ART medication 
adherence. The Demographic Data Questionnaire provided information on the demo-
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graphic characteristics of the participants and their ART regimens. Participants' ART 
Adherence self-efficacy was assessed using the HIV Treatment Adherence Self-
Efficacy Scale (HIV-ASES). The medication beliefs of the study participants were as-
sessed using the Beliefs about Medicines Questionnaire (BMQ) and the medication ad-
herence was assessed with the AIDS Clinical Trial Group (ACTG) Adherence Question-
naire. 
 
3.4.5.1 The demographic data questionnaire 
 
The demographic data questionnaire was developed by the researcher after extensive 
literature review and was based on the research objectives. The questionnaire was pre-
tested by the researcher by using it to collect information from twenty randomly sampled 
patients in a clinic that was not included in the final study sample; it was subsequently 
adjusted, tested again and later finalized before the actual data collection started. The 
demographic data questionnaire, a 15-item self-report instrument provided information 
on the demographic characteristics of the participants. Demographic data captured 
were age, gender, marital status, education, occupation, social habits. Other information 
included in the demographic data questionnaire is length of time since HIV diagnosis, 
disclosure of HIV status, possible way of being infected with HIV, length of time on anti-
retroviral therapy, antiretroviral regimen, number of pills taken daily and available social 
support in terms of treatment buddy.  
 
3.4.5.2 HIV treatment adherence self-efficacy scale (HIV-ASES) 
 
Self-Efficacy in this research is conceptualized as medication-taking self-efficacy be-
liefs, or one’s belief in his/her ability to plan and perform a desired behaviour (ART ad-
herence). General self-efficacy instruments have little explanatory and predictive value, 
therefore self-efficacy tools must be tailored to the specific behavioural discipline that is 
of interest to researchers (Bandura 2004:145). According to Bandura (2004:145) in or-
der to accurately measure medication-taking self-efficacy, the tool must measure the 
participant’s beliefs about their abilities to execute different levels of medication adher-
ence. Self-efficacy in this study was measured using the HIV Treatment Adherence 
Self-Efficacy Scale (HIV-ASES). The scale developed in the context of HIV treatment to 
provide a measure of ART adherence self-efficacy in HIV-infected patients on ART, is a 
12-item scale (Johnson, Neilands, Dilworth, Morin, Remien & Chesney 2007:359). Psy-
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chometric properties of the instrument including content validity, construct validity and 
internal consistency and stability have been established (Johnson et al 2007:364). Fac-
tor analysis supports subscales measuring Adherence Integration (eigenvalue=6.12) 
and Adherence Perseverance (eigenvalue=1.16) accounting for 61% of the variance in 
scale items. The instrument demonstrates robust internal consistency (ρs> .90) and 
test-retest reliability of (rs> .70) at 3-month and (rs> .40) at 15-month. The authors fur-
ther state that the concurrent validity analyses showed relationships with ART adher-
ence, clinical status, psychosocial measures and health service utilization (Johnson et 
al 2007:364). 
 
The HIV-ASES has an 11-point Likert response format with possible range of scores 
from 0 (“cannot do at all”) to 10 (“completely certain can do”). The questions were asked 
in the form of how confident are that you can do the following? An exemplar question is 
‘how confident have you been that you can integrate your treatment into your daily rou-
tine? High and low categories of ART adherence self-efficacy were defined as above 
and below the median of the 11 summed items respectively. For this study self-efficacy 
items score were added and divided by the total number of items to form a composite 
adherence self-efficacy score. 
 
3.4.5.3 Beliefs about medicines questionnaire (BMQ) 
 
The Beliefs about Medicines Questionnaire (BMQ) is an 18-item scale designed to 
measure cognitive representations of medication in patients on chronic therapy (Horne, 
Weinman & Hankins 1999:18). The questionnaire assesses beliefs about specific medi-
cations and beliefs about medications in general. The reliability, criterion-related and 
discriminant validity of the scale has been demonstrated (Horne, Weinman & Hankins, 
1999:18; Mårdby, Åkerlind & Hedenrud 2009). It has been validated for use in patients 
with chronic illnesses and has been shown to predict adherence to treatment (Porteous 
et al 2010:227; Tordera, Moragon, Fuster, Bayo & Ciscar 2009:220; Aikens, Nease, 
Nau, Klinkman & Schwenk 2005:27; Russell & Kazantzis 2008). People with strong be-
liefs in the necessity of taking medication to maintain their health were found to be more 
adherent to treatment, and those with higher levels of concern about medication, com-
monly about the dangers of dependence and long-term side-effects, were more likely to 
be non-adherent (Ireland & Wilsher 2010:40; Chia, Schlenk & Dunbar-Jacob 2006:198; 
Neame & Hammond 2005:765; Riekert & Drotar 2002:183).  
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The BMQ is made up of two sections namely, the BMQ-Specific which assesses the 
representation of medications prescribed for personal use and the BMQ-General which 
assesses beliefs about medications in general. The BMQ-Specific comprises two 5-item 
subscales assessing beliefs about the necessity and efficacy of medicines prescribed 
(Specific-Necessity) and concerns about the harmful effects of the prescribed medicines 
based on belief about the drug and its long-term adverse effects (Specific-Concerns). 
The BMQ-General has two 4-item subscales; one assesses beliefs about harm associ-
ated with medications in general (General-Harm) and the other assesses beliefs about 
the overuse of medicines in general (General-Overuse) (Horne, Weinman & Hankins 
1999:21). 
 
When the instrument was analyzed for construct validity using principle component 
analysis, factor analysis on combined items from the BMQ-Specific and BMQ-General 
factors on pooled data for six illness groups (n=524) showed eigenvalue of 3.38 for 
Specific-Concerns; 2.92 for Specific-Necessity; 1.60 for General-Harm and 1.44 for 
General-Overuse (Horne, Weinman & Hankins 1999:12). In a separate study to validate 
the BMQ conducted by Tordera et al (2009:218-223), data from 126 respondents were 
analyzed for internal consistency, analysis of the 2 components of the questionnaire re-
vealed excellent internal consistency for the 4 subscales (general overuse, α=0.70; 
specific necessity, α=0.83; specific concern, α=0.72; and α=0.68 for the general harm 
subscale (Tordera et al 2009:220). 
 
The exemplar questions for the 4 subscales in relation to HIV/AIDS include:  
 
1. Assessing beliefs about the necessity and efficacy of medicines prescribed for 
HIV/AIDS (e.g. “Without ARVs I would be quite ill”). 
 
2. Assessing beliefs on concern about the harmful effects of medicines prescribed 
for HIV/AIDS (e.g. “Having to take ARVs worries me”). 
 
3. Assessing beliefs about the overuse of medicines in general (e.g. “Doctors use 
too many medications”).  
 
4. Assessing beliefs about harm associated with medications in general (e.g. 
“medicines do more harm than good”).  
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The response options for this instrument are rated on a 5-point Likert scale ranging 
from: Strongly agree, Agree, Uncertain, Disagree to Strongly disagree. Higher score in-
dicates a stronger belief about the corresponding concepts in each sub-scale. 
 
3.4.5.4 AIDS clinical trial group (ACTG) adherence questionnaire 
 
The ACTG Adherence questionnaire is a 5-item tool that assesses adherence to doses, 
scheduling and dietary instructions, it is less expensive and a much more convenient 
method for collecting adherence data (Reynolds et al 2007:407). This tool is also a 
measure of patient’s reason for missing medication or dietary requirements. The tool 
has been used in various studies and found to be a reliable and valid measure of self-
reported adherence to ART (Peltzer et al 2010:111; Mathews et al 2002:157; Reynolds 
et al 2007:408; Chesney et al 2000).  
In a series of analyses conducted to estimate the reliability of the 5-item ACTG Adher-
ence Questionnaire by Reynolds and colleagues, Cronbach α coefficients for the stand-
ardized scores for the ACTG Adherence Questionnaire items (5 items and 8 variables) 
were all  greater than 0.80, demonstrating good reliability. The authors also confirmed 
that the measure of adherence using items 1 to 4 of the ACTG Adherence Question-
naire was found to be strongly associated with plasma HIV RNA outcome and was also 
comparable to adherence measured by medication events monitoring system (Reynolds 
et al 2007:406). 
 
The questionnaire queries the participants on the number of doses missed of a medica-
tion during each of the 4 days before a clinic visit (e.g., ‘‘How many doses did you miss 
yesterday, the day before yesterday, 3 days ago, and 4 days ago?’’). In addition, other 
adherence behaviour were assessed with 4 questions regarding adherence with the dai-
ly schedule as follows; ‘‘Most ARV medications need to be taken on a schedule … How 
closely did you follow your specific schedule over the last 4 days?’’ ‘‘Do any of your 
medications have special instructions? If so, how often did you follow those instructions 
over the last 4 days?’’ ‘‘When was the last time you missed any of your medications?’’ 
The constructs for the three behavioural questions and the response categories are as 
follow:  
1. How closely was the schedule followed? 0=never, 1=sometime, 2=half of the 
time, 3=most of the time, 4=all of the time.  
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2. How closely were instructions followed? 0=never, 1=sometime, 2=half of the 
time, 3=most of the time, 4=all of the time.  
 
3. When any medication was last skipped? 0=never, 1=>3 months, 2=1 to 3 
months, 3=2 to 4 weeks, 4=within past 2 weeks, 5=within past 2 days.  
 
Medication adherence is defined as the percentage of prescribed medications taken in 
any form for the last 4 days; instructions adherence is defined as the percentage of 
medications for which the correct special instructions were followed at each prescribed 
dose. Adherence to ART in this study is defined as patients compliant to HIV medication 
in previous four days. Adherence is calculated as the percentage of doses taken over 
those prescribed. 
 
3.5 PILOT STUDY 
 
Pilot study assists researchers in identifying possible problems in the proposed study 
and allows for revision of the methods and instruments before data collection (Terre 
Blanche, Durrheim & Painter 2008:94). The researcher carried out a pilot study at a 
separate clinic that was not included in the final study sample. The four instruments 
were tested among randomly selected 30 participants that had similar characteristics to 
the sample selected for this study for contents clarity before being administered to the 
selected sample. The respondents were asked to give constructive feedback with re-
gard to clarity of the questions, comprehension and time necessary to answer all the 
questions in the questionnaire. The respondents did not experience difficulty in complet-
ing the questionnaires and completed the questionnaire between 45-60 minutes, they 
made some valuable comments described below which were considered during the 
administration of the questionnaires to the 232 patients selected for this study. The fol-
lowing were the comments made by the 30 participants who participated in the pilot 
study. 
 
Question 9 on the demographic data questionnaire: What is/are the most likely way(s) 
that you became infected with HIV? When asked about the modality of acquiring HIV 
infection, about half of the respondents indicated they did not know. This prompted the 
researcher to include an option “Don’t know” in the revised questionnaire. 
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Question 14 on the demographic data questionnaire: What is the number of pills you 
swallow every day? Participants queried what the number of pills meant; as there were 
some participants who had co-morbidities e.g. asthma, diabetes, hypertension etc. who 
were also on ART. They wanted to know if they should add up all the ARVs and other 
pills. In the revised questionnaire the researcher specified the number of pills to mean 
ARVs only to avoid confusing the participants.  
 
Furthermore, the participants in the pilot study identified some similarity between ques-
tions 4 and 7 in the HIV-ASES questionnaire. Question 4 asked: “How confident are you 
that you can stick to your treatment schedule even when your daily routine is dis-
rupted?” Question 7 asked: “How confident are you that you can continue with your 
treatment even if doing so interferes with your daily activities?” The researcher clarified 
the ambiguity noted here with the participants during the administration of the question-
naires to the 232 selected individuals. Sticking to treatment schedule mentioned in 
question 4 meant continuing taking medication as prescribed in terms of dosing, sched-
uling and dietary instructions. To continue with treatment mentioned in question 7 meant 
continuing taking medication without emphasizing sticking to dosing, scheduling and 
dietary instructions. 
 
Some participants indicated they did not know the meaning of T-cells in question 8, 
where participants were asked how confident they were in continuing with their treat-
ment plan prescribed by their physician even if their T-cell drops significantly in the next 
three months. The researcher changed T-cell to CD4 in the revised questionnaire that 
was eventually used in this study since all HIV-infected patients on ART know what CD4 
means; they are informed of it during the counselling process. 
 
The researcher having revised the questionnaire based on the above feedback from the 
pilot study informed the research assistants to note them and educated them on how to 
handle the query that may arise from the perceived similarity between questions 4 and 7 
on the HIV-ASES questionnaire. 
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3.6 DATA ANALYSIS 
 
The Statistical Package for Social Sciences (SPSS) version 19.0 manufactured by IBM 
was used for data analysis. Descriptive statistics including means, percentages and fre-
quency distribution were used to summarize the demographic data, HIV-ASES, BMQ 
and ACTG questionnaire. Measures of variability were applied to characterize the dif-
ferences that exist among the scores and the central tendency of the data. Pearson cor-
relation analysis was used to assess the bivariate associations among the variables, 
and multivariable logistic regression was used to determine predictors of medication 
adherence. A p-value of <0.05 was considered to be significant; an alpha level of 0.05 is 
the probability of a type I error, that is, the probability of rejecting the null hypothesis 
given that that the null hypothesis is true. The significance of each independent variable 
as well as the combined significance of the independent variables to the dependent var-
iable was explained by the variance observed in the dependent variable. Variables in-
cluded in the model are summary scores from the BMQ and HIV-ASES that were signif-
icantly associated with adherence as measured by ACTG questionnaire. 
 
3.7 INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
Internal validity is the extent to which causal conclusion can be drawn from a study find-
ings and a study is said to have external validity if the finding can be generalised be-
yond the confines of the design and the study settings (Van der Riet & Durrheim 
2008:90). The use of cross-sectional design to investigate adherence to HIV medication 
at a point in time, will limits the degree to which causal inferences and generalizations 
can be made from the research findings, but the use of systematic random sampling 
ensured the selected samples were representative of the target population, and the use 
of a fairly large sample size enhanced the external validity of the study.  
 
3.8 CONTENT VALIDITY OF THE RESEARCH INSTRUMENTS 
 
Content validity is based on the extent to which a measurement reflects the specific in-
tended domain of content; it focuses on the adequacy with which the domain of the 
characteristics is captured by the measure (Vogt, King & King 2004:232). To ensure that 
all the measures in this study represent the facets of the constructs under investigation, 
the following steps were taken by the researcher: 
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 An extensive review of relevant literature on the constructs being investigated; 
this enabled the researcher to conceptually define the domains of the character-
istics i.e. specifying what the variables are and what they are not. 
 Ongoing refinement of definitions of the constructs being investigated. 
 Consultation with members of the target population to increase the chance that 
items are content valid for their intended purpose.  
 Consultation with subject matter experts in the field of this research for content 
validity of the instruments.  
 
3.9 RELIABILITY OF RESEARCH INSTRUMENTS 
 
In quantitative research summated scales are often used in survey instruments to probe 
underlying constructs of interest to the researcher. These are often comprised of in-
dexed responses to dichotomous or multi-point questionnaires which are later added up 
to arrive at a composite score for individual participant (Kanjee 2008:488).  Since these 
summated scales are an assembly of interrelated items that are designed to measure 
underlying constructs, it is very crucial to know their reliability. Reliability testing allows 
the researcher to know whether the same set of items would provide a good assess-
ment that if the questionnaire is re-administered; there is a good chance of getting the 
same result.  According to (Durrheim & Painter 2008:152-154) reliability is best de-
scribed as the dependability of a measurement instrument; it is the extent to which the 
instrument yields the same results repeatedly.  
 
3.9.1 Cronbach's Alpha: an index of reliability 
 
One of the common reliability statistics that is used in statistical analysis is Cronbach's 
alpha; it determines the internal consistency or average correlation of items in a survey 
instrument to gauge its reliability (Durrheim & Painter 2008:152-154). The value of 
Cronbach’s coefficient alpha ranges from 0 (no internal consistency) to 1 (maximum in-
ternal consistency) and may be used to describe the reliability of factors extracted from 
dichotomous (that is, questions with two possible answers) and/or multi-point formatted 
questionnaires or scales (i.e., rating scale: 1=poor, 5=excellent). The higher the score, 
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the more reliable the generated scale is. In questionnaire type scales, alpha value 
greater than 0.75 are considered reliable (Durrheim & Painter 2008:154). 
Although three of the research instruments used in this study have been validated in 
many studies as reliable research tools, Cronbach’s coefficient alpha was determined 
for the four combined research instruments in the current study and the results showed 
the following: Number of items in the scale=49, Average inter-item correlation=0.0719, 
and Cronbach’s coefficient alpha of 0.7915. These results indicate the internal consis-
tency of the research instruments used in this study. 
 
3.10 ETHICAL CONSIDERATIONS 
 
In research ethics refers to a set of standard principles, values and behavioural expec-
tations that guide the research process about accepted conduct towards study partici-
pants and other stakeholders in the research community (De Vos et al 2005:57). Impor-
tant among these principles are justice and respect for human right. In this research, a 
vulnerable group of people (HIV-infected) were the participants; therefore strict ethical 
consideration was adhered to throughout the study. 
 
3.11.1 Ethical permission 
 
The researcher obtained ethical clearance from the Higher Degrees Committee of De-
partment of Health Studies, University of South Africa before data collection com-
menced (Annexure A). Furthermore, permission was sought and obtained from the 
management of the health institution where the study was carried out (Annexure C). 
 
3.11.2 Informed consent 
 
The researcher informed the participants about the nature and topic of the study, pur-
pose, risk, benefit, type of information to be collected and time commitment (Annexure 
E). This provided opportunity for the participants to have their concerns and questions 
addressed. All participants were able to sign the consent form that allowed them to par-
ticipate in this research; the choice and decision to participate in the study were made 
voluntarily by the participants through written consent. They were assured that they 
were free to withdraw at anytime and that they will not be punished for doing so. 
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3.11.3 Confidentiality 
 
The researcher assured participants that the information collected in the process of this 
research would be treated with strict confidence. The research assistants for this study 
received training on the issue of confidentiality and were required to sign a document 
pledging to keep research data confidential. Further to this, all collected data were 
stored electronically in a secured location and protected with password. Raw data were 
also securely stored and access to them restricted. 
 
3.11.4 Anonymity 
 
Identification numbers were used for the questionnaires that bore no link with partici-
pants’ name or hospital number, and the sample participants were not identified in pub-
lished or disseminated results. 
 
3.11.5 The principle of justice 
 
Right to fair treatment and privacy 
 
Every participant was accorded fair and equal treatment by the research team. The re-
searcher ensured that the research team handled all participants with courtesy and 
showed sense of patience and tolerance in their conduct towards the participants. Par-
ticipants were given the opportunity of arranging time for completion of the question-
naires which was conducted in separate rooms to ensure their right to privacy was not 
violated. 
 
3.11.6 Principle of beneficence 
 
Freedom from harm 
 
Although no major risk was anticipated in this study, the researcher ensured that partic-
ipants were fully protected from any harm, research assistants were well trained to han-
dle sensitive issues and interviews were conducted in safe environment. Participants 
were also told they could report any adverse incidents to the researcher in the course of 
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data collection. The researcher assured participants that their HIV-positive status would 
not be exploited for any personal or financial gain by the research team. 
 
Benefit from the research 
 
Participants did not receive any monetary gain for their participation in the study; they 
however contributed to the existing body of knowledge in the field of HIV/AIDS and 
would benefit from the outcome of the study through their participation.  
 
3.11.7 Principle of respect for human dignity 
 
The right to self-determination 
 
The participants were be able to consent to participate in the research and were not co-
erced into taking part. They were also able to exercise the right to refuse answering any 
questions and could withdraw from the study without any consequences. 
 
The right to full disclosure 
 
All aspect of the study was disclosed to the hospital management where the study was 
conducted and to the participants. Name and phone numbers of the researcher and his 
supervisor were provided in the event that any concerns regarding the research arose. 
 
3.11.8 The right of vulnerable subjects 
 
As the participants in this study are vulnerable group in the society who has had to deal 
with stigma and emotional trauma due to their HIV status, the researcher took neces-
sary steps to ensure that the research process did not subject them to more stigma and 
psychological trauma. All aspect of the study that involves interaction between partici-
pants and the members of the research team were handled with respect and partici-
pants were not judged based on their responses. Furthermore, the researcher honoured 
all agreement of follow-up from study participants and counselling services were made 
available for participants who developed emotional trauma as a result of their participa-
tion in this research. 
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3.12 CONCLUSION 
 
This chapter described the research methodology used in the current study and justified 
why such design was chosen. Method of statistical analysis was also described together 
with the quantitative research instruments, and the pilot study conducted prior to data 
collection. It concluded with the description of ethical issues related to the research and 
the measures taken by the researcher to ensure all ethical standards were strictly com-
plied with. The next chapter contains the results of the research. 
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CHAPTER 4 
 
ANALYSIS, PRESENTATION AND DESCRIPTION OF THE RESEARCH 
FINDINGS  
 
4.1 INTRODUCTION 
 
The previous chapter dealt with the research methodology adopted for the current study 
and described the design used together with the ethical considerations related to the 
study. This chapter presents the results of the participants’ responses regarding the im-
plications of self-efficacy and beliefs about medicines on adherence to ART. It contains 
both the descriptive and analytical statistics of the research. 
 
The specific objectives of this research were to:  
 
1. Explore the cognitive variables of adherence self-efficacy and beliefs about 
medicines that influence adherence among patients on ART. 
 
2. Determine the inter-relationships among adherence self-efficacy, beliefs about 
medicines and ART adherence. 
 
3. Describe the modalities of enhancing adherence to ART through focused inter-
ventions on the identified factors that are strongly associated with ART adher-
ence. 
 
4. Develop a framework for the improvement of ART adherence based on the fac-
tors identified in this study. 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
 
The data collected were captured into Excel spreadsheet and analysed with the Statisti-
cal Package for Social Sciences (SPSS) version 19.0 manufactured by IBM.  Before 
data analysis each questionnaire was checked for completion by the researcher to en-
sure that they were answered correctly and subsequently scrutinized by the researcher 
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again before the data were eventually entered into Excel spreadsheet using double en-
try method, checked for errors, cleaned and then exported into the SPSS programme 
for processing and analysis. The data that differed during double entry were cross-
checked against the questionnaires concerned. Before data analysis each variable was 
examined separately through various SPSS functions for accuracy of data entry, miss-
ing values, and fit between their distributions and the assumptions of multivariate analy-
sis. Accuracy of data entry was confirmed by checking univariate descriptive statistics 
for strange data such as values out of range, means, standard deviations and univariate 
outliers. ART adherence is the variable that the researcher believes would be influenced 
by changes in other variables; therefore it was depicted as the dependent variable, and 
the other variables referred to as independent variables. Descriptive analysis was done 
for the dependent variable (ART adherence) which was measured by the ACTG ques-
tionnaire and independent variables (Demographic data questionnaire, HIV adherence 
self-efficacy questionnaire and beliefs about medicines questionnaire), followed by cor-
relation and regression analysis. 
 
Frequencies were run for all variables in the demographic data questionnaire, these in-
clude age group, gender, marital status, highest level of education, smoking habits, al-
cohol consumption, work status, period of HIV diagnosis, mode of HIV infection, disclo-
sure of HIV status, availability of treatment buddy, extent of treatment buddy assistance, 
period of ART use, amount of pills consumed daily and history of ART adverse reac-
tions.  
 
The HIV adherence self-efficacy section consisted of twelve questions, all expressing 
confidence on a scale of 0–10, high and low scores were defined as above and below 
the median of the 11 summed possible score (0–10). For each of the 12 items on the 
HIV-ASES scale, participants that scored 5 and above were categorized as high score 
and those that scored 4 and below were categorized as low score. In addition, compo-
site adherence self-efficacy score (SES) for each participant was calculated; to arrive at 
composite score for each participant, the twelve scores were averaged to produce a 
composite score out of 10 as an index of overall confidence in complying with the treat-
ment schedule. 
 
The beliefs about medicines-specific section consisted of ten questions rated on a 1–5 
scale of strongly agree, agree, uncertain, disagree, and strongly disagree. The 10 ques-
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tions were in the direction that an optimal score was 5. The frequencies of responses on 
the Beliefs about Medicines questionnaire were calculated after categorizing the Likert 
scale responses into three (Agree, uncertain and disagree). To calculate composite 
score for each participant on the BMQ-specific scale, these ten scores were averaged 
to produce a composite score out of 5 as an index of positive beliefs about medicines – 
specific. Higher scores indicated a stronger belief in necessity and concerns about spe-
cific medicines prescribed for use in antiretroviral therapy.  
 
The Beliefs about medicines-general section consisted of eight questions rated on a 1–
5 scale of strongly agree, agree, uncertain, disagree, and strongly disagree. The 8 
questions were in the direction that an optimal score was 5. The frequencies of re-
sponses were calculated after categorizing the Likert scale responses into three (Agree, 
uncertain and disagree).  To calculate composite score for each participant the eight 
scores were averaged to produce a composite score out of 5 as an index of positive be-
liefs about medicines – general. Higher scores indicated a stronger belief in overuse 
and harm associated with medicines prescribed for use in medical conditions.  
 
Adherence to ART using the ACTG questionnaire was calculated as total number of 
doses taken divided by total number of doses prescribed over four days and expressed 
as a percentage.  Proportion of doses missed in last 4 days was calculated for each 
participant together with the extent to which they complied with prescribed dosing 
scheduled of ART and the extent of their compliance with special dietary instructions.  
 
Correlation analysis was performed on the variables to establish the relationships 
among HIV adherence self-efficacy, Beliefs about medicines and ART adherence. Cor-
relation coefficients among the predictor variables HIV-ASES BMQ-S, BMQ-G and the 
outcome variable (ART adherence) were examined. Finally, multiple regression analysis 
was conducted to examine the relationships among the independent variables and ART 
adherence.  
 
4.3 DESCRIPTIVE ANALYSIS OF THE STUDY POPULATION 
 
The socio-demographic characteristics of the study population are presented in Table 
4.1 below. Two hundred and thirty-two patients took part in this study, 69 (30%) were 
male and 163 (70%) were female. The majority 208 (90%) fell largely in the 25-55 years 
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age group, and clustered at 100 (43%) in the 35-44 years age group. There were 6 
(2.6%) in the 18-24 years age group, and 18 (7.8%) over 55 years of age.   
 
Table 4.1 Socio-demographic characteristics of study population 
Characteristics Frequency 
(N=232) 
% 
Age  
18-24 
25-34 
35-44 
45-55 
>55 
 
6 
50 
100 
58 
18 
 
2.6 
21.6 
43 
25 
7.8 
Sex  
Male  
Female  
 
69 
163 
 
30 
70 
Marital status 
Never married 
Married 
Cohabiting 
Widowed 
Separated 
Divorced  
 
141 
60 
2 
12 
12 
5 
 
61 
26 
1 
5 
5 
2 
Highest level of education 
No schooling 
Primary education 
Secondary education 
Tertiary education  
 
15 
54 
140 
23 
 
7 
23 
60 
10 
Employment status 
Employed  
Unemployed 
Student 
Social grant 
Retired  
 
82 
131 
2 
16 
1 
 
35.3 
56.5 
1 
6.9 
0.4 
Frequency of alcohol consumption 
More than once daily 
Once daily 
A few times per week 
About once a week 
Seldom 
Never  
 
4 
2 
10 
30 
41 
145 
 
1.7 
0.9 
4.3 
12.9 
17.7 
62.5 
No of cigarette smoked daily 
None 
1-4 sticks 
5-9 sticks 
10-14 sticks 
15 and more 
 
204 
13 
10 
4 
1 
 
87.9 
5.6 
4.4 
1.7 
0.4 
 
 
A large proportion, 141 (61%), had never been married, and a further 60 (26%) were 
married. The remainder were split between 2 (1%) cohabiting, 12 (5%) separated, 12 
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(5%) widowed and 5 (2%) divorced. In terms of education, most patients – 140 (60%) 
had a secondary education, and a fair number – 54 (23%) had a primary education.  
 
There were 15 (7%) with no schooling, and 23 (10%) with tertiary education. The work 
status in the previous three months was that the majority – 131 (56.5%) were unem-
ployed and 62 (35.3%) had employment. There were 16 (7%) social grant recipients, 2 
(1%) students, and a retired person. 
 
When looking at smoking and drinking habits, it was noted that most of the participants 
– 204 (88%) did not smoke cigarettes at all. 13 (6%) smoked 1-4 cigarettes per day, 10 
(4%) smoked 5-9 cigarettes per day, 4 (2%) smoked 10-14 cigarettes per day, only one 
person smoke more than 15 cigarettes per day. There was a similar pattern with alcohol 
consumption, where the majority – 145 (63%) never drank, 41 (18%) seldom drank, 30 
(13%) drank about once a week, 10 (4%) drank a few times a week, 2 (1%) drank once 
daily, and only one patient drank more than once daily. 
 
4.3.1 Duration of HIV diagnosis 
 
The duration of HIV diagnosis among study participants is described in Figure 4.1 be-
low. Majority, 129 (55.6%) of the participants have been living with HIV/AIDS for more 
than 36 months. About one-fifth 44 (19%) were diagnosed with HIV in less than 24 
months and 59 (25%) have been diagnosed between 24–36 months. 
 
 
Figure 4.1 Duration of HIV diagnosis (N=232) 
44 (19%) 
59 (25% 
129 (56%) 
0 
20 
40 
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80 
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4.3.2 Modality of acquiring HIV infection 
 
The majority – 146 (63%) believe that they had become infected with HIV by having sex 
with an HIV-positive person. Another 75 (32%) did not know how they had become in-
fected. The remainder were spread between 5 (2.2%) cases of sexual assault, 3 (1.3%) 
with occupational exposure to blood or body fluid, and one each of shared needles with 
an HIV-positive person, mother-to-child transmission, and blood transfusion or medical 
procedure.  
 
 
Table 4.2 Modality of acquiring HIV infection 
 Frequency 
(N=232) 
% 
Sex with HIV+ person 146 63 
Shared needles with HIV+ person 1 0.4 
Mother-to-child transmission 1 0.4 
Occupational exposure to blood/body fluids 3 1.3 
Sexual assault 5 2.2 
Blood transfusion or medical procedure 1 0.4 
Don’t know 75 32 
TOTAL 232 100 
 
 
4.3.3 Disclosure of HIV status 
 
As shown in Figure 4.2 below almost 227 (98%) all the participants have already dis-
closed their HIV status to their family members and only 5 (2%) had not. 
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Figure 4.2 Disclosure of HIV status (N=232) 
 
4.3.4 Proportion of participants with treatment buddies 
 
Majority 217 (94%) of the participants in the study reported having treatment buddies as 
depicted in Figure 4.3 below. Out of the 217 respondents who have treatment buddies, 
about two-thirds 134 (62%) said their buddies help them a lot in adhering to their medi-
cations with just 1% who described their treatment buddies as not helpful at all in adher-
ing to their antiretroviral therapy (Figure 4.4). 
 
 
Figure 4.3 Proportion of participants with treatment buddies (N=232) 
Yes 
98% 
No 
2% 
Yes 
94% 
No 
6% 
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Figure 4.4 Extent of treatment buddies’ assistance (N=232) 
 
4.3.5 Duration of ART use 
  
Figure 4.5 shows the duration of ART use among the participants. Over half 128 (55%) 
have been on treatment for more than 36 months, followed by 74 (32%) who have been 
on ART for between 2–3 years. 
 
Figure 4.5 Duration of antiretroviral use (N=232) 
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4.3.6 Amount of pills consumed daily 
 
The number of pills ingested by the participants is represented in Figure 4.6 below. Ma-
jority 190 (82%) take between 2-3 pills daily, followed by 41 (18%) who consumed be-
tween 6-10 pills daily. Only one participant reported having to take more than 10 pills 
daily which represent less than 1% of the study population. 
 
 
Figure 4.6 Number of pills consumed daily (N=232) 
 
4.3.7 History of adverse reactions to ART 
 
Participants were asked if they have ever experienced adverse reactions to ART that 
would require them to stop the medications (Figure 4.7). Most of them 201 (87%) re-
ported never having such reactions. 
Between 2-5 
82% 
Between 6-10 
18% 
More than 10 
0% 
Number of pills consumed daily 
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Figure 4.7 History of adverse reactions to ART (N=232) 
 
4.3.8 HIV treatment adherence self- efficacy 
 
Self-efficacy in this research was conceptualized as medication-taking self-efficacy be-
liefs, or one’s belief in his/her ability to plan and perform desired behaviour that would 
result in adhering to ART. The HIV adherence self-efficacy section consisted of twelve 
questions, all expressing confidence on a scale of 0–10. High and low categories of 
ART adherence self-efficacy were defined as above and below the median of the 11 
summed possible score (0–10). For each of the 12 items on the HIV-ASES scale, partic-
ipants that score 5 and above were categorized as high score and those that score 4 
and below were categorized as low score. The summary of both high and low scores 
are shown in Table 4.3 below.  
 
The participants demonstrated high level of confidence on all the 12 items tested in the 
HIV-ASES scale. When asked how confident they were integrating HIV treatment plans 
into daily activities, about 169 (73%) of the participants obtained high score in that cate-
gory. When asked how confident they were about sticking to treatment schedule when 
they don’t feel well, 172 (74%) of the study participants scored high. The item where the 
participants seem to score the least is item 9; when they were asked how confident they 
were in continuing with the HIV treatment even when they are feeling discouraged about 
their health; the participants that got high score in this item were 162 (69.8%). 
Yes 
13% 
No 
87% 
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A composite adherence self-efficacy score (SES) for each participant was calculated; 
for each participant, the twelve scores were averaged to produce a composite score out 
of 10 as an index of overall confidence in complying with the treatment schedule. The 
mean score on the HIV-ASES was 6.45 (SD= 2.47). The score ranged from 0.17 to 10 
with a higher score indicating greater self-efficacy. Only one participant scored a perfect 
score of 10. The summary score of HIV-ASES may be seen in Table 4.3 below. 
 
Table 4.3 Summary scores of HIV-ASES high and low score categories (N=232) 
 High score Low score 
Freq % Freq % 
1. Stick to your treatment plan even when side effects begin to inter-
fere with your daily activities? 
 
169 
 
72.8 
 
63 
 
27.2 
2. Integrate your treatment into your daily routine? 
 
 
171 
 
73.7 
 
61 
 
26.3 
3. Integrate your treatment into daily routine even if it means taking 
medication or doing other things in front of people who don’t know 
you are HIV+ 
 
170 
 
73.3 
 
62 
 
26.7 
4. Stick to your treatment schedule even when your daily routine is 
disrupted? 
171  
73.7 
 
61 
 
26.3 
5. Stick to your treatment schedule when you aren’t feeling well? 
172  
74.1 
 
60 
 
25.9 
6. Stick to your treatment schedule when it means changing your 
eating habits? 
 
170 
 
73.3 
 
62 
 
26.7 
7. Continue with your treatment even if doing so interferes with your 
daily activities? 
 
165 
 
71.1 
 
67 
 
28.9 
8. Continue with the treatment plan your physician prescribed even if 
your CD4 count drop significantly in the next three months? 
 
174 
 
75 
 
58 
 
25 
9. Continue with your treatment even when you are feeling discour-
aged about your health? 
 
162 
 
69.8 
 
70 
 
30.2 
10. Continue with your treatment even when getting to your clinic ap-
pointments is difficult? 
 
166 
 
71.6 
 
66 
 
28.4 
11. Continue with your treatment even when people close to you tell 
you that they don’t think that it is doing any good? 
 
175 
 
75.4 
 
57 
 
24.6 
12. Get something positive out of your participation in treatment, even 
if the medication you are taking does not improve your health? 
 
172 
 
74.1 
 
60 
 
25.9 
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4.3.9 Beliefs about medicines-specific  
 
The BMQ-S measurements reflected participants’ beliefs about the perceived necessity 
and concerns about use of ARVs in treating HIV/AIDS, it consisted of ten questions rat-
ed on a 1–5 scale of strongly agree, agree, uncertain, disagree, and strongly disagree. 
The first 5 items on the scale related to the beliefs about the necessity of the ARVs 
medicines for maintaining health (Specific-Necessity) and items 6-10 dealt with con-
cerns about ARVs (Specific-Concerns).  
 
Table 4.4   Frequency of responses on the Beliefs about Medicines-Specific scale (N=232) 
 Agree Uncertain Disagree 
Freq % Freq % Freq % 
 
1. My health, at present, depends on my ARVs 
 
225 
 
97.4 
 
3 
 
1.3 
 
3 
 
1.3 
 
2. My life would be impossible without my ARVs  
 
218 
 
94 
 
8 
 
3.5 
 
6 
 
2.5 
 
3. Without my ARVs I would become very ill  
 
222 
 
95.6 
 
9 
 
3.8 
 
 
2 
 
0.8 
 
4. My health in the future will depend on my ARVs  
 
217 
 
93.5 
 
12 
 
5.2 
 
3 
 
1.3 
 
5. My ARVs protect me from becoming worse  
 
216 
 
93 
 
8 
 
3.5 
 
8 
 
3.5 
 
6. Having to take ARVs worries me  
 
36 
 
15.5 
 
14 
 
6.1 
 
182 
 
78.4 
 
7. I sometimes worry about long-term effects of my ARVs 
 
71 
 
30.6 
 
27 
 
11.6 
 
134 
 
57.8 
 
8. I don’t know how my ARVs work 
 
50 
 
21.6 
 
24 
 
10.3 
 
158 
 
68.1 
 
9. My ARVs disrupt my life  
 
26 
 
11.2 
 
35 
 
15.1 
 
171 
 
73.7 
 
10. I sometimes worry about becoming too dependent on 
my ARVs  
 
42 
 
18.1 
 
41 
 
17.7 
 
149 
 
62.2 
 
To calculate frequencies of participants’ responses on the BMQ-Specific scale, the 5 
Likert scale responses were categorised into three (agree, uncertain and disagree). 
These may be seen in Table 4.4 above. Most participants 225 (97.4%) for the first vari-
able (at present) and 217 (93.5%) for the second variable (future) believed that their 
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health depends on antiretroviral medication. Only 36 (15.5%) of the participants report-
ed that having to take ARVs worries them, few 50 (21.6%) claimed not to know how 
their ARVs work and 26 (11.2%) confirmed that ARVs cause disruption in their lives. 
Most 222 (95.6%) of the sample reported that their medications kept their health from 
deteriorating. Majority 134 (58%) of the participants were not worried about the long-
term effects of ARVs including dependency 149 (62.2%).  
 
To calculate the composite score for each participant, the scores on the 10 items were 
averaged to produce a composite score out of 5 as an index of positive beliefs about 
medicines – specific. The participants’ score on the BMQ-S ranged from 2.9 to 4.9, with 
a mean of 4.05 (SD=0.42). Higher scores indicated a stronger belief in specific medicine 
prescribed in antiretroviral therapy, in this case antiretroviral drugs. 
 
4.3.10 Beliefs about medicines-general  
 
The BMQ-G measurements reflected participants’ beliefs about the harm and overuse 
associated with use of medicines in general, it consisted of eight questions rated on a 
1–5 scale of strongly agree, agree, uncertain, disagree, and strongly disagree. The 8 
questions were in the direction that an optimal score was 5. To calculate frequencies of 
participants’ responses on the BMQ-General scale; the 5 Likert scale responses were 
categorised into three (agree, uncertain and disagree). These may be seen in Table 4.5 
below.  Items 1–4 on the BMQ-general dealt with nature of medicines (General-Harm) 
and the remaining four items dealt with views about how they are used by doctors 
(General-Overuse). 
 
One hundred and nineteen participants (51%) believed that doctors overused medica-
tions in general, placed too much trust on medicines 193 (83.2%) and spent little time 
with patients thereby prescribing many medications 127 (54.7%). Almost half 106 
(45.7%) of the participants believed that medicines are addictive. Few 12 (5.2%) en-
dorsed the belief that natural remedies are safer than medicine, all medicines are poi-
sons 29 (12.5%) and that people on chronic medicines should stop taking them very of-
ten 24 (10.3%). 
 
To calculate the composite score for each participant, the eight scores were averaged 
to produce a composite score out of 5 as an  index  of positive beliefs about medicines 
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– general, the mean score was 3.18 (SD=0.5), with scores ranging from 1.87 to 4.62. 
Higher scores indicated stronger beliefs about the harm and overuse associated with 
the use of medicines in general in the management of disease conditions. 
 
Table 4.5 Frequency of responses on the Beliefs about Medicines-General scale (N=232) 
 
Agree 
 
Uncertain 
 
Disagree 
Freq % Freq % Freq % 
 
1. Doctors use too many medicines 
 
 
119 
 
51 
 
30 
 
13 
 
83 
 
36 
 
2. People who take medications should stop their 
treatment for a while every now and again 
 
 
24 
 
10.3 
 
22 
 
9.5 
 
186 
 
80.2 
 
3. Most medicines are addictive 
 
 
106 
 
45.7 
 
42 
 
18.1 
 
84 
 
36.2 
 
4. Natural remedies are safer than medicines 
 
 
12 
 
5.2 
 
20 
 
8.6 
 
200 
 
86.2 
 
5. Medicines do more harm than good 
 
 
70 
 
30.2 
 
45 
 
19.4 
 
117 
 
50.4 
 
6. All medicines are poisons 
 
 
29 
 
12.5 
 
28 
 
12.1 
 
175 
 
75.4 
 
7. Doctors place too much trust on medicines. 
 
 
193 
 
83.2 
 
16 
 
6.8 
 
23 
 
10 
 
8. If doctors had more time with patients they would 
prescribe fewer medicines 
 
 
127 
 
54.7 
 
58 
 
25 
 
47 
 
20.3 
 
. 
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4.3.11 Antiretroviral therapy adherence  
 
Medication Adherence was calculated as the proportion of medication taken out of the 
amount prescribed over the last four days and expressed as percentages. Mean adher-
ence for the total population (232) was 95% (SD=13.2). For the purpose of this study, a 
participant is said to be adherent at above 95%, therefore 189 (81.5%) participants were 
adherent. Thirteen (5.6%) were 80%-95% adherent, 29 (12.5%) were 50%-79% adher-
ent, and only one patient (0.4%) was assessed at <50%.  
 
 
Figure 4.8 Medication adherences over previous 4days (N=232) 
 
When adherence was further broken down,  as shown in Table 4.6 below, it was found 
that in the previous four days 208 (89.7%) patients reported never missing any doses, 
18 (7.8%) reported missing a dose on one day, and 16 (2.6%) reported missing a dose 
on two days.  
 
  
adherent 
81% 
non-adherent 
19% 
Medication adherence 
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Table 4.6   During the past 4 days, on how many days have you missed taking all  
your doses? (N=232) 
Responses Frequency Percentage Cumulative % 
None 208 89.7 89.7 
1 day 18 7.8 97.5 
2 days 6 2.6 100 
Total 232 100  
 
 
The ACTG questionnaire has a section where the following statement was made; most 
anti-HIV medications need to be taken on a schedule, such as “2 times a day” or “3 
times a day” or “every 8 hours”. How closely did you follow your specific schedule over 
the last 4 days? The results are shown in Table 4.7 below. 
 
Table 4.7   How closely did you follow your medication’s specific schedule over the last 4 
days? (N=232) 
Responses Frequency Percentage Cumulative % 
All of the time 110 47.4 47.4 
Never 57 24.6 72 
Most of the time 39 16.8 88.8 
Some of the time 18 7.8 96.6 
About half of the time 8 3.5 100 
Total 232 100  
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In terms of following the specific dosage schedule, 110 (47%) patients said they did so 
all of the time, 39 (17%) said most of the time, 8 (3%) said about half of the time, 18 
(8%) said some of the time, and 57 (25%) said never. 
 
The ACTG questionnaire has a section where the following question was asked; Does 
any of your anti-HIV medications have special instructions, such as “take with food” or 
“on an empty stomach” or “with plenty of fluids?” If yes, how often did you follow those 
special instructions over the last four days? The results are shown below in figure 4.8 
 
Regarding medication with specific instructions which is depicted in Figure 4.8, 146 
(63%) said their medications did have specific instructions, while 86(37%) said they did 
not. Of those with the specific instructions, (Table 4.8), 63 (43%) followed them all of the 
time, 51 (35%) followed them most of the time, 2 (1%) followed them about half the 
time, 14 (10%) followed them some of the time, and 16 (11%) never followed them. 
 
 
Figure 4.9 Does any of your HIV medications have special dietary instructions? (N= 
232) 
 
 
 
 
 
Yes 
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No 
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108 
Table 4.8   How often did you follow your medication’s special dietary instructions over 
the last 4 days? (N=146) 
Responses Frequency Percentage Cumulative % 
All of the time 63 43 43 
Most of the time 51 35 78 
Never  16 11 89 
Some of the time 14 10 99 
About half of the time 2 1 100 
Total 146 100  
 
 
Table 4.9   Summary of Scale Scores 
 HIV-ASES BMQ-S BMQ-G ACTG 
Number 232 232 232 232 
Mean 6.45 4.05 3.18 95 
Median 7.08 4.05 3.18 - 
Standard deviation 2.47 0.42 0.5 13.2 
Range 0.17-10 2.9-4.9 1.87-4.62 10-100 
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4.4 CORRELATIONS ANALYSES 
 
All of the patients’ scores for HIV-ASES, BMQ-S, BMQ-G and ACTG were tested for 
significant relationships using Pearson correlation analysis. The correlation matrix is 
shown in Table 4.10 below.  These results effectively showed no correlation between 
HIV-ASES and BMQ-S, HIV-ASES and BMQ-G, HIV-ASES and ACTG, and BMQ-S and 
ACTG. There was a weak positive correlation between BMQ-G and ACTG (r=0.2). 
There was a moderate positive correlation between BMQ-S and BMQ-G (r=0.4). These 
results may therefore be taken to indicate that two of the cognitive or attitudinal varia-
bles under investigation, HIV-ASES and BMQ-S, had no any link with adherence among 
the study participants, as measured in this research. The link between BMQ-G and ad-
herence was weak, but statistically significant. There was a moderate link between the 
two independent variables, BMQ-S and BMQ-G. 
 
Table 4.10   Correlation matrix for HIV-ASES, BMQ-S, BMQ-G and ACTG 
 BMQ-S BMQ-G ADHERENCE 
HIV-ASES r=0.171 r=0.037 r=0.036 
 t=2.626 t=0.564 t=0.539 
 p=0.009 p=0.573 p=0.590 
    
BMQ-S - r=0.419 r=0.040 
  t=7.004 t=0.606 
  p < 0.001 p=0.545 
    
BMQ-G  - r=0.219 
   t=3.403 
   p=0.001 
    
No. of valid cases=232 
r=Pearson Product Moment Correlation 
t=t-statistic 
p=p-value (level of significance) at <0.05 
 
 
The interpretation of these findings is that perceived beliefs about the general harm and 
overuse of medicines influence adherence behaviour among the participants. An indi-
vidual with strong beliefs about the general harm and overuse of medicines is likely to 
adhere to antiretroviral therapy. Conversely, the correlation between the two independ-
ent variables BMQ-G and BMQ-S indicates that specific necessity and concerns about 
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ARVs and perceived beliefs about the general harm and overuse of medicines have in-
fluence on each other. A patient with strong beliefs about the general harm and overuse 
of medicines will likely have strong beliefs about specific necessity and concerns about 
ARVs. 
 
4.4.1 Correlations in non-adherence 
 
There were 43 patients who indicated adherence of 95% or less. These scores were 
isolated and independently correlated with the HIV-ASES, BMQ-S and BMQ-G 
measures. The correlation matrix may be seen in Table 4.11 below. These results 
showed no correlation between BMQ-S and ACTG, and between BMQ-G and ACTG. 
There was a weak positive correlation between HIV-ASES and ACTG. Amongst the in-
dependent variables, there was a weak positive correlation between HIV-ASES and 
BMQ-G, a moderate positive correlation between BMQ-S and BMQ-G, and a strong 
positive correlation between HIV-ASES and BMQ-S. Taken together these results may 
indicate a small link between HIV-ASES and adherence in the case of non-adherent pa-
tients. 
 
Table 4.11  Correlation matrix for HIV-ASES, BMQ-S, BMQ-G and ACTG for adherence 
<95% 
 BMQ-S BMQ-G ADHERENCE (ACTG)  
HIV-ASES r=0.711 r=0.373 r=0.313  
 t=6.483 t=2.575 t=2.107   
 p=0.000 p=0.014 p=0.041   
    
BMQ-S - r=0.459 r=0.130  
  t=3.304 t=0.838   
  p=0.002 p=0.407   
    
BMQ-G  - r=0.145  
   t=0.937   
   p=0.354   
    
No. of valid cases=43 
r=Pearson Product Moment Correlation 
t=t-statistic 
p=p-value (level of significance) at <0.05 
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The interpretation of these findings is that HIV adherence self-efficacy influence adher-
ence behaviour among the participants who were non-adherent to their treatment. 
Therefore a patient with low self-efficacy is likely to be non-adherent to ART. The corre-
lation between the two independent variables HIV-ASES and BMQ-G indicates that HIV 
adherence self-efficacy have influence on perceived beliefs about the general harm and 
overuse of medicines. An individual with high self-efficacy is likely to have strong beliefs 
in the general harm and overuse of medicines. Furthermore, the correlation between the 
two independent variables BMQ-G and BMQ-S indicates that specific necessity and 
concerns about ARVs and perceived beliefs about the general harm and overuse of 
medicines have influence on each other. A patient with strong beliefs about the general 
harm and overuse of medicines will likely have strong beliefs about the specific con-
cerns and necessity of ARVs. In addition, the strong positive correlation between HIV-
ASES and BMQ-S means that HIV adherence self-efficacy have influence on specific 
necessity and concerns about ARVs. An individual with high self-efficacy is likely to 
have strong beliefs about the specific necessity and concerns of ARVs. 
 
4.5 REGRESSION ANALYSIS 
 
Multiple regression analysis in advanced statistical analysis is used to examine the sep-
arate and collective contributions of multiple independent variables to the variation of 
the dependent variable (Tredoux, Pretorius & Steele 2008:255). The multiple correlation 
coefficient (R) is the correlation between the dependent variable and the best linear 
combination of the predictors i.e. a strength-of-relationship index that indicates the cor-
relation between predicted scores and the dependent variable score. In this study R and 
R2 (which refers to the percentage of accountable variation) were used to assess how 
well the linear combination of explanatory variables in the regression model predicted 
the dependent variable (Tredoux, Pretorius & Steele 2008:255). 
 
All predictors were initially entered into the model and then eliminated one by one in the 
backward method (backward deletion) based on how insignificant they were (level of 
significance alpha=0.05). A backward stepwise regression of scores from all patients 
indicated significance for BMQ-G on ACTG (F(1;231)=11,583;p<0,001) with BMQ-G ex-
plaining 4,8% of the variance. When a regression analysis was run on only those pa-
tients who were 95% or less adherent, there was significance for HIV-ASES on ACTG 
(F(1;41)=4.440;p<0.041), with HIV-ASES explaining 9,8% of the variance. These results 
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would indicate that in perceived general harmful effects and overuse of medications was 
a very weak predictor of adherence, and when patients with less than 95% adherence 
were isolated HIV adherence self-efficacy was a weak predictor of their adherence be-
haviour. 
 
4.6 OVERVIEW OF RESEARCH FINDINGS 
 
Findings from the study indicated that majority of the participants were females 163 
(70%), age group 35-44 years constitute the highest percentage among the participants, 
most are not married 60 (61%), unemployed 131 (56.5%), do not smoke 204 (88%) or 
consume alcohol 145 (63%) and very few had no formal education 15 (7%). Majority 
(55.6%) have been living with HIV/AIDS for more than 3 years, sex with HIV infected 
appeared to be the modality of acquiring HIV 146 (63%). Almost all 227 (98%) have dis-
closed their HIV status to family members and a high proportion 217 (94%) have treat-
ment buddies, over half 128 (55%) have been on ART for more than 3 years, most of 
the participants 190 (82%) consume between 2-3 pills daily and never experienced 201 
(87%) adverse reaction that require them to stop taking ARVs. 
 
The participants demonstrated high level of confidence on all the 12 items tested in the 
HIV-ASES scale. After calculating composite scores for each participant, the mean 
score on the HIV-ASES was 6.45 (SD=2.47), with a high score indicating greater self-
efficacy. Only one participant scored a perfect score of 10. The participants score on the 
BMQ-Specific ranged from 2.9 to 4.9, with a mean of 4.05 (SD=0.42). Higher scores in-
dicated a stronger belief in specific medicine prescribed in antiretroviral therapy in this 
case antiretroviral drugs. The mean score on BMQ-general was 3.18 (SD=0.5), with 
scores ranging from 1.87 to 4.62. Higher scores indicated a stronger beliefs in general 
medicines prescribed in the management of disease conditions 
 
Mean adherence for the total 232 participants was 95% (SD=13.2), 189 (81%) partici-
pants were adherent, 208 (89.7%) patients reported never missing any doses, 110 
(47%) were adherent to specific dosage schedule. Out of the 146 participants whose 
ARVs have specific dietary instructions, only 63 (43%) followed them all the time. 
 
Correlation analysis showed a weak link between perceived general harmful effects and 
overuse of medications and adherence, and moderate link between the two independ-
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ent variables, BMQ-S and BMQ-G. Among non-adherent participants a strong positive 
correlation was found between HIV adherence self-efficacy and BMQ-S. Regression 
analysis revealed that HIV adherence self-efficacy is a weak predictor of adherence to 
ART, and perceived general harmful effects and overuse of medications is a weak pre-
dictor of adherence among non-adherent participants.  
 
4.7 FACTOR ANALYSIS 
 
This is a statistical method used in identifying a relatively small number of factors in or-
der to represent the relationship among sets of interrelated variables (Tredoux, Preto-
rius & Steele 2008:248). Factor analysis is often done in order for the researcher to 
know if a wide range of variables could be more meaningfully represented by a smaller 
number of underlying dimensions. This is useful in future research and in the planning 
of interventions than the wide range of variables (Tredoux, Pretorius & Steele 
2008:248). The researcher carried out factor analysis on the variables in the research 
instruments; from Figure 4.10 above, it can be observed how the variables cluster ac-
cording to the factor loadings. Factor 1 essentially marks the importance of the B1–B12 
(HIV adherence self-efficacy) performance and that explains about 53% of the variabil-
ity. The second factor is more on the bmqs1, bmqs2, bmqs3, bmqs4 and bmqs5 (per-
ceived necessity and concerns about medicines) which explains about 15.7% and the 
third factor relates mostly to bmqs7, bmqs9, bmqs10, bmqg3 & bmqg5 (items on the 
perceived harm and overuse of medicines and perceived necessity and concerns about 
medicines). It can also be observed that D1 which measure of medication adherence in 
terms of proportion of medication missed out of the quantity prescribed is also a factor 
to be reckoned with (factor 5). The scree chart shown in Figure 4.11 below indicates 
that only 4 factors (factors 1, 2, 3 and 4) will be needed to explain the relevant variability 
in the current research. 
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Figure 4.10    Factor loadings 
 
Table 4.12 Rotated factor loadings (pattern matrix) and unique variances 
 
    ----------------------------------------------------------------------------------------- 
        Variable |  Factor1   Factor2   Factor3   Factor4   Factor5   Factor6 |   Uniqueness  
    -------------+------------------------------------------------------------+-------------- 
              b1 |   0.7968                                                   |      0.3191   
              b2 |   0.8579                                                   |      0.2559   
              b3 |   0.6997                                                   |      0.5022   
              b4 |   0.7360                                                   |      0.4171   
              b5 |   0.7864                                                   |      0.3372   
              b6 |   0.7783                                                   |      0.3421   
              b7 |   0.7560                                                   |      0.4116   
              b8 |   0.7255                                                   |      0.4434   
              b9 |   0.7447                                                   |      0.3815   
             b10 |   0.6948                                                   |      0.4678   
             b11 |   0.8015                                                   |      0.3389   
             b12 |   0.6393                                                   |      0.5372   
           bmqs1 |             0.6268                                         |      0.5836   
           bmqs2 |             0.5820                                         |      0.5941   
           bmqs3 |             0.5780                                         |      0.6419   
           bmqs4 |             0.8039                                         |      0.2634   
           bmqs5 |             0.4391                                  0.3833 |      0.5837   
           bmqs6 |                                                     0.3397 |      0.7325   
           bmqs7 |                       0.3555                               |      0.7813   
           bmqs8 |                                 0.3408                     |      0.8149   
           bmqs9 |                       0.4223                               |      0.7743   
          bmqs10 |                       0.4601    0.3265                     |      0.6656   
           bmqg1 |                                                     0.3902 |      0.7349   
           bmqg2 |   0.3874                        0.3595                     |      0.6492   
           bmqg3 |                       0.5527                               |      0.6306   
           bmqg4 |                                                            |      0.8788   
           bmqg5 |                       0.3637              0.4782           |      0.4859   
           bmqg6 |                                 0.5737                     |      0.5933   
           bmqg7 |                                                            |      0.9206   
           bmqg8 |                                                     0.3350 |      0.7941   
              D1 |                                           0.5285           |      0.7084   
    ----------------------------------------------------------------------------------------- 
    (blanks represent abs(loading)<.3) 
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Figure 4.11 Scree plot of eigen values after factor loading 
 
4.8 CONCLUSION  
 
This chapter described the analysis and presentation of the research findings. Demo-
graphic characteristics of the study population were described; frequencies of re-
sponses on the HIV-ASES, BMQ and adherence were also shown in this chapter. Cor-
relation and multiple regression analyses were performed on the variables to identified 
relationships among them. Finally, factor analysis of the wide range of variables in the 
research instruments were done and indicated that only four factors explain the variabil-
ity of the current study. In the next chapter the results of the research would be dis-
cussed in the context of existing literature, conclusions of the study findings would be 
elaborated and appropriate recommendations made on modalities of enhancing adher-
ence. 
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CHAPTER 5 
 
DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 INTRODUCTION 
 
The purpose of this study was to identify modifiable cognitive factors that are strongly 
associated with ART adherence with a view to providing a framework for antiretroviral 
therapy adherence among patients in South Africa. With the rapid roll-out of ART that 
has resulted in over a million people on treatment, few studies have examined cognitive 
factors that influence adherence to ART in South Africa. This study addresses the gap 
in knowledge by examining the predictive relationships of HIV adherence self-efficacy 
and Beliefs about medicines on adherence to ART in persons with HIV infections who 
are taking antiretroviral therapy. The significance of the predictor variables with the de-
pendent variable was also examined; understanding the factors influencing adherence 
to ART is very crucial in enhancing interventions that could improve adherence among 
patients which would results in good clinical outcomes and good quality of life.  
 
In this chapter, the interpretation of the research findings will be discussed, the implica-
tions for ART adherence will also be highlighted, study limitations and suggestions for 
further research will be mentioned. Finally, a framework for enhancing antiretroviral 
therapy adherence among patients on life-long treatment will be described.  
 
5.2  DISCUSSIONS OF THE RESEARCH FINDINGS 
 
5.2.1 Demographic characteristics of the study participants 
 
Participants for this study were drawn from a large clinic within the Tshwane Metropoli-
tan area which is part of the Comprehensive Care, Management and Treatment pro-
gram of the Gauteng Department of Health. The research findings in the current study 
are consistent with the national trends of HIV/AIDS distribution pattern in South Africa 
(NDOH 2010c). HIV infection in South Africa affects mostly people in the age group 15-
49 years, a report released by the National Department of Health in 2010 revealed that  
while the national prevalence of HIV was 10.5%, the prevalence among people within 
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15-49 age group was 15% (NDOH 2010c:20). This is reflected in this study as 156 
(67%) of the participants fell into 18-44 years age group. Furthermore, HIV prevalence 
remains disproportionately high for females in comparison to males in South Africa. It is 
highest among women within 25-29 years age group, where one in three women are 
found to be HIV positive (NDOH 2010c:20). It is therefore not surprising that majority 
163 (70%) of the participants in this study were women as they are the worst affected 
by the HIV epidemic in South Africa. This also indicates that there are more females on 
ART than males. This assertion is supported by earlier studies that show that more 
women are accessing HIV treatment than men (Johnson 2012:24). The percentage of 
HIV infected patients, aged 55 years and above was 18 (7.8%) in this study which is 
similar to the national average of around 6% reported for people aged 50 and above 
(NDOH 2010c:24). 
 
The majority 141 (61%), had never been married, 140 (60%) had only secondary edu-
cation, only 62 (35%) of the participants were employed, the rest were either unem-
ployed or relied on social grants. The fact that most of these participants were unem-
ployed and lacked tertiary education may have influence on their psychosocial well-
being; unstable housing, depression, decreased quality of life, work and family respon-
sibility have been described as potential barriers in adhering to antiretroviral therapy 
(Glass et al 2010:200; Protopopescu et al 2009:603; Mills et al 2006:687). In their study 
conducted among patients on ART in Zimbabwe, Skovdal et al (2011:309) reveal how 
poverty and sources of economic and materialistic support influence patients’ ability to 
adhere to ART. The authors found adherence to be highly influenced by lack of food 
and difficulties in meeting the costs associated with treatment. 
 
Most of the participants did not smoke 204 (88%) or consume alcohol 145 (63%). Alco-
hol consumption and substance abuse have been associated with poor compliance with 
medication which often results in poor clinical outcomes in the management of HIV in-
fection (Glass et al 2010:200). Psychosocial factors like drugs and alcohol use have 
been linked with non-adherence. Studies have found that these serve as barriers to ad-
herence among HIV-infected patients on life-long treatment (Glass et al 2010:200; 
Protopopescu et al 2009:603; Mills et al 2006:687). In terms of psychosocial response 
of patients to ART, Skovdal et al (2011:309) found that men in particular consume ex-
cessive alcohol to avoid their perceived reality of having lost their manhood to AIDS as 
they are constantly reminded of this reality when they take their ARVs every day. 
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There have been some studies which suggest that socio-demographic characteristics 
do not often predict adherence to ART. The authors contend that it is not quite simple to 
use socio-demographics characteristics to predict adherence to ART among patients as 
studies have found mixed results between demographic characteristics and patient ad-
herence level (Rougemont et al 2009:21; Cauldbeck et al 2009:7). This has made it dif-
ficult for adherence counsellors to use socio-demographics as a strong predictor of ad-
herence to antiretroviral therapy. What research has found is that socio-demographic 
factors can be used to identify particular populations that may benefit more extensively 
from targeted interventions that address specific barriers (Gordillo et al 1999:1766; 
Cauldbeck et al 2009:7). The importance of these findings in ART initiation is that deny-
ing an individual the benefit of ART based on the assumption that the person will not 
adhere due to his or her demographic characteristics is a futile exercise as no scientific 
data are available to substantiate such action (Ickovics & Meade 2002:S99). 
 
Furthermore, various studies have found that socio-economic factors could be part of 
barriers to adherence to ART in multiple settings in sub-Saharan Africa. These include 
the cost of ART, availability and accessibility to medications (Weiser et al 2003:284; 
Hawkins & Murphy 2007:1041; Iliyasu et al 2005:92; Mukhtar-Yola, Adeleke, Gwarzo & 
Ladan 2006:142; Hardon et al 2007:661; Tuller et al 2009). In addition to this, there are 
indirect costs associated with ART which influence adherence; these are the time taken 
off work, the time spent in hospital and inability to fend for one’s family during bouts of 
opportunistic infections (Castro 2005:e338; Hardon et al 2007:660). Therefore, high ad-
herence to ART demonstrated by the participants in this study needs to be interpreted 
with caution as they all received free ART services as part of the government’s ART roll-
out to ensure wide access to treatment in South Africa. 
 
Due to the conflicting findings on the role of socio-demographics in influencing adher-
ence to ART, Campbell & Cornish (2010:1577) have advocated for a health enabling 
social environment model in the context of HIV/AIDS management. According to 
Skovdal et al (2011:314), such an environment allows for attention to be paid to contex-
tual and psychosocial dimensions that influence adherence to prescribed ART. 
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5.2.2 Modality of acquiring HIV infection 
 
HIV transmission in South Africa has been shown to be predominantly through hetero-
sexual transmission between couples, followed by mother-to-child transmission (NDOH 
2010c:20). This is also reflected in the current study as majority 146 (63%) of the study 
participants were infected through sexual intercourse with an HIV-positive person. This 
is further supported by available literature which shows that HIV transmission in sub-
Saharan Africa is largely transmitted heterosexually (UNAIDS 2010), and the identified 
drivers of the HIV epidemic in South Africa include intergenerational sex, multiple con-
current partners, low condom use, excessive use of alcohol and low rates of male cir-
cumcision (NDOH 2010c:20).  
 
The mode of HIV transmission differs in developed countries. However, it appears to be 
mainly through homosexual transmission as reported by Gauchet, Tarquinio & Fischer 
(2007:143) in the study among 127 HIV-infected persons in a Hospital in France where 
44% of the participants contracted HIV through homosexual transmission. Nevertheless, 
another study among women in the USA reported that over 70% of the women acquired 
HIV infection heterosexually (Jones, Owens, Lydston, Tobin, Brondolo & Weiss et al 
2010:1503). 
 
Sexual assault is another mode of contracting HIV that has been documented in South 
Africa although very few 5 (2.2%) of the participants in this study reported being infected 
through sexual assault. Occupational exposure to blood or body fluid; sharing needles 
with an HIV-positive person; mother-to-child transmission; and blood transfusion or 
medical procedure account for very little as the modality of HIV transmission in the 
study. These findings differ sharply from the study referred to above where 12% of the 
participants were infected through needle sharing (Gauchet, Tarquinio & Fischer 
2007:143). An explanation for this may be due to the high number of injection drug us-
ers in developed countries compared to South Africa. 
 
The continuous trend in heterosexual transmission of HIV in South Africa has informed 
policy around increased campaign about consistent use of condom and awareness of 
uptake of medical male circumcision among sexually active males. Studies have report-
ed reduced risk of about 60% in sexually HIV transmission among circumcised men 
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(Auvert et al 2005:11; Bailey, Moses, Parker et al 2007:651; Gray, Kigozi, Serwadda et 
al 2007:664). 
 
5.2.3 Duration of HIV diagnosis and ART use 
 
Majority 129 (55.6%) of the participants have been living with HIV/AIDS for more than 
36 months and a large proportion of the participants have disclosed their HIV status to 
their family members 227 (98%) which is an indication of having come to terms with the 
disease. Disclosure is very vital in HIV management as research has shown that people 
who disclosed their status are likely to adhere to treatment as well as receive support 
from their families (Glass et al 2010:200; Protopopescu et al 2009:603; Mills et al 
2006:687), which is why social support and ability to disclose one’s status have been 
described as important issues to be considered when assessing treatment adherence 
(Nachega et al 2006b:131). The stigma and discrimination associated with HIV/AIDS 
within the society unlike any other chronic illnesses constitute one of the greatest chal-
lenges facing people on ART (Elliott, Utyasheva & Zack 2009:29). Due to this stigma, 
some patients would prefer to take their ARVs in secrecy which might invariably may 
affect their compliance to the  treatment (Hardon et al 2007:662; Weiser et al 2003:285). 
 
A large proportion of the participants in this research were people who have been using 
antiretroviral for quite a long period as 202 (87%) of them have been on treatment for 
more than 2 years. This percentage is similar to the 75-82% reported nationally (NDOH 
2010c:25). Survival on ART has been associated with good clinical outcomes which re-
sulted from halting the proliferation of the viral replication, improvement in immune re-
sponse and reduction in the viral load (Reddi, Leeper, Grobler et al 2007:13; Wool-
Kaloustian et al 2006:43). The clinical outcomes achieved with the use of ART been 
linked to adherence level, research has shown that prior opportunistic infections in an 
HIV patients before initiating ART has the potential of influencing adherence as the pa-
tient may perceive the disease to be severe enough requiring good adherence to treat-
ment in order to achieve the treatment outcome (Cauldbeck et al 2009:7). Duration of 
treatment with ART and time since HIV diagnosis were found to influence adherence in 
the study conducted by Gauchet, Tarquinio and Fischer (2007:145), although this find-
ing differs from the Swiss HIV Cohort Study revealed that long standing HIV disease 
was among the predictors of worsening adherence (Glass et al 2010:201).  
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The majority, 190 (82%) take between 2-3 pills daily, followed by 41 (18%) who con-
sumed between 6-10 pills daily. Only one participant reported having to take more than 
10 pills daily which represent less than 1% of the study population. The amount of pills 
that patients on chronic medication take every day influences adherence; pill burden 
has been described as a major challenge in ART as patients have to take a combination 
of ARVs (Protopopescu et al 2009:602). The pill burden is a major challenge for patients 
taking ART as some of them may also have co-morbidities like asthma, diabetes, hyper-
tension and arthritis. These may require them to take multiple doses of tablets including 
prophylaxes against opportunistic infections, multi vitamins and even tuberculosis 
drugs. The pill burden therefore becomes enormous and constitutes a major challenge 
in the administration of ART (Frank 2002:S10). 
 
5.2.4 History of adverse reactions to ART 
 
Adverse reactions to ARVs have been associated with non-adherence in ART in various 
research carried out among HIV-infected populations who were on antiretroviral therapy 
(Waters & Nelson 2007:986; Weiser et al 2003:285). Most of the participants 201 (87%) 
in this study reported never having adverse reactions to ART that would require them to 
stop the medications. This might have resulted in the high level (95%) of adherence re-
ported among them. According to previous research, ART regimens with significant 
side-effects have been shown to result in poor adherence among patients on antiretrovi-
ral therapy which subsequently results in increased HIV-related morbidity and mortality 
(Glass et al 2010:200; Cauldbeck et al 2009:7). This is why it has been proposed that 
health care providers need to consider the individual patient’s circumstance while initiat-
ing them on ART (Harries, Zachariah, Lawn & Rosen 2010:71). Regimen-based strate-
gies such as reduced pill burden and simplification of ART regimens that fit perfectly in-
to the patient’s daily schedule, have been shown to assist in the long term adherence to 
treatment and maintaining efficacy of treatment (Harries, Zachariah, Lawn & Rosen 
2010:72; Protopopescu et al 2009:604; Howard et al 2002:2180; Frank 2002:S12; 
Cauldbeck et al 2009:7). 
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5.2.5 HIV treatment adherence self- efficacy  
 
According to Bandura, although SCT acknowledges that knowledge of health risk and 
benefit of treatment are necessary to perform health behaviour, this in itself is not 
enough, additional self-influences are necessary to achieve necessary changes that will 
result in the desired health behaviour, this concept is called self-efficacy (Bandura 
2004:145). Self-efficacy is a known predictor of a wide range of health behaviour of pa-
tients on chronic medication including medication adherence, and has been shown to 
influence adherence to ART (Johnson et al 2007:367; Rudy et al 2009:188), although a 
study in the USA has found that adherence self-efficacy is not associated with adher-
ence to ART among older patients (Barclay et al 2007:46). According to Clark and 
Dodge (1999:84), individuals with health promoting behaviour possess self-beliefs, ena-
bling them to exercise control over their thoughts, feelings, and actions. People who en-
gage in self-management of health habits reduce major health risks and live healthier 
and more productive lives (Clark & Dodge 1999:86). 
 
With a mean score of 6.45 out of possible 10, the participants demonstrated high level 
of confidence on all the 12 items tested in the HIV-ASES scale. This compares well with 
the findings of Berg et al (2009:245), where the mean of adherence self-efficacy was a 
moderate 1.81 on a scale of zero to three in a study that seek to find if self-efficacy and 
depression mediate in the relationship between pain and adherence to antiretroviral 
therapy. The participants in the current study showed high ability in integrating HIV 
treatments plans into their daily activity, including sticking to their daily treatment sched-
ule when feeling sick, and continuing HIV treatment even when they are feeling dis-
couraged about their health. In addition, the participants demonstrated that they were 
confident with continuing with their treatment even when they felt discouraged about 
their health, when taking the treatment interferes with their daily activities, and when ex-
periencing side effects of ARVs. This high level of belief regarding their capabilities to 
carry out these tasks is hinged on the belief that doing so will result in better and living 
quality life despite being HIV-infected. In the context of adherence self-efficacy in ART, 
patients who demonstrated stronger confidence have been shown to adhere well to 
treatment and those with low confidence in carrying out tasks that would result in ad-
herence have been shown to be non-adherent to treatment (Johnson et al 2007:367; 
Rudy et al 2009:188). 
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5.2.6 Beliefs about medicines-specific  
 
Beliefs about medicines questionnaire is a measure of cognitive representation of medi-
cation among patients on chronic treatment. The BMQ-S measurements reflected par-
ticipants’ beliefs about the necessity and concerns about the use of specific medicines, 
in this study antiretroviral drug. The use of medication is strongly influenced by patient’s 
perception on the benefits of taking such medication (Munro et al 2007:104) and posi-
tive or negative medication beliefs would influence medication use behaviour. According 
to the self-regulatory theory, patients’ treatment perceptions and illness representations 
also influence medication adherence. Furthermore, patients on chronic treatment often 
undertake a cost–benefit analysis, considering whether their beliefs about the necessity 
of medications for maintaining health outweigh their concerns about the potential ad-
verse effects of taking them (Reynolds 2003:117-124). 
 
Beliefs about the importance of antiretroviral therapy in the management of HIV infec-
tion was generally positive among the respondents, the mean score of 4.05 out of 5 in-
dicates strong belief in the use of antiretroviral therapy. Over 97% (n=225) agreed that 
their current health is dependent on the antiretroviral medication and 94% (217) also 
agreed that their future health would depend on the medication. Most of the sample re-
ported that their medications kept their health from deteriorating 222 (95.6%), and more 
than half 134 (58%), were not worried about the long-term effects of ARVs.  
 
The strong belief about the necessity of medication use and concerns about medication 
use shown among the participants are in line with findings from the literature. Research 
suggests that patients who are highly adherent are those who have positive beliefs 
about the use of medications for chronic medical conditions (Neame & Hammond 
2005:764; Porteous, Francis, Bond & Hannaford 2010:228; Ireland & Wilsher 2010:39). 
 
5.2.7 Beliefs about medicines-general  
 
The BMQ-G measurements reflected participants’ beliefs about the harm and overuse 
associated with the use of medicines in general. Medication use behaviour of patients 
has been shown to be influenced by the direct experience of medication adverse ef-
fects; medication use behaviour of such patient is therefore influenced by belief of po-
tential adverse effects of the medications (Munro et al 2007:104). A patient with prior 
 
124 
adverse drug reactions to medication which is an indication of personal negative experi-
ence with medications may logically strengthen such belief to attribute adverse event 
easily to ARVs. Mean score of participants on this scale was 3.18 out of a possible 5, 
although this is less than the average score on BMQ-Specific, the participants still dem-
onstrated they have strong belief about the overuse and harm that medications in gen-
eral can cause. This was revealed among the participants as 51% (n=119) believed that 
doctors overused medications in general, 83.2% (193) agreed that doctors placed too 
much trust on medicines and 55% (127) believed doctor spent little time with patients 
thereby prescribing many medications. Almost half 45.7% (106) of the participants be-
lieved that medicines were addictive. Concerning harm associated with use of medi-
cines generally, few 12 (5.2%) endorsed the belief that natural remedies are safer than 
medicine, all medicines are poisons 29 (12.5%) and that people on chronic medicines 
should stop taking them very often 24 (10.3%). 
 
In their study, Porteous et al (2010:228) found that perceived general harm and overuse 
of medicines appear to remain stable over time, irrespective of changes in health status. 
The implication of this in patients on chronic medication is that the general beliefs about 
medicines remained a useful variable for intervention in enhancing adherence. The au-
thors further state that it is advisable to asses these beliefs in patients being prescribed 
medication given the association between beliefs about medicines and adherence to 
medication regimes, but the writers caution on the assumption of easily changing these 
beliefs as such beliefs are often difficult to change (Porteous et al 2010:228). 
 
5.2.8 Antiretroviral therapy adherence  
 
The Adherence questionnaire used in this study measured compliance with prescribed 
medication over the previous 4 days. Medication adherence was calculated as the pro-
portion of the ARVs taken out of the amount prescribed. Although adherence is one of 
the modifiable variables in ART, its monitoring is difficult among patients as no standard 
method exists to monitor adherence in ART, various authors have advised multiple ap-
proaches in adherence monitoring (Nachega et al 2009:66; Mills et al 2006:687; Simoni 
et al 2006:S25). This study only employed self-report in measuring adherence. Partici-
pants in this study appeared to be highly adherent to antiretroviral therapy with 81% be-
ing 100% adherent; this is higher than the self-report adherence rate of 55-77% report-
ed among patients on ART by Mills et al (2006:687) and Malangu (2008:49) who report-
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ed only 50% of his study participants being adherent to prescribed ARVs. Several ex-
planatory factors for this finding can be offered. First, the study participants received 
free ART services; this might influence their level of adherence. Secondly, the institution 
where these patients receive ART provides adherence counselling and support on an 
on-going basis for the participants in this study and this also might have influenced their 
adherence level.  
 
Previous studies indicate that adherence at 95% and above is necessary to achieve 
good clinical outcomes in ART (Bangsberg et al 2003:1930; Paterson et al 2000:26; 
Bangsberg 2006:940; Nachega et al 2007:569) and patients who fall below this level are 
at risk of developing resistance to ARVs and have increased chances of morbidity and 
mortality associated with the HIV disease (Graham et al 2010:1541). Research has 
shown that non-adherence is common among patients on ART, and it is estimated that 
non-adherence is between 30-50% among patients and more than 10% of patients usu-
ally miss one or more of their daily doses of antiretroviral drugs (Chesney 2000:S172).  
 
Instructions adherence is defined as the percentage of medications for which the correct 
special instructions were followed at each prescribed dose. The percentage of the par-
ticipants who strictly followed the specific dosage schedule was only 110 (47%); while 
the remaining 122 (53%) did not do so or partially followed schedule instructions. In fact, 
a quarter 57 (25%) of the participants never followed these instructions. Of the 146 par-
ticipants with specific instructions on how to take their ARVs (e.g. take with food, on an 
empty stomach or with plenty of fluids), only 63 (43%) followed them all of the time, out 
of the remaining 83 (57%) who did not comply, 16 (11%) never followed these instruc-
tions. This implies that though the participants in this study were highly adherent to their 
medications, majority did not follow the necessary instructions that require them to take 
medication at certain intervals. Since non-adherence is not limited to non-intake of med-
ication but includes other acts like not following instructions regarding the schedule, die-
tary or fluid restrictions and not taking medication at the prescribed time; participants in 
this study appeared to have been adherent to taking the prescribed medication only. 
They were non-adherent to instructions regarding dietary or fluid restrictions and did not 
take medication at the prescribed time. Non compliant with prescribed medicines in ART 
has been linked to recurrent opportunistic infections and poor clinical outcomes among 
patients (Graham et al 2010:1541; Moore et al 2005:290; Nachega et al 2006a:83). 
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5.3 RELATIONSHIPS AMONG STUDY VARIABLES 
 
Correlation analyses showed that there was a weak positive correlation between BMQ-
G and ACTG that is statistically significant and a moderate positive correlation between 
BMQ-S and BMQ-G. These results may therefore be taken to indicate that two of the 
cognitive or attitudinal variables under investigation, HIV-ASES and BMQ-S, had no link 
with adherence among the sample participants as measured in this research. This study 
revealed that participants’ general beliefs about medicines and adherence to ART were 
correlated; and two independent variables, BMQ-S and BMQ-G correlated. These find-
ings are consistent with previous studies (Neame & Hammond, 2005:764; Porteous, 
Francis, Bond & Hannaford 2010:228; Ireland & Wilsher 2010:39). This demonstrates 
that the stronger the beliefs about the harm and overuse associated with prescribed 
medications for chronic medical conditions, the stronger the adherence to ART. When 
Beliefs about medications subscales were related to each other, BMQ-S and BMQ-G 
correlated with each other. This implies that the stronger the beliefs about the necessity 
and concerns about ARVs prescribed for HIV/AIDS, the stronger the beliefs about the 
overuse and harm that medications in general can cause. 
 
When the scores of the 43 (18.5%) patients with adherence of 95% or less were isolat-
ed and independently correlated with the HIV-ASES, BMQ-S and BMQ-G measures, 
there was a weak positive correlation between HIV-ASES and ACTG. Amongst the in-
dependent variables, there was a weak positive correlation between HIV-ASES and 
BMQ-G, a moderate positive correlation between BMQ-S and BMQ-G, and a strong 
positive correlation between HIV-ASES and BMQ-S. HIV-ASES and ACTG were found 
to correlate with each other. This can be interpreted to mean that the stronger the confi-
dence in the patient’s ability to carry out tasks that would results in adherence, the high-
er the adherence to ART.  
 
In addition, positive correlation between HIV-ASES and BMQ-G means that the stronger 
the confidence in the patient’s ability to carry out tasks that would results in adherence, 
the stronger the beliefs about the overuse and harm that medications in general can 
cause. When Beliefs about medications subscales were related to each other, BMQ-S 
and BMQ-G correlated with each other, meaning that the stronger the beliefs about the 
necessity and concerns about ARVs prescribed for HIV/AIDS, the stronger the beliefs 
about the overuse and harm that medications in general can cause. This finding is simi-
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lar to that of Ireland & Wilsher (2010:40) who reported positive correlation between the 
two subscales among patients on chronic treatment. Finally, among non-adherent par-
ticipants a strong positive correlation between HIV-ASES and BMQ-G was found, indi-
cating that the stronger the confidence in the patient’s ability to carry out tasks that 
would result in adherence, the stronger the beliefs about the overuse and harm that 
medications in general can cause.  
 
The findings of this study are similar to that of Gauchet, Tarquinio and Fischer 
(2007:147); where the authors found patients’ beliefs about medicines to be related to 
adherence as the researcher found in the current study. The authors showed further 
that the influence of beliefs about medicines on medication adherence is also mediated 
by patient-provider relationship and by HIV illness/medication representation on the part 
of the patients. Their finding is therefore consistent with self-regulatory model described 
by Reynolds (2003:117-124) which postulates that the association between the patient-
provider relationship and medication adherence is mediated by HIV illness/medication 
representation. According to Gauchet, Tarquinio and Fischer (2007:147), “the relation-
ship between confidence in physician and adherence is in part positively mediated by 
patients’ beliefs about the necessity of antiretroviral treatment and negatively mediated 
by patients’ beliefs about the harmfulness of medication in general”. Although the cur-
rent study did not find the above associations, it is possible that some factors influenc-
ing adherence which were not investigated in the current study might be responsible. 
Further studies on patient-provider relationship and beliefs about medicines could pro-
vide a better understanding of these in the future. 
 
5.3.1 HIV adherence self-efficacy as predictor of non-adherence to ART 
 
The current research findings are consistent with previous findings that sought to evalu-
ate the relationship of self-efficacy and adherence to ART (Johnson et al 2007:367; 
Rudy et al 2009:188). HIV adherence self-efficacy or individual’s personal belief regard-
ing their capabilities to carry out prescribed instructions in adhering to ART was a signif-
icant variable in the regression analysis predicting adherence to ART among patients 
who were non-adherent. Previous studies have shown that self-efficacy is a known pre-
dictor of adherence in antiretroviral therapy (Johnson et al 2007:367; Rudy et al 
2009:188). There was significance for HIV-SES on ACTG (F(1;41)=4.440;p<0.041), with 
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HIV-SES explaining 9.8% of the variance, indicating self-efficacy had a weak predictive 
value. One can therefore conclude that HIV-SES is a weak predictor of ART adherence 
among patients who are non-adherent to therapy.  
 
5.3.2 Perceived general harm and overuse of medicines as predictor of ART ad-
herence 
 
In this study, general beliefs about medicines, a measure to gauge patients’ beliefs 
about the general harm and overuse of medicines was the significant variable in the re-
gression analysis that was conducted. It predicted adherence among patients on an-
tiretroviral therapy, as the regression analysis showed significance for BMQ-G on ACTG 
(F(1;231)=11,583; p<0,001) with BMQ-G explaining 4,8% of the variance. This indicates 
that BMQ-G had a weak predictive value. Therefore, among patients on ART, general 
BMQ-G is a very weak predictor of adherence. The findings above are in keeping with 
findings of various studies where low rates of adherence among patients on chronic 
medications have been found to be consistently related to doubts about personal need 
for medications (Neame & Hammond 2005:764; Porteous, Francis, Bond & Hannaford 
2010:228; Ireland & Wilsher 2010:39). 
 
This study failed to confirm the necessity-concerns framework (BMQ-specific) as a pre-
dictor of adherence to medication, perceived necessity and concerns beliefs has been 
used to predict medication use behaviour in other chronic illnesses such as asthma, 
diabetes, hypertension (Neame & Hammond, 2005:764; Porteous, Francis, Bond & 
Hannaford 2010:228; Ireland & Wilsher 2010:39). 
 
5.4 ENHANCING ADHERENCE TO ART THROUGH FOCUSED INTERVENTIONS 
BASED ON SELF-EFFICACY AND BELIEFS ABOUT MEDICINES MODEL 
 
This study identified HIV adherence self-efficacy and perceived harm and overuse of 
medicines as a predictor of adherence. Self-efficacy is an individual’s personal belief 
regarding their capabilities to carry out a specific task to achieve a desired outcome. 
However, such behaviour is likely to be carried out by the patient if he/she believes that 
such action can be performed.   
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Figure 5.1  Modality of enhancing adherence to ART focusing on self-efficacy and beliefs 
about medicines 
 
IMPROVED ADHERENCE TO ANTIRETROVIRAL THERAPY 
REDUCED HIV/AIDS RELATED MORBIDITY AND MORTALITY 
Enhance HIV-infected people’s 
adherence to ART 
1. Modelling behaviour and Observational learning from 
highly adherent HIV patient to serve as "role models" 
2. Verbal persuasion and encouragement 
3. Positive reinforcement of positive medication beliefs 
4. Assuage negative medication beliefs 
5. Educational intervention: HIV/AIDS, antiretroviral drugs, 
adherence, recommended diet and lifestyle in HIV/AIDS 
6. Learning new skills and exploring more self-care behav-
iours e.g. pills organizer, diaries, SMS reminders etc. 
7. Teaching patients how to avoid negative self-talk 
8. Teaching patient to monitor self-defeating thoughts and 
stop them consciously 
9. Replace negative thoughts with task-focused ones 
10. Building on one’s personal self-efficacy 
11. Teaching relaxation skills and anxiety management 
12. Individualized treatment education to adapt treatment to 
patient lifestyle 
 
High HIV adherence self-efficacy 
Stronger beliefs in general harm and overuse of medicines 
ADHERENCE COUNSELLING & MONITORING IN ANTIRETROVIRAL THERAPY 
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Figure 5.1 represents a modality of enhancing adherence to ART focusing on self-
efficacy and beliefs about medicines. It shows the goals, intervention and outcome of 
the intervention that aim to improve patients’ adherence self-efficacy and stronger be-
liefs about general harm and overuse of medicines.  
 
A strategy such as vicarious experiences or modelling behaviour by other patients 
who are HIV positive and reinforcing mastery of the patient’s self-care behaviours are 
approaches that can be used by adherence counsellors in enhancing ART adherence. 
Vicarious experience occurs from observing others complete a task successfully con-
tributing as a source of modeling self-efficacy in performing that task (Bandura 
1988:284).  
 
Patients’ beliefs about medicines are dynamic, and these beliefs are often due to pa-
tients’ misunderstanding of the role of medications in chronic illnesses. Educational in-
tervention in adherence serves as an opportunity for patients on chronic medications to 
improve their knowledge about the disease condition, gain better understanding of the 
role of medications and have any misconceptions harbored about their medications clar-
ified (Magadza et al 2009:369). Patients’ beliefs can be modified positively through edu-
cational interventions which will result in a change of behaviour. Addressing the risks 
and benefits of therapy could reinforce positive medication beliefs (such as perceived 
need for medication) and assuage negative ones (such as general harm and overuse of 
medicines) through appropriate information and counselling. Increase in knowledge is 
expected to lead to a change in the participants’ beliefs about medicines and improved 
adherence. 
 
Observational learning or modelling describes how a person acquires skills and in-
formation through the actions of other people (Redding et al 2000:185). Counsellors can 
provide observational learning by finding a highly adherent HIV patient to serve as "role 
models". Through observation, a person can learn from other people’s actions and go 
further to develop an understanding of and be prepared for the consequences of such 
actions. The support groups that are formed among HIV-infected patients may serve as 
a good model where people learn how to do certain things by observing others within 
the group (Skovdal et al 2011:309). This would improve the individual’s self-care behav-
iour leading to improved adherence to antiretroviral therapy 
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Verbal persuasion, which is the most often used source of self-efficacy by health care 
professionals, is used to convince persons that they can succeed at a task. Verbal or 
social persuasion serves to reinforce feelings of efficacy when facing the minor failures 
mentioned above (Bandura 1988:285). Adherence counsellors should utilize verbal per-
suasion and encouragement, and seek to strengthen patients’ adherence self-efficacy 
beliefs by expressing confidence in their capabilities. This form of support results in 
learning new skills and exploring more self-care behaviours. In addition to this, health 
workers need to be persistent with encouragement as self-efficacy develops over time, 
therefore continuous positive reinforcement is needed to enhance adherence among 
patients on antiretroviral therapy. 
 
Performance mastery refers to the knowledge and skill gained through experience and 
perseverance (Bandura 1988:285). Adherence counsellors should teach patients how to 
avoid negative self-talk, monitor these self-defeating thoughts, and stop them con-
sciously. The patients need to be thought how to replace negative thoughts with task-
focused ones, so hopelessness associated with adhering to antiretroviral therapy can 
be avoided. Another strategy is building on one’s personal self-efficacy, if a person in-
fected with HIV has the personal belief regarding his/her capabilities to carry out specific 
tasks to achieve good adherence to ART and believe that by doing so he/she will have 
improved health and lead quality life, then such individual is more likely to perform the 
behaviours.  
 
Cognitive technique in counselling by health care workers assist the patient to learn rel-
evant information about HIV/AIDS and the courses of action to make in taking decision 
about their disease and solving problems (Skovdal et al 2011:309). The support groups 
in HIV/AIDS can use cognitive and behavioural strategies to empower patients to han-
dle problem and establish supportive relationships. Issues around disclosure of HIV sta-
tus, relaxation skills, anxiety management and treatment education are skill taught in 
these groups that may result in better adherence to treatment (Skovdal et al 2011:309).  
 
5.5 DEVELOPMENT OF A FRAMEWORK TO ENHANCE ART ADHERENCE  
 
There is much information from various studies that explain several factors that serve as 
barriers and facilitators of ART adherence. Some of these studies, like the current re-
search, were guided by health behaviour theories focussing on the individual level of 
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analysis, with behaviour viewed as the outcome of conscious rational choice. Research 
has shown that patients’ medication beliefs can be altered through focused intervention 
(Magadza et al 2009:369). The framework described here is based on the findings of 
the current research and focuses on the individual behaviour assuming that it is shaped 
by cognitions such as attitudes, beliefs, motivations and self-efficacy. HIV-infected pa-
tients need to have confidence in their ability to perform the required self-management 
activities (self-efficacy) and hold positive beliefs about their medications. They must be-
lieve that exhibiting self-care behaviour and holding the right beliefs about their medica-
tions lead to good clinical outcomes which translate to quality health. 
 
Developing a framework to enhance adherence to antiretroviral therapy is necessary in 
assisting these patients to attain competence in self-efficacy and to develop positive be-
liefs about medications that would result in good adherence and a subsequent better 
clinical outcomes on ART. This study revealed cognitive factors, such as self-efficacy 
and perceived general harm and overuse of medicines, as part of the factors influencing 
adherence to ART. The researcher proposed that attention should be given to these 
cognitive-behavioural variables that can influence successful compliance to treatment. 
 
5.5.1 Structure of the framework 
 
The framework for enhancing ART adherence among HIV-infected patients comprises 
of the following: 
 
 Purpose of the framework 
 Assumptions of the framework 
 Participants within the framework 
 
5.5.1.1 Purpose of the framework 
 
The purpose of the framework is to provide modalities for adherence counsellors and 
other health care providers involved in HIV management on how to enhance adherence 
of patients on antiretroviral therapy using the identified cognitive factors in this study. 
The major aim of the framework is to improve adherence to ART among patients 
thereby reducing the morbidity and mortality associated with HIV/AIDS. 
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The research findings revealed that HIV adherence self-efficacy is a predictor of adher-
ence to ART among patients who are non-adherent to antiretroviral therapy and general 
beliefs about medicines is a predictor of ART adherence among HIV-infected patients 
on ART. In addition, there is inter-relationship between adherence self-efficacy and 
general beliefs about medicines; and between specific beliefs about medicines and 
general beliefs about medicines.  
 
5.5.1.2 Assumptions of the framework 
 
The guidelines for the initiation of ART in South Africa stipulate the minimum counsel-
ling sessions for a potential HIV-infected patient to be initiated on treatment. Since ART 
is a life time commitment, it is very important to counsel a patient adequately before ini-
tiation of treatment. The assumptions of this framework are based on the following in 
cognizance of ART guidelines: 
 
 Adequate counselling will precede initiation of ART initiation. 
 The adherence counsellors will identify the potential barriers and facilitators of 
adherence before initiation of ART. 
 Where necessary, treatment buddies will be involved in counselling sessions with 
the patient. 
 Adherence monitoring and counselling is a continuum and will not be treated as 
once-off event in antiretroviral therapy. 
 
5.5.1.3 Participants within the framework 
 
This is a framework for enhancing ART adherence among patients on antiretroviral 
treatment. However, other stakeholders will be involved to achieve the desired outcome 
of this framework. Participants in the framework will include: 
 
 HIV-infected patients on ART 
 Health care providers 
 Treatment buddies and family members of patients 
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It is important to include people with whom patients on ART would collaborate in the 
framework. As such, the health care providers, treatment buddies and family members 
are the population that forms the core of the framework. All these stakeholders work in 
an interactive fashion to enhance adherence by assisting the patient to change the un-
realistic expectations or behaviour through education that helps to learn how to do 
things in a new or different ways. According to Bandura (2004:144), patients can control 
or influence the events that affect their lives by integrating cognitive, social, and behav-
ioural sub-skills related to beliefs of personal efficacy in performing these skills. 
 
5.5.2 Overview and structural description of the framework 
 
The researcher therefore proposes a framework that encompasses HIV-ASES and 
BMQ-G, BMQ-S and ACTG questionnaires to be used by adherence counsellors in en-
hancing adherence among HIV-infected patients on ART. Figure 5.2 is a structural rep-
resentation of the framework for enhancing ART adherence among HIV-infected pa-
tients. The oval structures on the left side represent the potential facilitators and barriers 
to ART adherence namely: 
 
 Socio-demographic characteristics, accessibility to health services, social sup-
port. 
 HIV adherence self-efficacy. 
 Perceived general harmful effects and overuse of medications. 
 Specific necessity and concerns about ARVs. 
 
The solid pillar-shaped column on the right side represents adherence to ART which is 
the desired outcome of antiretroviral therapy use. The arrows pointing to the right indi-
cate direction of the activity and end results of intervention. The up-down arrows indi-
cate interrelationship between certain cognitive variable and the down-arrow callout 
(marked blue) depicts the intervention carried out after potential barriers to adherence 
have been identified. The enhancement of adherence is effected through the interven-
tion targeted at the identified barrier or facilitator of adherence. 
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Figure 5.2   Analytical diagram of the framework for enhancing ART adherence 
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5.5.2.1 STEP 1: Baseline screening for adherence facilitators and barriers 
 
The activity in the framework begins when patients are being counselled and empow-
ered with the necessary information about the ART treatment process.  The oval struc-
tures in Figure 5.3 represent the factors influencing ART adherence. The framework for 
enhancing ART adherence among HIV patients focuses on empowering the patients 
with the necessary skills. This will assist them to attain competence in self-efficacy and 
poses stronger beliefs about medications that will result in better adherence to ART 
which will subsequently result in good clinical outcomes and reduced morbidity associ-
ated with HIV/AIDS. 
 
The goal at this stage is to identify the cognitive-behavioural factors that will influence 
the individual in adhering to ART. Adherence counsellors and other health care provid-
ers involved in counselling will use the screening tools to identify these factors. At this 
stage two instruments are used to assess the HIV adherence self-efficacy and about the 
general harm and overuse of medicines. BMQ-G (Table 5. 1) is used to screen for be-
liefs about the general harm and overuse of medicines. The patient’s average score is 
recorded and optimal score is 8points. Any patient that scores below 4points is identi-
fied and prioritized for further intervention based on the responses on the BMQ-G scale. 
 
Table 5.1 Beliefs about Medicines Questionnaire-General (BMQ-G) 
 
 Strongly 
agree 
Agree Uncertain Disagree Strongly 
disagree 
Doctors use too many medicines 1 2 3 4 5 
People who take medications should stop 
their treatment for a while every now and 
again 
1 2 3 4 5 
Most medicines are addictive 1 2 3 4 5 
Natural remedies are safer than medicines 1 2 3 4 5 
Medicines do more harm than good 1 2 3 4 5 
All medicines are poisons 1 2 3 4 5 
Doctors place too much trust on medicines 1 2 3 4 5 
If doctors had more time with patients they 
would prescribe fewer medicines 
1 2 3 4 5 
 
 
At this stage also, the HIV-ASES is used to assess the confidence of the patients in 
their ability to carry out the tasks outlined in Table 5.2 below. The performance of these 
tasks results in the desired outcome which is adherence to ART. The patients are asked 
the 12 questions on the HIV-ASES and each item is scored between 0-10, the average 
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score is then calculated, the optimal score is 10. A score below 5 is identified and priori-
tized for intervention based on the patient’s responses on the HIV-ASES scale. 
 
Table 5.2 HIV adherence self-efficacy scale (HIV-ASES) 
 
 Score 
0-10 
1. Stick to your treatment plan even when side effects begin to interfere with your daily 
activities? 
 
2. Integrate your treatment into your daily routine?  
3. Integrate your treatment into daily routine even if it means taking medication or doing 
other things in front of people who don’t know you are HIV+ 
 
4. Stick to your treatment schedule even when your daily routine is disrupted?  
5. Stick to your treatment schedule when you aren’t feeling well?  
6. Stick to your treatment schedule when it means changing your eating habits?  
7. Continue with your treatment even if doing so interferes with your daily activities?  
8. Continue with the treatment plan your physician prescribed even if your CD4 count 
drop significantly in the next three months? 
 
9. Continue with your treatment even when you are feeling discouraged about your 
health? 
 
10. Continue with your treatment even when getting to your clinic appointments is difficult?  
11. Continue with your treatment even when people close to you tell you that they don’t 
think that it is doing any good? 
 
12. Get something positive out of your participation in treatment, even if the medication 
you are taking does not improve your health? 
 
 
       Total 
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Figure 5.3 Baseline screening for adherence facilitators and barriers 
STEP 1 
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5.5.2.2 STEP 2: Focused interventions on identified barriers of art adherence 
 
The main objective at this stage is to address the identified factors in step 1 that could 
serve as barriers to ART adherence. The researcher proposes minimum score on the 
BMQ-G as 4, and minimum score on the HIV-ASES as 5. Patients that score below the-
se cut-off marks are categorized as possessing cognitive-behavioural factors that serve 
as barriers to ART adherence. The adherence counsellors will define and communicate 
to the patients the factors that have been identified for intervention. He will then set 
goals and strategies for the intervention according to the identified psychological and 
physical needs of the patient.  
 
Figure 5.4 shows a schematic diagram of the identified cognitive variables. The arrows 
pointing to the right indicate the desired outcome for the patient and the down-arrow 
callout (marked blue) marks the point of intervention outlined for a specific patient. The 
activities that could be used at this stage include but not limited to the following: 
 
1. Address the identified cognitive variables in the scales where the individual 
scores low points by education, counselling, skills development and provide prac-
tical assistance where necessary. This may involve discussion with other mem-
bers of the health team on the need to review ART regimen, schedule etc. 
 
2. Review the individual perception of health goal, HIV disease, purpose of antiret-
roviral therapy, benefits of adherence and consequences of non-adherence to 
ART. 
 
3. Educate the individual further on the facts about ART adherence, factors influ-
encing adherence and consequences of non-adherence. 
 
4. Assist the patient to assume a participatory role in decision made about his/her 
health especially in the timing of medications intake, regimens that suit his/her 
daily routine etc. 
 
5. Assist the individual to develop a greater sense of self-care behaviour, setting 
personal goals and implementing strategies to achieve the set goals.  
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6. Developing skills to incorporate treatment needs into their lifestyle. 
 
7. Assist the patient in terms of self-management training for taking daily medica-
tions, motivational interview and social support, if necessary. 
 
8. Reminder devices such as pillboxes, pill chart, medication diaries, beepers and 
alarms etc may be provided for certain individuals, depending on their circum-
stances. 
 
Learning occurs through information acquisition and is often interactive. This stage em-
phasizes the need for learning through feedback and internalization of the processes 
that lead to behavioural change.  Patients need to demonstrate self-reinforcement and 
self-enhancement through feedback to the adherence counsellors and ability to develop 
an action plan to achieve improved adherence to ART. The development of cognitive-
behavioural competency skills, such as adherence self-efficacy and beliefs about medi-
cines in HIV management, at this stage will result in better adherence. 
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Figure 5.4 Focused interventions on identified barriers to ART adherence 
 
5.5.2.3 STEP 3: Outcome of focused intervention – ART adherence 
 
Figure 5.5 depicts the diagrammatic picture of what occurs in step 3. The solid column 
on the far right represents adherence to ART that is achieved by cognitive-behavioural 
intervention carried out in stage 2. The aim of this step is to emphasize the importance 
of adherence to ART following development of competency in self-efficacy and posses-
sion of stronger beliefs in the use of medicines. The achievement of this competency 
will result in sustained adherence to antiretroviral therapy which will be evident in re-
duced HIV/AIDS morbidity and mortality. According to Bandura (2004:145), competent 
individuals are more self-directed and goal oriented which lead to self actualization. The 
competent patient has the ability to cope with encountered situations and maintain self-
care management skills at all time. 
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Figure 5.5 Outcome of focused intervention- ART adherence 
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The ACTG questionnaire is used at this stage and it determines the medication adher-
ence to prescribed ARVs in the previous four days, the compliance of the patient with 
dosing schedule and the extent to which the patient has followed dietary instructions for 
ARV use.  
 
The framework described above can be summarized as follows: 
 
Step 1: an HIV-infected patient is screened for cognitive-behavioural factors that could 
serve as barriers to ART adherence using two instruments (BMQ-Q & HIV-ASES). 
Based on the score on the instruments, a patient is identified for further intervention. 
 
Step 2: focused intervention on identified barriers is done at this stage with emphasis 
on interactive learning and feedback. 
 
Step 3: the final stage involves the outcome of the intervention at the previous stage 
and indicates how successful the intervention was.  
 
5.6 CONCLUSIONS 
 
The purpose of this study was to determine the influence of adherence self-efficacy and 
beliefs about medicines on ART adherence among patients on lifelong treatment and 
subsequently use the information obtained to provide a framework for enhancing adher-
ence to antiretroviral therapy. This section looks at the extent to which the objectives of 
the study have been met. 
 
5.6.1 Objective 1: Explore the cognitive variables of adherence self-efficacy and 
beliefs about medicines that influence adherence among patients on ART 
 
This objective was achieved through conducting a study using correlation design. Data 
were collected from participants who are HIV-infected on antiretroviral therapy using 
quantitative instruments that include HIV adherence self-efficacy scale, the Beliefs 
about Medicines questionnaire and the ACTG questionnaire. Findings revealed that the 
participants were highly adherent to ART (average adherence was 95%), had strong 
confidence in their ability to carry out tasks would enable them to adhere to ART, had 
high positive beliefs in the necessity that prescribed medications were necessary for 
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HIV/AIDS and strong beliefs about the overuse and harm that medications in general 
can cause.  
 
5.6.2 Objective 2: Determine the inter-relationships among adherence self-
efficacy, beliefs about medicines and ART adherence 
 
This objective was met through the performance of correlation and regression analyses 
on the collected data. The predictive relationship of HIV adherence self-efficacy, beliefs 
about medicines and ART adherence was demonstrated. Multivariate regression was 
illustrated with ART adherence predicted by HIV adherence self-efficacy among non-
adherent patients and predicted by beliefs about the overuse and harm that medications 
in general can cause among the general population.  
 
5.6.3 Objective 3: Describe the modalities of enhancing adherence to ART 
through focused interventions on the identified factors that are strongly 
associated with ART adherence 
 
This objective was met by the researcher through the description of various modalities 
to enhance ART adherence by focusing on cognitive variables that serve as barrier to 
adherence. The study revealed that interventions could be manipulated to address the 
identified cognitive factors of self-efficacy and Belief about medicines that would serve 
as barriers to adherence to antiretroviral therapy. An HIV-infected person with strong 
self-efficacy and high belief in medicines has personal belief regarding his capabilities to 
carry out specific tasks to achieve good adherence to ART and beliefs that prescribed 
medications were necessary for HIV/AIDS. Therefore, such individual is likely to adhere 
to prescribed antiretroviral medicines. 
 
5.6.4 Objective 4: To develop a framework for the improvement of ART adher-
ence based on the factors identified in this study 
 
This objective was met through the design and description of a framework that would 
enhance adherence to ART among patients. The findings of this study suggest that 
health care workers that are involved with patients on ART should target personal self-
efficacy beliefs and beliefs about medicines that would enhance adherence among HIV-
infected patients on antiretroviral therapy. The researcher went further by describing a 
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3-step approach framework that include (1) Baseline screening for adherence self-
efficacy and perceived general harm and overuse of medicines (2) Focused interven-
tions on identified barriers of ART adherence and (3) Outcome of focused Intervention: 
ART adherence. 
 
The researcher concludes by stating that all the objectives of this study have been met. 
 
5.7 CONTRIBUTIONS OF THE STUDY 
 
This study examined a theoretical framework encompassing health beliefs/attitudes, 
ART self-efficacy and demographic characteristics in relationship to antiretroviral ther-
apy adherence. The researcher examined the relationships between two individual fac-
tors (self-efficacy and beliefs about medicines) and health behaviour (HIV medication 
adherence) in an attempt to identify the potential area for focused interventions that 
could be used in enhancing ART adherence. It was anticipated that relationship exists 
among the study variables using the Cognitive perspective of health behaviour as theo-
retical framework. The study established the predictive relationships between HIV ad-
herence self-efficacy and adherence to ART; secondly it also described the predictive 
relationship between perceived harm and overuse of medicines and adherence. Finally, 
the current research also identified the relationships that existed among the independ-
ent variables.  
 
This study has significant implications for HIV/AIDS clinical care and research in that it 
provides a framework that would assist health providers in identifying patients at high 
risk for medication non-adherence and also the modalities of enhancing their adherence 
to antiretroviral therapy. The early identification of patients who are likely to be non-
adherent in the course of taking ART would assist in reducing the morbidity and mortal-
ity associated with HIV/AIDS among non-compliant patients. Secondly, the cost associ-
ated with HIV/AIDS management would be reduced if more patients are adhering to 
their treatment. Furthermore, the development of resistance that results from non-
adherence to ART would also be minimized if potential non-adherent patients are identi-
fied early and intervention put in place to ensure their good adherence to ART. 
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5.8 LIMITATIONS OF THE STUDY 
 
The use of cross-sectional design to investigate adherence to HIV medication at a point 
in time limits the degree to which causal inferences and generalizations can be made 
from the research findings. A longitudinal study design, which involves taking multiple 
measures over a defined length of time, could possibly give more information about 
changes that occur over time in terms of adherence to antiretroviral therapy.  
 
This study was conducted in a public health facility that provides free ART services and 
psycho-social support to patients on ART, certain socio-economic factors that have 
been described as barriers to adherence may not have affected the participants in this 
study. This might have influence on the responses of the participants and the high level 
of adherence reported in this study. 
 
The proportion of non-adherent patients in this sample appear to be small to make con-
crete conclusion on non-adherent patients, subsequent studies could focus mainly on 
non-adherent patient; outcome of such research could shed more light on barriers to 
ART adherence that are unique among such group of patients.  
 
There are several potential predictors of medication adherence that were not assessed 
as part of this study e.g. transportation costs, accessibility to health institutions and so-
cial support. Their inclusion might have given a different outcome. Another limitation is 
the self-report questionnaire that was used; self-report could be affected by participant 
motivation, poor recall and social desirability in responding. Adherence to ART may be 
over-estimated by participants and non-adherence may be underreported, it is possible 
that other measures of adherence such as a medication event monitoring system 
(MEMS), pill count, pharmacy records and laboratory blood monitoring could have 
yielded different results. As there is no gold standard for measuring adherence to ART 
(Johnson et al 2005:201), the researcher is of the opinion that ACTG adherence ques-
tionnaire, a validated measure of adherence that has demonstrated meaningful relation-
ships with important outcomes such as CD4 count and viral load in other studies em-
ployed in this study is an adequate measure of adherence. 
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5.9 RECOMMENDATIONS 
 
The following recommendations are suggested for future efforts in enhancing ART ad-
herence among patients. 
 
1. Baseline data on adherence should be obtained for all patients before initiation of 
ART using the tools described in this study irrespective of their socio-economic 
and demographic characteristics. This would assist in identifying patients that 
need further cognitive intervention before commencement of ART. 
 
2. In future, studies may utilize multiple measures of adherence, such as medica-
tion event monitoring system (MEMS), pill count, CD4 count, viral loads to vali-
date the accuracy of self-reported measures. This would enhance the accuracy 
of self-reported measure like the ACTG questionnaire. 
 
3. Future research may seek to include different healthcare providers, such as pri-
vate, public and faith-based organisations. This could bring to light differences in 
the strategies used by these providers to foster and sustain adherence to ART 
among their patients, and secondly provide better understanding of potential bar-
riers to ART adherence among patients who are not receiving free ART services. 
 
4. The current study did not investigate how patient-provider relationship influence 
patients’ adherence to antiretroviral therapy. Further studies on patient-provider 
relationship and beliefs about medicines could provide better understanding of 
these in the future. 
 
5. A strategy such as vicarious experiences or modelling behaviour by other pa-
tients who are HIV positive and reinforcing mastery of the patient’s self-care be-
haviours (Bandura) are approaches that could be used by adherence counsellors 
in enhancing ART adherence. This would improve the individual’s self-care be-
haviour leading to improved adherence to antiretroviral therapy. 
 
6. Another strategy is building on one’s personal self-efficacy, which has been 
shown to be highly influential in adherence. If persons infected with HIV have the 
belief regarding their capabilities to carry out specific tasks to achieve good ad-
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herence to ART and that believe that by doing so they will have improved health 
and lead quality life, then they may be more likely to perform the behaviours.  
 
7. Health workers need to be persistent with encouragement as self-efficacy devel-
ops over time, therefore continuous positive reinforcement is needed to enhance 
adherence among patients on chronic medications. 
 
5.10 SUMMARY 
 
HIV is a chronic disease that is managed with medications; successful clinical outcome 
depends on patient’s self-efficacy in adhering to ART and positive beliefs about medica-
tions. As health-related knowledge and patients beliefs alone are insufficient to achieve 
behaviour change especially in chronic condition like HIV/AIDS, there is need for better 
understanding of other factors that predict patients’ behavioural changes that would re-
sult in adherence to prescribed medication. The framework described in this study can 
make a meaningful contribution to adherence monitoring and enhancement among pa-
tients on antiretroviral therapy thereby resulting in good clinical outcomes and reduction 
in morbidity and mortality associated with HIV/AIDS. In conclusion, further study is en-
couraged in this field of adherence in HIV/AIDS management to assist patients in main-
taining quality life as they live with this chronic disease. 
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ANNEXURE D: Research instruments 
                                              QUESTIONNAIRE                                       Serial no ______ 
SELF-EFFICACY AND BELIEFS ABOUT MEDICINES: IMPLICATIONS FOR ANTIRETROVIRAL 
THERAPY ADHERENCE 
SECTION A: DEMOGRAPHIC DATA 
1. How old are you?                                                                                                 For office use                                                                                                                                
18-24 years                                                    1   
25-34 years                                                     2   
35-44 years                                                    3   
45-55 years                                                   4   
>55 years                                                     5 1  
 
2. What is your gender?              
Male 1   
Female 2 2  
                                                                                                                                     
3. Marital status 
Never married  1   
Married  2   
Cohabiting   3   
Widowed   4   
Separated    5   
Divorced. 6 3  
 
4. Highest level of education completed 
No schooling 1   
Primary education 2   
Secondary education 3   
Tertiary education 4 4  
2 
 
 
5. How many cigarettes do you smoke per day? 
None 1   
1-4 2   
5-9 3   
10-14 4   
15 and more 5 5  
 
6. How often do you consume alcohol? 
More than once daily 1   
Once daily 2   
A few times per week 3   
About once a week 4   
Seldom 5   
Never 6 6  
 
7.  Work status in the last 3 months? 
Employed 1   
Unemployed 2   
Student 3   
Social grant 4   
Retired 5 7  
 
8.  When was the first time you were told about your HIV status?   
Between 12 - 23 months 1   
Between 24 – 36 months  2   
More than 36 months 3 8  
 
  
3 
 
9.  What is/are the most likely way(s) that you became infected with HIV? 
Sex with HIV+ person 1   
Shared needles with HIV+ person 2   
Mother-to-child transmission 3   
Occupation exposure to blood/body fluid 4   
Sexual assault 5   
Blood transfusion or medical procedure 6   
Don’t know 7   
Other 8 9  
 
 
10.  Have you disclosed your status to any of your family members? 
Yes 1   
No 2 10  
 
11. Do you have a treatment buddy presently? 
Yes 1   
No 2 11  
 
12.  If yes, to what extent does your treatment buddy helps you to remember taking your medica-
tion? 
Not at all 1   
A little 2   
Sometimes 3   
A lot 4 12  
 
13. How long have you been on ART? Would you say 
Between 12 - 23 months 1   
Between 24 - 36 months 2   
More than 36 months 3 13  
 
4 
 
14. What is the number of pills you swallow every day? 
2-5 1   
6-10 2   
More than 10 3 14  
  
15. Have you experienced any adverse reactions of ART that required you to stop the medica-
tions? 
Yes 1   
No 2 16  
 
 
SECTION B: HIV TREATMENT ADHERENCE SELF-EFFICACY SCALE (HIV-ASES) 
 
I am going to ask you about situations that could occur during your treatment for HIV. 
Treatment can involve different things for different people. Sometimes, this might refer to 
taking medications, and other times it could refer to other things that you do to deal with 
HIV such as diet and exercise or taking vitamins. So, in these questions, when I ask you 
about your “treatment” or your “treatment plan,” I am talking not only about any medica-
tions that you might be taking for HIV, but also other things that make up your self-care. 
 
For the following questions, I will ask you to tell me in the past month, including today, 
how confident you have been that you can do the following things. Use these responses 
scale ranging from 0 (“cannot do at all”) to 10 (“completely certain can do”). 
Cannot do at all                                                                                             00 
                                                                                                                      01 
                                                                                                                      02 
                                                                                                                      03 
                                                                                                                      04 
Moderately Certain Can Do                                                                          05 
                                                                                                                      06 
                                                                                                                      07 
                                                                                                                      08 
                                                                                                                      09 
Completely Certain Can Do                                                                          10 
 
 
 
5 
 
How confident you have been that you can do the following things in the past month, including today? 
 
 
 00 01 02 03 04 05 06 07 08 09 10 
1. Stick to your treatment plan even when side effects begin to interfere with 
your daily activities? 
           
2. Integrate your treatment into your daily routine?            
 
3. Integrate your treatment into daily routine even if it means taking medication 
or doing other things in front of people who don’t know you are HIV+ 
           
4. Stick to your treatment schedule even when your daily routine is disrupted?            
 
5. Stick to your treatment schedule when you aren’t feeling well?            
 
6. Stick to your treatment schedule when it means changing your eating habits?            
 
7. Continue with your treatment even if doing so interferes with your daily activi-
ties? 
           
8. Continue with the treatment plan your physician prescribed even if your CD4 
count drop significantly in the next three months? 
           
9. Continue with your treatment even when you are feeling discouraged about 
your health? 
           
10. Continue with your treatment even when getting to your clinic appointments 
is difficult? 
           
11. Continue with your treatment even when people close to you tell you that 
they don’t think that it is doing any good? 
           
12. Get something positive out of your participation in treatment, even if the 
medication you are taking does not improve your health? 
           
6 
 
SECTION C: BELIEFS ABOUT MEDICINES QUESTIONNAIRE (BMQ) 
 
I would like to ask your personal views about ARVs prescribed for you and your personal views about 
medicines in general. These are statements others people have made about their medications. 
Please indicate the extent to which you agree or disagree with them by circling the appropriate box. 
There is no right or wrong answers; I am only interested in your personal views. 
 
 
BMQ-Specific: Your views about ARVs prescribed for you 
 Strongly 
agree 
Agree Uncertain Disagree Strongly 
disagree 
My health, at present, depends on my ARVs 
 
5 4 3 2 1 
My life would be impossible without my ARVs  
 
5 4 3 2 1 
Without my ARVs I would become very ill  
 
5 4 3 2 1 
My health in the future will depend on my ARVs  
 
5 4 3 2 1 
My ARVs protect me from becoming worse  
 
5 4 3 2 1 
Having to take ARVs worries me  
 
 
1 
 
2 
 
3 
 
4 
 
5 
I sometimes worry about long-term effects of my 
ARVs 
  
 
1 
 
2 
 
3 
 
4 
 
5 
I don’t know how my ARVs work  
1 
 
2 
 
3 
 
4 
 
5 
My ARVs disrupt my life  
 
 
1 
 
2 
 
3 
 
4 
 
5 
I sometimes worry about becoming too depend-
ent on my ARVs  
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
BMQ-General: Your views about Medicines in general 
 Strongly 
agree 
Agree Uncertain Disagree Strongly 
disagree 
Doctors use too many medicines 
 
 
1 
 
2 
 
3 
 
4 
 
5 
People who take medications should stop their 
treatment for a while every now and again 
 
1 
 
2 
 
3 
 
4 
 
5 
Most medicines are addictive 
 
 
1 
 
2 
 
3 
 
4 
 
5 
Natural remedies are safer than medicines 
 
 
1 
 
2 
 
3 
 
4 
 
5 
Medicines do more harm than good 
 
 
1 
 
2 
 
3 
 
4 
 
5 
All medicines are poisons 
 
 
1 
 
2 
 
3 
 
4 
 
5 
Doctors place too much trust on medicines. 
 
 
1 
 
2 
 
3 
 
4 
 
5 
If doctors had more time with patients they would 
prescribe fewer medicines 
 
 
1 
 
2 
 
3 
 
4 
 
5 
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SECTION D: ANTIRETROVIRAL THERAPY ADHERENCE QUESTIONNAIRE 
You are currently taking the following drugs at the frequency and doses listed. 
DRUG NAME/DOSE Number of Pills each time 
(Pills Each Dose) 
Number of times per day 
(Doses Per Day) 
   
 
   
 
   
 
   
 
 
1. If you took only a portion of a dose on 1 or more of these days, report the dose(s) as be-
ing missed. 
 
 
Step 1 
Names of your ARVs 
 
HOW MANY DOSES DID YOU MISS . . . 
Step 2 
Yesterday 
Step 3 
 2 days ago 
Step 4 
3 days ago 
Step 5 
4 days ago 
 
 
 
-----doses 
 
-----doses 
 
-----doses 
 
-----doses 
 
 
 
-----doses 
 
-----doses 
 
-----doses 
 
-----doses 
 
 
 
-----doses 
 
-----doses 
 
-----doses 
 
-----doses 
 
 
 
-----doses 
 
-----doses 
 
-----doses 
 
-----doses 
 
2. During the past 4 days, on how many days have you missed taking all your doses?  
    
                       None            1 day                  2 days                3 days          4 days 
                       
                               1                    2                      3                           4                     5 
 
3. Most anti-HIV medications need to be taken on a schedule, such as “2 times a day” or 
“3 times a day” or “every 8 hours”. How closely did you follow your specific schedule 
over the last 4 days? 
                       Never          Some of                About half            Most of             All of  
                                            the time               of the time            the time           the time 
 
                               1                    2                           3                              4                   5 
 
4. Does any of your anti-HIV medications have special instructions, such as “take with 
food” or “on an empty stomach” or “with plenty of fluids?” 
                            •1 Yes                         •2 No 
5. If Yes, how often did you follow those special instructions over the last four days? 
                       Never          Some of                About half            Most of             All of  
                                            the time               of the time            the time           the time 
 
                              1                    2                             3                           4                     5 
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ANNEXURE E: AUTHORIZATION TO PARTICIPATE IN RESEARCH 
 
AUTHORIZATION TO PARTICIPATE IN RESEARCH 
Title of Study: Self-Efficacy and Beliefs about Medicines: Implications for An-
tiretroviral Therapy Adherence  
Introduction 
I am Dr Adefolalu Adegoke, the researcher responsible for this study and currently 
registered for DLitt et Phil degree at the Department of Health Studies at UNISA. This 
research seeks to explain and explore some cognitive correlates of adherence to an-
tiretroviral therapy among HIV-infected patients on treatment in South Africa. The pur-
pose of this doctoral research is to understand what assists or maintains HIV treatment 
adherence among men and women living with HIV in South Africa. The study specifical-
ly, aims at establishing whether an individual's level of confidence in performing role in 
taking medication and beliefs about medication have relationships with his or her ability 
to take HIV medication as needed.  
 
Procedure 
If you agree to participate in this study, you will be subjected to an interview which in-
volves answering questions about your demographic information, ART adherence self-
efficacy, beliefs about medicines and ART adherence. Please answer all questions 
honestly; you will not be judged based on your responses as there is no right or wrong 
answer. If you have any questions feel free to ask the research assistant or the re-
searcher.  
 
Voluntary nature and right to decline 
Please be advised that your participation is voluntary. If you decide to participate, but 
prefer not to answer certain questions, you are free to do so and for any reason. You 
have the right to decline to answer any questions that make you feel uncomfortable, or 
stop the interview at any time. There are no negative consequences if you decline to 
participate or refuse to answer any question. 
 
Confidentiality and anonymity 
The researcher undertakes to maintain at all time strict confidentiality of you as partici-
pant and the data collected during the research. All collected data will be stored elec-
tronically in a secured location, protected with password and only the researcher will 
have access to it. No personal identifiers such as names, birth-date, addresses, and 
email or telephone numbers will be attached to your responses on the questionnaires. 
Results of the research will be presented and published in such a manner that partici-
pants will not be identifiable.  
Risk and Benefits 
No major risk is anticipated to you as a participant; however counselling services will be 
readily available to you should you develop emotional trauma as a result of participating 
in the study. As a participant you will not receive any monetary benefit for your participa-
tion in the study and will not be coerced into participation; however you will contribute to 
the existing body of knowledge in the field of HIV/AIDS and may benefit from the out-
come of the study through your participation.  
 
You will be given a signed copy of this informed consent. Your consent to participate is 
indicated by completing the four questionnaires. If you have any questions or concerns 
2 
 
about the study, please contact the Researcher: Dr AO Adefolalu on 073 095 9319, 
47538031@mylife.unisa.ac.za or Prof ZZ Nkosi; 012 4296758, nkosizz@unisa.ac.za 
 
 
CONSENT TO PARTICIPATE IN THE STUDY 
I…………………………………………….understand that I have been asked to participate 
in the above named research which aims to find out the influence of self-efficacy and 
beliefs about medication on adherence among HIV-infected patients on ART. 
I confirm that the purpose and details of the research have been fully explained to me 
and I declare that I fully understand the content of this consent form. I have been given 
the opportunity to ask questions and I am satisfied with the answers provided. In addi-
tion, I have been told that if I decline to participate this will not affect the quality of care 
given to me in any way whatsoever.  
I confirm that I have not been forced or put under any pressure to participate. Further-
more, I have not been offered any reward, in cash or kind for my participation; and I 
confirm that my consent is voluntary. 
I authorize the researcher to use at his discretion the data collected in the course of the 
study for the purpose of writing the report of this research. 
I will be provided with a signed copy of this consent form and the researcher will keep 
the original copy in a safe place. 
I have read this information and hereby volunteer to participate in this study. 
 
Signed at…………………….. (Place) on ……………………………….(Date) 
 
………………………….                                                     ………………………………….. 
Participant’s signature                                                        Witness’ signature       
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ANNEXURE G: Factor Analysis Results for All Variables 
 
Factor Analysis  
 
Factor analysis/correlation                        Number of obs    =      232 
    Method: iterated principal factors             Retained factors =        6 
    Rotation: (unrotated)                          Number of params =      171 
 
    -------------------------------------------------------------------------- 
         Factor  |   Eigenvalue   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      7.25954      4.75481            0.5412       0.5412 
        Factor2  |      2.50473      0.81602            0.1867       0.7279 
        Factor3  |      1.68871      0.96215            0.1259       0.8538 
        Factor4  |      0.72656      0.07034            0.0542       0.9079 
        Factor5  |      0.65622      0.07715            0.0489       0.9568 
        Factor6  |      0.57907      0.13574            0.0432       1.0000 
        Factor7  |      0.44333      0.07869            0.0330       1.0331 
        Factor8  |      0.36464      0.05396            0.0272       1.0602 
        Factor9  |      0.31068      0.02933            0.0232       1.0834 
       Factor10  |      0.28135      0.05324            0.0210       1.1044 
       Factor11  |      0.22812      0.05342            0.0170       1.1214 
       Factor12  |      0.17470      0.05585            0.0130       1.1344 
       Factor13  |      0.11886      0.01443            0.0089       1.1433 
       Factor14  |      0.10443      0.05441            0.0078       1.1510 
       Factor15  |      0.05002      0.01907            0.0037       1.1548 
       Factor16  |      0.03095      0.00519            0.0023       1.1571 
       Factor17  |      0.02576      0.02763            0.0019       1.1590 
       Factor18  |     -0.00187      0.02914           -0.0001       1.1589 
       Factor19  |     -0.03101      0.00511           -0.0023       1.1565 
       Factor20  |     -0.03612      0.03418           -0.0027       1.1539 
       Factor21  |     -0.07030      0.01220           -0.0052       1.1486 
       Factor22  |     -0.08251      0.02886           -0.0062       1.1425 
       Factor23  |     -0.11137      0.02154           -0.0083       1.1342 
       Factor24  |     -0.13291      0.01804           -0.0099       1.1242 
       Factor25  |     -0.15096      0.04384           -0.0113       1.1130 
       Factor26  |     -0.19480      0.03511           -0.0145       1.0985 
       Factor27  |     -0.22991      0.02476           -0.0171       1.0813 
       Factor28  |     -0.25466      0.00138           -0.0190       1.0624 
       Factor29  |     -0.25605      0.01316           -0.0191       1.0433 
       Factor30  |     -0.26921      0.04198           -0.0201       1.0232 
       Factor31  |     -0.31119            .           -0.0232       1.0000 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated: chi2(465) = 2836.23 Prob>chi2 = 0.0000 
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Factor loadings (pattern matrix) and unique variances 
 
    ----------------------------------------------------------------------------------------- 
        Variable |  Factor1   Factor2   Factor3   Factor4   Factor5   Factor6 |   Uniqueness  
    -------------+------------------------------------------------------------+-------------- 
              b1 |   0.7901   -0.1221   -0.0856   -0.0673   -0.1711   -0.0244 |      0.3191   
              b2 |   0.8460   -0.1044   -0.0337    0.0863   -0.0885   -0.0346 |      0.2559   
              b3 |   0.6942   -0.1028   -0.0441    0.0124   -0.0147   -0.0542 |      0.5022   
              b4 |   0.7382   -0.0138    0.0739    0.1154    0.0866   -0.1070 |      0.4171   
              b5 |   0.8040    0.0371   -0.0352   -0.0883   -0.0435    0.0647 |      0.3372   
              b6 |   0.7894    0.0307   -0.0901    0.0800    0.0419   -0.1325 |      0.3421   
              b7 |   0.7545   -0.1012    0.0627   -0.0411    0.0347    0.0450 |      0.4116   
              b8 |   0.7194   -0.1136   -0.0649   -0.0392   -0.0352    0.1383 |      0.4434   
              b9 |   0.7566    0.0382    0.0551    0.0622    0.1519    0.1209 |      0.3815   
             b10 |   0.7021   -0.0310    0.1214   -0.0100    0.1395    0.0629 |      0.4678   
             b11 |   0.7891   -0.0630    0.0487    0.1577   -0.0724   -0.0433 |      0.3389   
             b12 |   0.6353   -0.1464    0.1249   -0.1289    0.0155    0.0731 |      0.5372   
           bmqs1 |   0.1050    0.4844   -0.3917    0.0280    0.0450   -0.1202 |      0.5836   
           bmqs2 |   0.0801    0.4957   -0.3651   -0.0527   -0.0672    0.1146 |      0.5941   
           bmqs3 |   0.0711    0.4539   -0.3754    0.0754    0.0102    0.0178 |      0.6419   
           bmqs4 |   0.1390    0.5369   -0.4852   -0.1907    0.3656   -0.1531 |      0.2634   
           bmqs5 |   0.1729    0.4244   -0.2159    0.2908   -0.0500    0.2695 |      0.5837   
           bmqs6 |   0.2400    0.3133   -0.0366   -0.1051   -0.1782    0.2601 |      0.7325   
           bmqs7 |   0.0197    0.3042    0.2913   -0.1435    0.0138    0.1419 |      0.7813   
           bmqs8 |   0.0527    0.3597    0.1332    0.0278   -0.1342   -0.1282 |      0.8149   
           bmqs9 |   0.1543    0.1910    0.2837   -0.1761    0.1149   -0.2018 |      0.7743   
          bmqs10 |   0.1489    0.3078    0.3500   -0.2805   -0.0729   -0.1050 |      0.6656   
           bmqg1 |   0.0088    0.3561    0.2946    0.0436   -0.0930    0.2020 |      0.7349   
           bmqg2 |   0.4161    0.2649    0.1115    0.0992   -0.1426   -0.2548 |      0.6492   
           bmqg3 |   0.1692    0.2708    0.3300   -0.2083    0.3105    0.1367 |      0.6306   
           bmqg4 |  -0.1502    0.2018    0.0781    0.1449   -0.1533   -0.0853 |      0.8788   
           bmqg5 |  -0.1325    0.4930    0.4319    0.2319    0.0850   -0.0773 |      0.4859   
           bmqg6 |   0.0317    0.4380    0.1371   -0.1814   -0.3884   -0.1066 |      0.5933   
           bmqg7 |   0.0597    0.0793    0.2268   -0.0713    0.1074   -0.0381 |      0.9206   
           bmqg8 |  -0.1357    0.1999    0.2572    0.1528    0.0837    0.2259 |      0.7941   
              D1 |   0.0366    0.1285    0.2565    0.4180    0.1430   -0.1130 |      0.7084   
    ----------------------------------------------------------------------------------------- 
 
. rotate, varimax horst 
 
Factor analysis/correlation                        Number of obs    =      232 
    Method: iterated principal factors             Retained factors =        6 
    Rotation: orthogonal varimax (Kaiser on)       Number of params =      171 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      7.14395      5.03620            0.5325       0.5325 
        Factor2  |      2.10775      0.73673            0.1571       0.6897 
        Factor3  |      1.37103      0.31844            0.1022       0.7919 
        Factor4  |      1.05259      0.17107            0.0785       0.8703 
        Factor5  |      0.88152      0.02352            0.0657       0.9360 
        Factor6  |      0.85800            .            0.0640       1.0000 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated: chi2(465) = 2836.23 Prob>chi2 = 0.0000 
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Rotated factor loadings (pattern matrix) and unique variances 
 
    ----------------------------------------------------------------------------------------- 
        Variable |  Factor1   Factor2   Factor3   Factor4   Factor5   Factor6 |   Uniqueness  
    -------------+------------------------------------------------------------+-------------- 
              b1 |   0.7968    0.0151   -0.0650    0.1007   -0.1687   -0.0543 |      0.3191   
              b2 |   0.8579    0.0173   -0.0599    0.0552    0.0056   -0.0338 |      0.2559   
              b3 |   0.6997    0.0272   -0.0059    0.0012   -0.0298   -0.0807 |      0.5022   
              b4 |   0.7360    0.0412    0.1038    0.0049    0.1540   -0.0705 |      0.4171   
              b5 |   0.7864    0.1221    0.0878    0.0485   -0.1257    0.0609 |      0.3372   
              b6 |   0.7783    0.1772    0.0275    0.0349    0.0740   -0.1153 |      0.3421   
              b7 |   0.7560   -0.0277    0.1037   -0.0464   -0.0540    0.0149 |      0.4116   
              b8 |   0.7255    0.0249   -0.0246   -0.0631   -0.1390    0.0750 |      0.4434   
              b9 |   0.7447    0.0995    0.1467   -0.1126    0.0721    0.1208 |      0.3815   
             b10 |   0.6948    0.0008    0.1919   -0.0945    0.0314    0.0529 |      0.4678   
             b11 |   0.8015   -0.0100   -0.0281    0.0777    0.1082    0.0006 |      0.3389   
             b12 |   0.6393   -0.1179    0.1445   -0.0482   -0.1274    0.0275 |      0.5372   
           bmqs1 |   0.0383    0.6268   -0.0193    0.1344    0.0390   -0.0447 |      0.5836   
           bmqs2 |   0.0139    0.5820   -0.0390    0.1453   -0.1117    0.1786 |      0.5941   
           bmqs3 |   0.0152    0.5780   -0.0799    0.0960    0.0324    0.0846 |      0.6419   
           bmqs4 |   0.0381    0.8039    0.2129   -0.0920   -0.0642   -0.1760 |      0.2634   
           bmqs5 |   0.1413    0.4391   -0.1511    0.0646    0.1723    0.3833 |      0.5837   
           bmqs6 |   0.2000    0.2233    0.0617    0.1793   -0.1622    0.3397 |      0.7325   
           bmqs7 |  -0.0247    0.0256    0.3555    0.1390   -0.0014    0.2679 |      0.7813   
           bmqs8 |   0.0128    0.1474    0.1587    0.3408    0.1316    0.0679 |      0.8149   
           bmqs9 |   0.1122   -0.0009    0.4223    0.1472    0.0624   -0.0958 |      0.7743   
          bmqs10 |   0.0932   -0.0070    0.4601    0.3265   -0.0603    0.0609 |      0.6656   
           bmqg1 |  -0.0245    0.0318    0.2246    0.2147    0.1212    0.3902 |      0.7349   
           bmqg2 |   0.3874    0.1345    0.1184    0.3595    0.1885   -0.0625 |      0.6492   
           bmqg3 |   0.1131    0.0593    0.5527   -0.0888    0.0328    0.1965 |      0.6306   
           bmqg4 |  -0.1592    0.0438   -0.0269    0.2466    0.1688    0.0621 |      0.8788   
           bmqg5 |  -0.1772    0.0723    0.3637    0.2606    0.4782    0.2204 |      0.4859   
           bmqg6 |  -0.0234    0.1418    0.1733    0.5737   -0.1057    0.1255 |      0.5933   
           bmqg7 |   0.0419   -0.0607    0.2621    0.0214    0.0671    0.0158 |      0.9206   
           bmqg8 |  -0.1463   -0.0315    0.1536   -0.0181    0.2176    0.3350 |      0.7941   
              D1 |   0.0447   -0.0404    0.0732    0.0297    0.5285    0.0494 |      0.7084   
    ----------------------------------------------------------------------------------------- 
 
 
 
 
 
Factor rotation matrix 
 
    -------------------------------------------------------------------- 
                 | Factor1  Factor2  Factor3  Factor4  Factor5  Factor6  
    -------------+------------------------------------------------------ 
         Factor1 |  0.9889   0.1046   0.0962   0.0344  -0.0226   0.0090  
         Factor2 | -0.1257   0.7102   0.3808   0.4331   0.2004   0.3272  
         Factor3 |  0.0086  -0.6580   0.5974   0.2267   0.3162   0.2424  
         Factor4 |  0.0691  -0.0067  -0.5070  -0.0406   0.8413   0.1695  
         Factor5 | -0.0339   0.2247   0.4688  -0.7816   0.2872  -0.1877  
         Factor6 |  0.0137  -0.0348  -0.1098  -0.3838  -0.2629   0.8775  
    -------------------------------------------------------------------- 
 
. 
    LR test: independent vs. saturated: chi2(1225)= 6140.04 Prob>chi2 = 0.0000 
 
. rotate, varimax horst blanks(0.3) 
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Factor analysis/correlation                        Number of obs    =      232 
    Method: iterated principal factors             Retained factors =        6 
    Rotation: orthogonal varimax (Kaiser on)       Number of params =      171 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      7.14395      5.03620            0.5325       0.5325 
        Factor2  |      2.10775      0.73673            0.1571       0.6897 
        Factor3  |      1.37103      0.31844            0.1022       0.7919 
        Factor4  |      1.05259      0.17107            0.0785       0.8703 
        Factor5  |      0.88152      0.02352            0.0657       0.9360 
        Factor6  |      0.85800            .            0.0640       1.0000 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated: chi2(465) = 2836.23 Prob>chi2 = 0.0000 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
    ----------------------------------------------------------------------------------------- 
        Variable |  Factor1   Factor2   Factor3   Factor4   Factor5   Factor6 |   Uniqueness  
    -------------+------------------------------------------------------------+-------------- 
              b1 |   0.7968                                                   |      0.3191   
              b2 |   0.8579                                                   |      0.2559   
              b3 |   0.6997                                                   |      0.5022   
              b4 |   0.7360                                                   |      0.4171   
              b5 |   0.7864                                                   |      0.3372   
              b6 |   0.7783                                                   |      0.3421   
              b7 |   0.7560                                                   |      0.4116   
              b8 |   0.7255                                                   |      0.4434   
              b9 |   0.7447                                                   |      0.3815   
             b10 |   0.6948                                                   |      0.4678   
             b11 |   0.8015                                                   |      0.3389   
             b12 |   0.6393                                                   |      0.5372   
           bmqs1 |             0.6268                                         |      0.5836   
           bmqs2 |             0.5820                                         |      0.5941   
           bmqs3 |             0.5780                                         |      0.6419   
           bmqs4 |             0.8039                                         |      0.2634   
           bmqs5 |             0.4391                                  0.3833 |      0.5837   
           bmqs6 |                                                     0.3397 |      0.7325   
           bmqs7 |                       0.3555                               |      0.7813   
           bmqs8 |                                 0.3408                     |      0.8149   
           bmqs9 |                       0.4223                               |      0.7743   
          bmqs10 |                       0.4601    0.3265                     |      0.6656   
           bmqg1 |                                                     0.3902 |      0.7349   
           bmqg2 |   0.3874                        0.3595                     |      0.6492   
           bmqg3 |                       0.5527                               |      0.6306   
           bmqg4 |                                                            |      0.8788   
           bmqg5 |                       0.3637              0.4782           |      0.4859   
           bmqg6 |                                 0.5737                     |      0.5933   
           bmqg7 |                                                            |      0.9206   
           bmqg8 |                                                     0.3350 |      0.7941   
              D1 |                                           0.5285           |      0.7084   
    ----------------------------------------------------------------------------------------- 
    (blanks represent abs(loading)<.3) 
 
Factor rotation matrix 
 
    -------------------------------------------------------------------- 
                 | Factor1  Factor2  Factor3  Factor4  Factor5  Factor6  
    -------------+------------------------------------------------------ 
         Factor1 |  0.9889   0.1046   0.0962   0.0344  -0.0226   0.0090  
         Factor2 | -0.1257   0.7102   0.3808   0.4331   0.2004   0.3272  
         Factor3 |  0.0086  -0.6580   0.5974   0.2267   0.3162   0.2424  
         Factor4 |  0.0691  -0.0067  -0.5070  -0.0406   0.8413   0.1695  
         Factor5 | -0.0339   0.2247   0.4688  -0.7816   0.2872  -0.1877  
         Factor6 |  0.0137  -0.0348  -0.1098  -0.3838  -0.2629   0.8775  
    -------------------------------------------------------------------- 
 
. estat rotatecompare 
 
 
 
 
5 
 
 
Rotation matrix -- orthogonal varimax (Kaiser on) 
 
    -------------------------------------------------------------------------------- 
        Variable |   Factor1    Factor2    Factor3    Factor4    Factor5    Factor6  
    -------------+------------------------------------------------------------------ 
         Factor1 |    0.9889     0.1046     0.0962     0.0344    -0.0226     0.0090  
         Factor2 |   -0.1257     0.7102     0.3808     0.4331     0.2004     0.3272  
         Factor3 |    0.0086    -0.6580     0.5974     0.2267     0.3162     0.2424  
         Factor4 |    0.0691    -0.0067    -0.5070    -0.0406     0.8413     0.1695  
         Factor5 |   -0.0339     0.2247     0.4688    -0.7816     0.2872    -0.1877  
         Factor6 |    0.0137    -0.0348    -0.1098    -0.3838    -0.2629     0.8775  
    -------------------------------------------------------------------------------- 
 
Rotated factor loadings 
 
    -------------------------------------------------------------------------------- 
        Variable |   Factor1    Factor2    Factor3    Factor4    Factor5    Factor6  
    -------------+------------------------------------------------------------------ 
              b1 |    0.7968     0.0151    -0.0650     0.1007    -0.1687    -0.0543  
              b2 |    0.8579     0.0173    -0.0599     0.0552     0.0056    -0.0338  
              b3 |    0.6997     0.0272    -0.0059     0.0012    -0.0298    -0.0807  
              b4 |    0.7360     0.0412     0.1038     0.0049     0.1540    -0.0705  
              b5 |    0.7864     0.1221     0.0878     0.0485    -0.1257     0.0609  
              b6 |    0.7783     0.1772     0.0275     0.0349     0.0740    -0.1153  
              b7 |    0.7560    -0.0277     0.1037    -0.0464    -0.0540     0.0149  
              b8 |    0.7255     0.0249    -0.0246    -0.0631    -0.1390     0.0750  
              b9 |    0.7447     0.0995     0.1467    -0.1126     0.0721     0.1208  
             b10 |    0.6948     0.0008     0.1919    -0.0945     0.0314     0.0529  
             b11 |    0.8015    -0.0100    -0.0281     0.0777     0.1082     0.0006  
             b12 |    0.6393    -0.1179     0.1445    -0.0482    -0.1274     0.0275  
           bmqs1 |    0.0383     0.6268    -0.0193     0.1344     0.0390    -0.0447  
           bmqs2 |    0.0139     0.5820    -0.0390     0.1453    -0.1117     0.1786  
           bmqs3 |    0.0152     0.5780    -0.0799     0.0960     0.0324     0.0846  
           bmqs4 |    0.0381     0.8039     0.2129    -0.0920    -0.0642    -0.1760  
           bmqs5 |    0.1413     0.4391    -0.1511     0.0646     0.1723     0.3833  
           bmqs6 |    0.2000     0.2233     0.0617     0.1793    -0.1622     0.3397  
           bmqs7 |   -0.0247     0.0256     0.3555     0.1390    -0.0014     0.2679  
           bmqs8 |    0.0128     0.1474     0.1587     0.3408     0.1316     0.0679  
           bmqs9 |    0.1122    -0.0009     0.4223     0.1472     0.0624    -0.0958  
          bmqs10 |    0.0932    -0.0070     0.4601     0.3265    -0.0603     0.0609  
           bmqg1 |   -0.0245     0.0318     0.2246     0.2147     0.1212     0.3902  
           bmqg2 |    0.3874     0.1345     0.1184     0.3595     0.1885    -0.0625  
           bmqg3 |    0.1131     0.0593     0.5527    -0.0888     0.0328     0.1965  
           bmqg4 |   -0.1592     0.0438    -0.0269     0.2466     0.1688     0.0621  
           bmqg5 |   -0.1772     0.0723     0.3637     0.2606     0.4782     0.2204  
           bmqg6 |   -0.0234     0.1418     0.1733     0.5737    -0.1057     0.1255  
           bmqg7 |    0.0419    -0.0607     0.2621     0.0214     0.0671     0.0158  
           bmqg8 |   -0.1463    -0.0315     0.1536    -0.0181     0.2176     0.3350  
              D1 |    0.0447    -0.0404     0.0732     0.0297     0.5285     0.0494  
    -------------------------------------------------------------------------------- 
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Unrotated factor loadings 
 
    -------------------------------------------------------------------------------- 
        Variable |   Factor1    Factor2    Factor3    Factor4    Factor5    Factor6  
    -------------+------------------------------------------------------------------ 
              b1 |    0.7901    -0.1221    -0.0856    -0.0673    -0.1711    -0.0244  
              b2 |    0.8460    -0.1044    -0.0337     0.0863    -0.0885    -0.0346  
              b3 |    0.6942    -0.1028    -0.0441     0.0124    -0.0147    -0.0542  
              b4 |    0.7382    -0.0138     0.0739     0.1154     0.0866    -0.1070  
              b5 |    0.8040     0.0371    -0.0352    -0.0883    -0.0435     0.0647  
              b6 |    0.7894     0.0307    -0.0901     0.0800     0.0419    -0.1325  
              b7 |    0.7545    -0.1012     0.0627    -0.0411     0.0347     0.0450  
              b8 |    0.7194    -0.1136    -0.0649    -0.0392    -0.0352     0.1383  
              b9 |    0.7566     0.0382     0.0551     0.0622     0.1519     0.1209  
             b10 |    0.7021    -0.0310     0.1214    -0.0100     0.1395     0.0629  
             b11 |    0.7891    -0.0630     0.0487     0.1577    -0.0724    -0.0433  
             b12 |    0.6353    -0.1464     0.1249    -0.1289     0.0155     0.0731  
           bmqs1 |    0.1050     0.4844    -0.3917     0.0280     0.0450    -0.1202  
           bmqs2 |    0.0801     0.4957    -0.3651    -0.0527    -0.0672     0.1146  
           bmqs3 |    0.0711     0.4539    -0.3754     0.0754     0.0102     0.0178  
           bmqs4 |    0.1390     0.5369    -0.4852    -0.1907     0.3656    -0.1531  
           bmqs5 |    0.1729     0.4244    -0.2159     0.2908    -0.0500     0.2695  
           bmqs6 |    0.2400     0.3133    -0.0366    -0.1051    -0.1782     0.2601  
           bmqs7 |    0.0197     0.3042     0.2913    -0.1435     0.0138     0.1419  
           bmqs8 |    0.0527     0.3597     0.1332     0.0278    -0.1342    -0.1282  
           bmqs9 |    0.1543     0.1910     0.2837    -0.1761     0.1149    -0.2018  
          bmqs10 |    0.1489     0.3078     0.3500    -0.2805    -0.0729    -0.1050  
           bmqg1 |    0.0088     0.3561     0.2946     0.0436    -0.0930     0.2020  
           bmqg2 |    0.4161     0.2649     0.1115     0.0992    -0.1426    -0.2548  
           bmqg3 |    0.1692     0.2708     0.3300    -0.2083     0.3105     0.1367  
           bmqg4 |   -0.1502     0.2018     0.0781     0.1449    -0.1533    -0.0853  
           bmqg5 |   -0.1325     0.4930     0.4319     0.2319     0.0850    -0.0773  
           bmqg6 |    0.0317     0.4380     0.1371    -0.1814    -0.3884    -0.1066  
           bmqg7 |    0.0597     0.0793     0.2268    -0.0713     0.1074    -0.0381  
           bmqg8 |   -0.1357     0.1999     0.2572     0.1528     0.0837     0.2259  
              D1 |    0.0366     0.1285     0.2565     0.4180     0.1430    -0.1130  
    -------------------------------------------------------------------------------- 
 
. 
The comparison of the rotated and the un-rotated factors are similar and does not af-
fect the interpretation. 
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The chart below showed that only 4factors will be needed to explain the relevant vari-
ability in your research 
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Kaiser-Meyer-Olkin measure of sampling adequacy 
 
    ----------------------- 
        Variable |     kmo  
    -------------+--------- 
              b1 |  0.9318  
              b2 |  0.9379  
              b3 |  0.9027  
              b4 |  0.9247  
              b5 |  0.8784  
              b6 |  0.9199  
              b7 |  0.9223  
              b8 |  0.8879  
              b9 |  0.9142  
             b10 |  0.8931  
             b11 |  0.8696  
             b12 |  0.9326  
           bmqs1 |  0.7670  
           bmqs2 |  0.7108  
           bmqs3 |  0.7287  
           bmqs4 |  0.6370  
           bmqs5 |  0.7237  
           bmqs6 |  0.7905  
           bmqs7 |  0.6589  
           bmqs8 |  0.7503  
           bmqs9 |  0.6041  
          bmqs10 |  0.6673  
           bmqg1 |  0.6607  
           bmqg2 |  0.8145  
           bmqg3 |  0.7619  
           bmqg4 |  0.6446  
           bmqg5 |  0.7172  
           bmqg6 |  0.7001  
           bmqg7 |  0.5845  
           bmqg8 |  0.6686  
              D1 |  0.4329  
    -------------+--------- 
         Overall |  0.8586   
    ----------------------- 
Overall estimate of KMO show measure of sampling adequacy.  
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ANNEXURE H 
 
MULTIPLE REGRESSION ANALYSIS 
 
ALL PARTICIPANTS 
 
----------------- STEP 1 ------------------ 
Determinant of correlation matrix =   0.7570 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   3  2116.121   705.374     4.223     0.006 
Residual   228 38083.568   167.033 
Total      231 40199.689 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.229     0.053     4.223     0.006    3  228 
Adjusted R Squared = 0.040 
 
Std. Error of Estimate =     12.924 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.038     0.204     0.349     0.585     0.559     1.031     
0.969 
     BMQ-S    -0.070    -2.187     2.246    -0.974     0.331     1.250     
0.800 
     BMQ-G     0.247     6.416     1.846     3.476     0.001     1.215     
0.823 
 
Constant =     81.783 
 
Partial Correlations 
 
Variables        SES       BMQ-S       BMQ-G   
                0.039      -0.064       0.224   
 
 
Variable 1 (SES) eliminated 
 
 
Backward Stepwise Multiple Regression  
 
----------------- STEP 1 ------------------ 
Determinant of correlation matrix =   0.7570 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   3  2116.121   705.374     4.223     0.006 
Residual   228 38083.568   167.033 
Total      231 40199.689 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.229     0.053     4.223     0.006    3  228 
Adjusted R Squared = 0.040 
 
Std. Error of Estimate =     12.924 
 
 
 
2 
 
 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.038     0.204     0.349     0.585     0.559     1.031     
0.969 
     BMQ-S    -0.070    -2.187     2.246    -0.974     0.331     1.250     
0.800 
     BMQ-G     0.247     6.416     1.846     3.476     0.001     1.215     
0.823 
 
Constant =     81.783 
 
Partial Correlations 
 
Variables        SES       BMQ-S       BMQ-G   
                0.039      -0.064       0.224   
 
 
Variable 1 (SES) eliminated 
 
----------------- STEP 2 ------------------ 
Determinant of correlation matrix =   0.7820 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   2  2058.862  1029.431     6.181     0.002 
Residual   229 38140.826   166.554 
Total      231 40199.689 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.226     0.051     6.181     0.002    2  229 
Adjusted R Squared = 0.043 
 
Std. Error of Estimate =     12.906 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
     BMQ-S    -0.063    -1.963     2.210    -0.888     0.375     1.213     
0.824 
     BMQ-G     0.245     6.375     1.842     3.461     0.001     1.213     
0.824 
 
Constant =     82.323 
 
Partial Correlations 
 
Variables      BMQ-S       BMQ-G   
               -0.059       0.223   
 
 
Variable 1 (BMQ-S) eliminated 
 
 
Backward Stepwise Multiple Regression  
 
----------------- STEP 1 ------------------ 
Determinant of correlation matrix =   0.7570 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   3  2116.121   705.374     4.223     0.006 
Residual   228 38083.568   167.033 
3 
 
Total      231 40199.689 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.229     0.053     4.223     0.006    3  228 
Adjusted R Squared = 0.040 
 
Std. Error of Estimate =     12.924 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.038     0.204     0.349     0.585     0.559     1.031     
0.969 
     BMQ-S    -0.070    -2.187     2.246    -0.974     0.331     1.250     
0.800 
     BMQ-G     0.247     6.416     1.846     3.476     0.001     1.215     
0.823 
 
Constant =     81.783 
 
Partial Correlations 
 
Variables        SES       BMQ-S       BMQ-G   
                0.039      -0.064       0.224   
 
 
Variable 1 (SES) eliminated 
 
----------------- STEP 2 ------------------ 
Determinant of correlation matrix =   0.7820 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   2  2058.862  1029.431     6.181     0.002 
Residual   229 38140.826   166.554 
Total      231 40199.689 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.226     0.051     6.181     0.002    2  229 
Adjusted R Squared = 0.043 
 
Std. Error of Estimate =     12.906 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
     BMQ-S    -0.063    -1.963     2.210    -0.888     0.375     1.213     
0.824 
     BMQ-G     0.245     6.375     1.842     3.461     0.001     1.213     
0.824 
 
Constant =     82.323 
 
Partial Correlations 
 
Variables      BMQ-S       BMQ-G   
               -0.059       0.223   
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Variable 1 (BMQ-S) eliminated 
 
----------------- STEP 3 ------------------ 
Determinant of correlation matrix =   0.9521 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   1  1927.486  1927.486    11.583     0.001 
Residual   230 38272.203   166.401 
Total      231 40199.689 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.219     0.048    11.583     0.001    1  230 
Adjusted R Squared = 0.044 
 
Std. Error of Estimate =     12.900 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
     BMQ-G     0.219     5.689     1.672     3.403     0.001     1.000     
1.000 
 
Constant =     76.553 
 
Partial Correlations 
 
Variables      BMQ-G   
                0.219   
 
 
NON-ADHERENT PARTICIPANTS: 
 
Backward Stepwise Multiple Regression  
 
----------------- STEP 1 ------------------ 
Determinant of correlation matrix =   0.3411 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   3  1341.134   447.045     1.779     0.167 
Residual    39  9798.436   251.242 
Total       42 11139.570 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.347     0.120     1.779     0.167    3   39 
Adjusted R Squared = 0.053 
 
Std. Error of Estimate =     15.851 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.438     4.052     1.981     2.045     0.048     2.037     
0.491 
     BMQ-S    -0.220    -8.315     8.464    -0.982     0.332     2.220     
0.450 
     BMQ-G     0.082     3.317     6.848     0.484     0.631     1.273     
5 
 
0.785 
 
Constant =     68.540 
 
Partial Correlations 
 
Variables        SES       BMQ-S       BMQ-G   
                0.311      -0.155       0.077   
 
 
Variable 3 (BMQ-G) eliminated 
 
 
Backward Stepwise Multiple Regression  
 
----------------- STEP 1 ------------------ 
Determinant of correlation matrix =   0.3411 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   3  1341.134   447.045     1.779     0.167 
Residual    39  9798.436   251.242 
Total       42 11139.570 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.347     0.120     1.779     0.167    3   39 
Adjusted R Squared = 0.053 
 
Std. Error of Estimate =     15.851 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.438     4.052     1.981     2.045     0.048     2.037     
0.491 
     BMQ-S    -0.220    -8.315     8.464    -0.982     0.332     2.220     
0.450 
     BMQ-G     0.082     3.317     6.848     0.484     0.631     1.273     
0.785 
 
Constant =     68.540 
 
Partial Correlations 
 
Variables        SES       BMQ-S       BMQ-G   
                0.311      -0.155       0.077   
 
 
Variable 3 (BMQ-G) eliminated 
 
----------------- STEP 2 ------------------ 
Determinant of correlation matrix =   0.4370 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   2  1282.194   641.097     2.601     0.087 
Residual    40  9857.375   246.434 
Total       42 11139.570 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.339     0.115     2.601     0.087    2   40 
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Adjusted R Squared = 0.071 
 
Std. Error of Estimate =     15.698 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.446     4.124     1.956     2.108     0.041     2.025     
0.494 
     BMQ-S    -0.188    -7.101     8.007    -0.887     0.380     2.025     
0.494 
 
Constant =     72.918 
 
Partial Correlations 
 
Variables        SES       BMQ-S   
                0.316      -0.139   
 
 
Variable 2 (BMQ-S) eliminated 
 
Backward Stepwise Multiple Regression  
 
----------------- STEP 1 ------------------ 
Determinant of correlation matrix =   0.3411 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   3  1341.134   447.045     1.779     0.167 
Residual    39  9798.436   251.242 
Total       42 11139.570 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.347     0.120     1.779     0.167    3   39 
Adjusted R Squared = 0.053 
 
Std. Error of Estimate =     15.851 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.438     4.052     1.981     2.045     0.048     2.037     
0.491 
     BMQ-S    -0.220    -8.315     8.464    -0.982     0.332     2.220     
0.450 
     BMQ-G     0.082     3.317     6.848     0.484     0.631     1.273     
0.785 
 
Constant =     68.540 
 
Partial Correlations 
 
Variables        SES       BMQ-S       BMQ-G   
                0.311      -0.155       0.077   
 
 
Variable 3 (BMQ-G) eliminated 
 
----------------- STEP 2 ------------------ 
Determinant of correlation matrix =   0.4370 
 
SOURCE    DF        SS      MS        F        Prob.>F 
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Regression   2  1282.194   641.097     2.601     0.087 
Residual    40  9857.375   246.434 
Total       42 11139.570 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.339     0.115     2.601     0.087    2   40 
Adjusted R Squared = 0.071 
 
Std. Error of Estimate =     15.698 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.446     4.124     1.956     2.108     0.041     2.025     
0.494 
     BMQ-S    -0.188    -7.101     8.007    -0.887     0.380     2.025     
0.494 
 
Constant =     72.918 
 
Partial Correlations 
 
Variables        SES       BMQ-S   
                0.316      -0.139   
 
 
Variable 2 (BMQ-S) eliminated 
 
----------------- STEP 3 ------------------ 
Determinant of correlation matrix =   0.9023 
 
SOURCE    DF        SS      MS        F        Prob.>F 
Regression   1  1088.377  1088.377     4.440     0.041 
Residual    41 10051.192   245.151 
Total       42 11139.570 
 
Dependent Variable: ADHERE 
 
       R        R2         F     Prob.>F  DF1  DF2 
   0.313     0.098     4.440     0.041    1   41 
Adjusted R Squared = 0.076 
 
Std. Error of Estimate =     15.657 
 
Variable       Beta      B         Std.Error t         Prob.>t   VIF       
TOL 
       SES     0.313     2.889     1.371     2.107     0.041     1.000     
1.000 
 
Constant =     52.294 
 
Partial Correlations 
 
Variables        SES   
                0.313   
 
 
